DE69839398T2 - Pyridinderivate - Google Patents
Pyridinderivate Download PDFInfo
- Publication number
- DE69839398T2 DE69839398T2 DE69839398T DE69839398T DE69839398T2 DE 69839398 T2 DE69839398 T2 DE 69839398T2 DE 69839398 T DE69839398 T DE 69839398T DE 69839398 T DE69839398 T DE 69839398T DE 69839398 T2 DE69839398 T2 DE 69839398T2
- Authority
- DE
- Germany
- Prior art keywords
- vinyl
- methylpyridin
- methyl
- methylpyridine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003222 pyridines Chemical class 0.000 title 1
- -1 cyano, ethynyl Chemical group 0.000 claims description 215
- 150000001875 compounds Chemical class 0.000 claims description 61
- 229920002554 vinyl polymer Polymers 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 43
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 29
- 150000002431 hydrogen Chemical class 0.000 claims description 23
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 9
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims description 6
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 210000000653 nervous system Anatomy 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 230000000848 glutamatergic effect Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims description 4
- HHOFXGSYOXBLCK-UHFFFAOYSA-N 2-[2-(3-bromophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(Br)C=CC=2)=N1 HHOFXGSYOXBLCK-UHFFFAOYSA-N 0.000 claims description 4
- MDKKZIPYNIZWGB-UHFFFAOYSA-N 2-[2-(6-methylpyridin-2-yl)ethenyl]benzonitrile Chemical compound CC1=CC=CC(C=CC=2C(=CC=CC=2)C#N)=N1 MDKKZIPYNIZWGB-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010010904 Convulsion Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 230000036461 convulsion Effects 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- MCSRDAAOPHMWRQ-UHFFFAOYSA-N n-ethyl-3-[2-(6-methylpyridin-2-yl)ethenyl]aniline Chemical compound CCNC1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1 MCSRDAAOPHMWRQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- XWLGPZHIBIDKMI-UHFFFAOYSA-N 2-[2-(3-bromophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(Br)C=CC=2)=N1 XWLGPZHIBIDKMI-UHFFFAOYSA-N 0.000 claims description 3
- GQSLKBHGURRQLG-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(F)C=CC=2)=N1 GQSLKBHGURRQLG-UHFFFAOYSA-N 0.000 claims description 3
- KYJSGWVPWUBKGL-UHFFFAOYSA-N 2-methyl-6-(2-pyridin-3-ylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=NC=CC=2)=N1 KYJSGWVPWUBKGL-UHFFFAOYSA-N 0.000 claims description 3
- VBUCDUWZPMKSPT-UHFFFAOYSA-N 3-[2-(6-methylpyridin-2-yl)ethenyl]benzonitrile Chemical compound CC1=CC=CC(C=CC=2C=C(C=CC=2)C#N)=N1 VBUCDUWZPMKSPT-UHFFFAOYSA-N 0.000 claims description 3
- FKODYULBKPINFM-UHFFFAOYSA-N 3-[2-(6-methylpyridin-2-yl)ethynyl]benzonitrile Chemical compound CC1=CC=CC(C#CC=2C=C(C=CC=2)C#N)=N1 FKODYULBKPINFM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- OVFQFWCPZCVGHK-UHFFFAOYSA-N (4-fluorophenyl)-[1-[2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridine-4-carbonyl]piperidin-4-yl]methanone Chemical compound N=1C(C)=CC(C(=O)N2CCC(CC2)C(=O)C=2C=CC(F)=CC=2)=CC=1C#CC1=CC=CC(F)=C1 OVFQFWCPZCVGHK-UHFFFAOYSA-N 0.000 claims description 2
- DNNGRDHVSYGNCR-UHFFFAOYSA-N (4-fluorophenyl)-[1-[6-[2-(3-fluorophenyl)ethenyl]-2-methylpyridine-3-carbonyl]piperidin-4-yl]methanone Chemical compound C=1C=C(C(=O)N2CCC(CC2)C(=O)C=2C=CC(F)=CC=2)C(C)=NC=1C=CC1=CC=CC(F)=C1 DNNGRDHVSYGNCR-UHFFFAOYSA-N 0.000 claims description 2
- OQCKLVPQCCOFIM-UHFFFAOYSA-N (4-fluorophenyl)-[1-[6-[2-(3-fluorophenyl)ethynyl]-2-methylpyridine-3-carbonyl]piperidin-4-yl]methanone Chemical compound CC1=NC(C#CC=2C=C(F)C=CC=2)=CC=C1C(=O)N(CC1)CCC1C(=O)C1=CC=C(F)C=C1 OQCKLVPQCCOFIM-UHFFFAOYSA-N 0.000 claims description 2
- YSWYUAZDUVLSKW-UHFFFAOYSA-N (4-fluorophenyl)-[1-[6-[2-(3-fluorophenyl)ethynyl]pyridine-3-carbonyl]piperidin-4-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C#CC=2C=C(F)C=CC=2)CC1 YSWYUAZDUVLSKW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 2
- FBVVXHASFFOBKR-UHFFFAOYSA-N 1-[1-[2-[2-[2-(2-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxyacetyl]piperidin-4-yl]imidazolidin-2-one Chemical compound C=1C=CC=C(Cl)C=1C=CC1=NC(C)=CC=C1OCC(=O)N(CC1)CCC1N1CCNC1=O FBVVXHASFFOBKR-UHFFFAOYSA-N 0.000 claims description 2
- XENROFZWOPYJRO-UHFFFAOYSA-N 1-[2-[2-(2-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC=C(C)N=C1C=CC1=CC=CC=C1Cl XENROFZWOPYJRO-UHFFFAOYSA-N 0.000 claims description 2
- HFTYCMWDUSJDLY-UHFFFAOYSA-N 1-[3-(2-pyridin-2-ylethynyl)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C#CC=2N=CC=CC=2)=C1 HFTYCMWDUSJDLY-UHFFFAOYSA-N 0.000 claims description 2
- CEAKCIFFNXYJKW-UHFFFAOYSA-N 1-[3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]-1,2,4-triazole-3-carboxylic acid Chemical compound CC1=CC=CC(C#CC=2C=C(C=CC=2)N2N=C(N=C2)C(O)=O)=N1 CEAKCIFFNXYJKW-UHFFFAOYSA-N 0.000 claims description 2
- OBDODVKFROBXDX-UHFFFAOYSA-N 1-[3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C#CC=2N=C(C)C=CC=2)=C1 OBDODVKFROBXDX-UHFFFAOYSA-N 0.000 claims description 2
- QMQZMAPROFVZNK-UHFFFAOYSA-N 1-[4-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]ethanol Chemical compound C1=CC(C(O)C)=CC=C1C=CC1=CC=CC(C)=N1 QMQZMAPROFVZNK-UHFFFAOYSA-N 0.000 claims description 2
- FGWWEBUPBZIUDF-UHFFFAOYSA-N 1-[6-(2-phenylethenyl)pyridin-2-yl]ethanone Chemical compound CC(=O)C1=CC=CC(C=CC=2C=CC=CC=2)=N1 FGWWEBUPBZIUDF-UHFFFAOYSA-N 0.000 claims description 2
- RAUCAUYMGSKHLE-UHFFFAOYSA-N 1-[6-[2-(3-fluorophenyl)ethynyl]-2-methylpyridin-3-yl]-n,n-dimethylmethanamine Chemical compound N1=C(C)C(CN(C)C)=CC=C1C#CC1=CC=CC(F)=C1 RAUCAUYMGSKHLE-UHFFFAOYSA-N 0.000 claims description 2
- JMPDONHZPFIVLD-UHFFFAOYSA-N 1-tert-butyl-3-[4-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]urea Chemical compound CC1=CC=CC(C=CC=2C=CC(NC(=O)NC(C)(C)C)=CC=2)=N1 JMPDONHZPFIVLD-UHFFFAOYSA-N 0.000 claims description 2
- RSHRGBLXHROHFQ-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-(6-methylpyridin-2-yl)ethenyl]phenol Chemical compound Cc1cccc(C=Cc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)n1 RSHRGBLXHROHFQ-UHFFFAOYSA-N 0.000 claims description 2
- BGDAABLEXCEAOB-UHFFFAOYSA-N 2-(1-bromo-2-phenylethenyl)-4-methylpyrimidine Chemical compound CC1=CC=NC(C(Br)=CC=2C=CC=CC=2)=N1 BGDAABLEXCEAOB-UHFFFAOYSA-N 0.000 claims description 2
- ZGBOTUTXJAYYRP-UHFFFAOYSA-N 2-(2-bromo-2-phenylethenyl)-6-methylpyridine Chemical compound CC1=CC=CC(C=C(Br)C=2C=CC=CC=2)=N1 ZGBOTUTXJAYYRP-UHFFFAOYSA-N 0.000 claims description 2
- KIKXLLSTHNLOHF-UHFFFAOYSA-N 2-(2-phenylethenyl)pyridin-3-ol Chemical compound OC1=CC=CN=C1C=CC1=CC=CC=C1 KIKXLLSTHNLOHF-UHFFFAOYSA-N 0.000 claims description 2
- ZPWOJLZZENFTPQ-UHFFFAOYSA-N 2-[1-(3-chlorophenyl)prop-1-en-2-yl]pyridine Chemical compound C=1C=CC=NC=1C(C)=CC1=CC=CC(Cl)=C1 ZPWOJLZZENFTPQ-UHFFFAOYSA-N 0.000 claims description 2
- BUINEFRLWWJVFF-UHFFFAOYSA-N 2-[2-(2,3-dichlorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C(=C(Cl)C=CC=2)Cl)=N1 BUINEFRLWWJVFF-UHFFFAOYSA-N 0.000 claims description 2
- LASLNJZLQIMSKY-UHFFFAOYSA-N 2-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C3OCCOC3=CC=2)=N1 LASLNJZLQIMSKY-UHFFFAOYSA-N 0.000 claims description 2
- MZZZHJXIFQDTMS-UHFFFAOYSA-N 2-[2-(2,3-dihydro-1-benzofuran-5-yl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C3CCOC3=CC=2)=N1 MZZZHJXIFQDTMS-UHFFFAOYSA-N 0.000 claims description 2
- KPHWSFUXSRYNDX-UHFFFAOYSA-N 2-[2-(2,3-dimethoxyphenyl)ethenyl]-6-methylpyridine Chemical compound COC1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1OC KPHWSFUXSRYNDX-UHFFFAOYSA-N 0.000 claims description 2
- RLJALDSSWWHHML-UHFFFAOYSA-N 2-[2-(2,5-difluorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C(=CC=C(F)C=2)F)=N1 RLJALDSSWWHHML-UHFFFAOYSA-N 0.000 claims description 2
- DDWVOTDHHHPQLZ-UHFFFAOYSA-N 2-[2-(2-chlorophenyl)ethenyl]-5-ethylpyridine Chemical compound N1=CC(CC)=CC=C1C=CC1=CC=CC=C1Cl DDWVOTDHHHPQLZ-UHFFFAOYSA-N 0.000 claims description 2
- XXMUMJDZFHOPSI-UHFFFAOYSA-N 2-[2-(2-chlorophenyl)ethenyl]-6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C(C=CC=2C(=CC=CC=2)Cl)=N1 XXMUMJDZFHOPSI-UHFFFAOYSA-N 0.000 claims description 2
- YSLLCDKCNRTXFG-UHFFFAOYSA-N 2-[2-(2-chlorophenyl)ethenyl]-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)C(C=CC=2C(=CC=CC=2)Cl)=N1 YSLLCDKCNRTXFG-UHFFFAOYSA-N 0.000 claims description 2
- LRJDQVNAVZNULH-UHFFFAOYSA-N 2-[2-(2-chlorophenyl)ethenyl]pyridin-3-ol Chemical compound OC1=CC=CN=C1C=CC1=CC=CC=C1Cl LRJDQVNAVZNULH-UHFFFAOYSA-N 0.000 claims description 2
- RKHDDFMLRHUOIY-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(Cl)C(Cl)=CC=2)=N1 RKHDDFMLRHUOIY-UHFFFAOYSA-N 0.000 claims description 2
- JLQQTZFBNVJFKJ-UHFFFAOYSA-N 2-[2-(3,4-difluorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(F)C(F)=CC=2)=N1 JLQQTZFBNVJFKJ-UHFFFAOYSA-N 0.000 claims description 2
- JUFMTBBOGLMUAZ-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)ethenyl]-6-methylpyridine Chemical compound C1=C(OC)C(OC)=CC=C1C=CC1=CC=CC(C)=N1 JUFMTBBOGLMUAZ-UHFFFAOYSA-N 0.000 claims description 2
- ZDTKWBJDBIGXFI-UHFFFAOYSA-N 2-[2-(3,5-dibromophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(Br)C=C(Br)C=2)=N1 ZDTKWBJDBIGXFI-UHFFFAOYSA-N 0.000 claims description 2
- IOUORNUTDCWVPG-UHFFFAOYSA-N 2-[2-(3,5-dichlorophenyl)ethenyl]-3-methoxy-6-methylpyridine Chemical compound COC1=CC=C(C)N=C1C=CC1=CC(Cl)=CC(Cl)=C1 IOUORNUTDCWVPG-UHFFFAOYSA-N 0.000 claims description 2
- QQDPSAWRISAMGW-UHFFFAOYSA-N 2-[2-(3,5-dichlorophenyl)ethenyl]-6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C(C=CC=2C=C(Cl)C=C(Cl)C=2)=N1 QQDPSAWRISAMGW-UHFFFAOYSA-N 0.000 claims description 2
- HJKMIHCXIZXHCZ-UHFFFAOYSA-N 2-[2-(3,5-dichlorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(Cl)C=C(Cl)C=2)=N1 HJKMIHCXIZXHCZ-UHFFFAOYSA-N 0.000 claims description 2
- UNXJSNSIEMXAEN-UHFFFAOYSA-N 2-[2-(3,5-dichlorophenyl)ethenyl]pyridin-3-ol Chemical compound OC1=CC=CN=C1C=CC1=CC(Cl)=CC(Cl)=C1 UNXJSNSIEMXAEN-UHFFFAOYSA-N 0.000 claims description 2
- IMBWXCFVJYRTIE-UHFFFAOYSA-N 2-[2-(3,5-difluorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(F)C=C(F)C=2)=N1 IMBWXCFVJYRTIE-UHFFFAOYSA-N 0.000 claims description 2
- NDNMZQKHRDGVAT-UHFFFAOYSA-N 2-[2-(3,5-dimethoxyphenyl)ethenyl]-6-methylpyridine Chemical compound COC1=CC(OC)=CC(C=CC=2N=C(C)C=CC=2)=C1 NDNMZQKHRDGVAT-UHFFFAOYSA-N 0.000 claims description 2
- ZONDUYQYCAKBSZ-UHFFFAOYSA-N 2-[2-(3,5-dimethylphenyl)-2-fluoroethenyl]-6-methylpyridine Chemical compound CC1=CC(C)=CC(C(F)=CC=2N=C(C)C=CC=2)=C1 ZONDUYQYCAKBSZ-UHFFFAOYSA-N 0.000 claims description 2
- FUJMTTHMNRDKSC-UHFFFAOYSA-N 2-[2-(3,5-dimethylphenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC(C)=CC(C=CC=2N=C(C)C=CC=2)=C1 FUJMTTHMNRDKSC-UHFFFAOYSA-N 0.000 claims description 2
- RKOJZFFXCKEVDY-UHFFFAOYSA-N 2-[2-(3-bromophenyl)-2-fluoroethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=C(F)C=2C=C(Br)C=CC=2)=N1 RKOJZFFXCKEVDY-UHFFFAOYSA-N 0.000 claims description 2
- FLBFNEVQJLLCSP-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethenyl]-3-methoxy-6-methylpyridine Chemical compound COC1=CC=C(C)N=C1C=CC1=CC=CC(Cl)=C1 FLBFNEVQJLLCSP-UHFFFAOYSA-N 0.000 claims description 2
- OWTMQUDGYXGREG-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(Cl)C=CC=2)=N1 OWTMQUDGYXGREG-UHFFFAOYSA-N 0.000 claims description 2
- PHMIEAGFDRJBOP-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(Cl)C=CC=2)=N1 PHMIEAGFDRJBOP-UHFFFAOYSA-N 0.000 claims description 2
- DFCVTAYOUSCHSW-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)prop-1-enyl]-6-methylpyridine Chemical compound C=1C=CC(Cl)=CC=1C(C)=CC1=CC=CC(C)=N1 DFCVTAYOUSCHSW-UHFFFAOYSA-N 0.000 claims description 2
- LQIDUBXCGLQYBX-UHFFFAOYSA-N 2-[2-(3-ethoxy-4-fluorophenyl)ethynyl]-6-methylpyridine Chemical compound C1=C(F)C(OCC)=CC(C#CC=2N=C(C)C=CC=2)=C1 LQIDUBXCGLQYBX-UHFFFAOYSA-N 0.000 claims description 2
- MJESGBZIPJVDCC-UHFFFAOYSA-N 2-[2-(3-ethynylphenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(C=CC=2)C#C)=N1 MJESGBZIPJVDCC-UHFFFAOYSA-N 0.000 claims description 2
- IKPDGQGPCQGDPQ-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethenyl]-6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C(C=CC=2C=C(F)C=CC=2)=N1 IKPDGQGPCQGDPQ-UHFFFAOYSA-N 0.000 claims description 2
- KMIYARXEDXQZNV-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(F)C=CC=2)=N1 KMIYARXEDXQZNV-UHFFFAOYSA-N 0.000 claims description 2
- KQTBAJXWEROAGR-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethenyl]-6-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(C=CC=2C=C(F)C=CC=2)=N1 KQTBAJXWEROAGR-UHFFFAOYSA-N 0.000 claims description 2
- UJHKPDGLNNSQRC-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-3-methoxy-6-methylpyridine Chemical compound COC1=CC=C(C)N=C1C#CC1=CC=CC(F)=C1 UJHKPDGLNNSQRC-UHFFFAOYSA-N 0.000 claims description 2
- RLPZRHSTVZNXRG-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-4,6-dimethylpyridine Chemical compound CC1=CC(C)=NC(C#CC=2C=C(F)C=CC=2)=C1 RLPZRHSTVZNXRG-UHFFFAOYSA-N 0.000 claims description 2
- LIUYVEITASCEBM-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-6-methoxypyridine Chemical compound COC1=CC=CC(C#CC=2C=C(F)C=CC=2)=N1 LIUYVEITASCEBM-UHFFFAOYSA-N 0.000 claims description 2
- DWPCZALKHZDWSV-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(C#CC=2C=C(F)C=CC=2)=N1 DWPCZALKHZDWSV-UHFFFAOYSA-N 0.000 claims description 2
- GMRFSSURVOZQBN-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]quinoline Chemical compound FC1=CC=CC(C#CC=2N=C3C=CC=CC3=CC=2)=C1 GMRFSSURVOZQBN-UHFFFAOYSA-N 0.000 claims description 2
- PKLPQOYRNKZJOV-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)ethenyl]-6-methylpyridine Chemical compound COC1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1 PKLPQOYRNKZJOV-UHFFFAOYSA-N 0.000 claims description 2
- STDHINPODVHROK-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)ethynyl]-6-methylpyridine Chemical compound COC1=CC=CC(C#CC=2N=C(C)C=CC=2)=C1 STDHINPODVHROK-UHFFFAOYSA-N 0.000 claims description 2
- NFTQPJVUAHNPTC-UHFFFAOYSA-N 2-[2-(3-nitrophenyl)ethenyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CC(C=CC=2N=CC=CC=2)=C1 NFTQPJVUAHNPTC-UHFFFAOYSA-N 0.000 claims description 2
- HAFHYJOWOREELZ-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=CC(Cl)=CC=2)=N1 HAFHYJOWOREELZ-UHFFFAOYSA-N 0.000 claims description 2
- XLSILTKLRRAEMH-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=CC(F)=CC=2)=N1 XLSILTKLRRAEMH-UHFFFAOYSA-N 0.000 claims description 2
- ADXIEBFYDRXJJB-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=CC(F)=CC=2)=N1 ADXIEBFYDRXJJB-UHFFFAOYSA-N 0.000 claims description 2
- FSKXIZKQSKCRMA-UHFFFAOYSA-N 2-[2-(6-methylpyridin-2-yl)ethenyl]-4-nitrophenol Chemical compound CC1=CC=CC(C=CC=2C(=CC=C(C=2)[N+]([O-])=O)O)=N1 FSKXIZKQSKCRMA-UHFFFAOYSA-N 0.000 claims description 2
- RSLHKKWIKHZOFV-UHFFFAOYSA-N 2-[2-(6-methylpyridin-2-yl)ethenyl]benzoic acid Chemical compound CC1=CC=CC(C=CC=2C(=CC=CC=2)C(O)=O)=N1 RSLHKKWIKHZOFV-UHFFFAOYSA-N 0.000 claims description 2
- FKQSXJZUAVVESJ-UHFFFAOYSA-N 2-[2-(6-methylpyridin-2-yl)ethenyl]phenol Chemical compound CC1=CC=CC(C=CC=2C(=CC=CC=2)O)=N1 FKQSXJZUAVVESJ-UHFFFAOYSA-N 0.000 claims description 2
- YNUNGIXVOKCKJO-UHFFFAOYSA-N 2-[2-(6-methylpyridin-2-yl)ethynyl]pyrimidine Chemical compound CC1=CC=CC(C#CC=2N=CC=CN=2)=N1 YNUNGIXVOKCKJO-UHFFFAOYSA-N 0.000 claims description 2
- XDBWHETZLSYWOC-UHFFFAOYSA-N 2-[2-[2-(2-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxyacetic acid Chemical compound CC1=CC=C(OCC(O)=O)C(C=CC=2C(=CC=CC=2)Cl)=N1 XDBWHETZLSYWOC-UHFFFAOYSA-N 0.000 claims description 2
- GINKSARLRPGCFU-UHFFFAOYSA-N 2-[2-[3,5-bis(trifluoromethyl)phenyl]-1-ethoxyethenyl]-6-methylpyridine Chemical compound C=1C=CC(C)=NC=1C(OCC)=CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GINKSARLRPGCFU-UHFFFAOYSA-N 0.000 claims description 2
- OUSOELMXDDCQNR-UHFFFAOYSA-N 2-[2-[3-(3,5-dichlorophenoxy)phenyl]ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=N1 OUSOELMXDDCQNR-UHFFFAOYSA-N 0.000 claims description 2
- UXXUVXDYSLWNPL-UHFFFAOYSA-N 2-[2-[4-ethoxy-3-(trifluoromethyl)phenyl]ethynyl]-6-methylpyridine Chemical compound C1=C(C(F)(F)F)C(OCC)=CC=C1C#CC1=CC=CC(C)=N1 UXXUVXDYSLWNPL-UHFFFAOYSA-N 0.000 claims description 2
- PCSIZISDGAZMTH-UHFFFAOYSA-N 2-[3-[2-[2-(3-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxypropyl]isoindole-1,3-dione Chemical compound N=1C(C)=CC=C(OCCCN2C(C3=CC=CC=C3C2=O)=O)C=1C=CC1=CC=CC(Cl)=C1 PCSIZISDGAZMTH-UHFFFAOYSA-N 0.000 claims description 2
- CWPBCGPADQMCLP-UHFFFAOYSA-N 2-[6-(2-phenylethenyl)pyridin-2-yl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC(C=CC=2C=CC=CC=2)=N1 CWPBCGPADQMCLP-UHFFFAOYSA-N 0.000 claims description 2
- BDKZKLFZJXCHFO-UHFFFAOYSA-N 2-amino-n-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]-3-phenylpropanamide Chemical compound CC1=CC=CC(C=CC=2C=C(NC(=O)C(N)CC=3C=CC=CC=3)C=CC=2)=N1 BDKZKLFZJXCHFO-UHFFFAOYSA-N 0.000 claims description 2
- VTVNYBZGFPVOIA-UHFFFAOYSA-N 2-amino-n-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]acetamide Chemical compound CC1=CC=CC(C=CC=2C=C(NC(=O)CN)C=CC=2)=N1 VTVNYBZGFPVOIA-UHFFFAOYSA-N 0.000 claims description 2
- GODYVRCUBXFSIF-UHFFFAOYSA-N 2-azido-4-iodo-5-[2-(6-methylpyridin-2-yl)ethynyl]phenol Chemical compound CC1=CC=CC(C#CC=2C(=CC(=C(O)C=2)N=[N+]=[N-])I)=N1 GODYVRCUBXFSIF-UHFFFAOYSA-N 0.000 claims description 2
- QWUYFYXHQLIWCL-UHFFFAOYSA-N 2-ethyl-6-[2-(3-fluorophenyl)ethynyl]pyridine Chemical compound CCC1=CC=CC(C#CC=2C=C(F)C=CC=2)=N1 QWUYFYXHQLIWCL-UHFFFAOYSA-N 0.000 claims description 2
- ZPFRVVJVALUQMT-UHFFFAOYSA-N 2-ethynyl-6-[2-(3-fluorophenyl)ethynyl]pyridine Chemical compound FC1=CC=CC(C#CC=2N=C(C=CC=2)C#C)=C1 ZPFRVVJVALUQMT-UHFFFAOYSA-N 0.000 claims description 2
- SLASRLFBHOEHNS-UHFFFAOYSA-N 2-methoxy-4-[2-(6-methylpyridin-2-yl)ethenyl]phenol Chemical compound C1=C(O)C(OC)=CC(C=CC=2N=C(C)C=CC=2)=C1 SLASRLFBHOEHNS-UHFFFAOYSA-N 0.000 claims description 2
- XKZSEEFYCJSIJU-UHFFFAOYSA-N 2-methyl-5-[2-(6-methylpyridin-2-yl)ethynyl]pyridine Chemical compound C1=NC(C)=CC=C1C#CC1=CC=CC(C)=N1 XKZSEEFYCJSIJU-UHFFFAOYSA-N 0.000 claims description 2
- CZLNWHQVWWRKHG-UHFFFAOYSA-N 2-methyl-6-(2-naphthalen-2-ylethenyl)pyridine Chemical compound CC1=CC=CC(C=CC=2C=C3C=CC=CC3=CC=2)=N1 CZLNWHQVWWRKHG-UHFFFAOYSA-N 0.000 claims description 2
- QFKXUDHGSXTPAU-UHFFFAOYSA-N 2-methyl-6-(2-pyridin-3-ylethenyl)pyridine Chemical compound CC1=CC=CC(C=CC=2C=NC=CC=2)=N1 QFKXUDHGSXTPAU-UHFFFAOYSA-N 0.000 claims description 2
- AERBGEIHFFETEE-UHFFFAOYSA-N 2-methyl-6-(2-pyridin-4-ylethenyl)pyridine Chemical compound CC1=CC=CC(C=CC=2C=CN=CC=2)=N1 AERBGEIHFFETEE-UHFFFAOYSA-N 0.000 claims description 2
- VCABWIQGYHBMHS-UHFFFAOYSA-N 2-methyl-6-(2-thiophen-2-ylethenyl)pyridine Chemical compound CC1=CC=CC(C=CC=2SC=CC=2)=N1 VCABWIQGYHBMHS-UHFFFAOYSA-N 0.000 claims description 2
- QFKXUDHGSXTPAU-BQYQJAHWSA-N 2-methyl-6-[(e)-2-pyridin-3-ylethenyl]pyridine Chemical compound CC1=CC=CC(\C=C\C=2C=NC=CC=2)=N1 QFKXUDHGSXTPAU-BQYQJAHWSA-N 0.000 claims description 2
- AERBGEIHFFETEE-AATRIKPKSA-N 2-methyl-6-[(e)-2-pyridin-4-ylethenyl]pyridine Chemical compound CC1=CC=CC(\C=C\C=2C=CN=CC=2)=N1 AERBGEIHFFETEE-AATRIKPKSA-N 0.000 claims description 2
- FQEYMYMQJYKUOU-UHFFFAOYSA-N 2-methyl-6-[2-(2,3,4-trifluorophenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C(=C(F)C(F)=CC=2)F)=N1 FQEYMYMQJYKUOU-UHFFFAOYSA-N 0.000 claims description 2
- QSMGXZNGQUIZNB-UHFFFAOYSA-N 2-methyl-6-[2-(2,3,5-trichlorophenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C(=C(Cl)C=C(Cl)C=2)Cl)=N1 QSMGXZNGQUIZNB-UHFFFAOYSA-N 0.000 claims description 2
- FMKSMVIWDVEQEA-UHFFFAOYSA-N 2-methyl-6-[2-(2,4,5-trifluorophenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C(=CC(F)=C(F)C=2)F)=N1 FMKSMVIWDVEQEA-UHFFFAOYSA-N 0.000 claims description 2
- GDYSBRVYTYYALX-UHFFFAOYSA-N 2-methyl-6-[2-(2-methylphenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C(=CC=CC=2)C)=N1 GDYSBRVYTYYALX-UHFFFAOYSA-N 0.000 claims description 2
- WSHYTVWFLRRRFM-UHFFFAOYSA-N 2-methyl-6-[2-(3,4,5-trifluorophenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C=C(F)C(F)=C(F)C=2)=N1 WSHYTVWFLRRRFM-UHFFFAOYSA-N 0.000 claims description 2
- LZDBKMARSIOMMV-UHFFFAOYSA-N 2-methyl-6-[2-(3-nitrophenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C=C(C=CC=2)[N+]([O-])=O)=N1 LZDBKMARSIOMMV-UHFFFAOYSA-N 0.000 claims description 2
- ACSFSFJYEAQDMX-UHFFFAOYSA-N 2-methyl-6-[2-(3-phenoxyphenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C=C(OC=3C=CC=CC=3)C=CC=2)=N1 ACSFSFJYEAQDMX-UHFFFAOYSA-N 0.000 claims description 2
- OXAJYAJKPJZNSC-UHFFFAOYSA-N 2-methyl-6-[2-(3-phenylmethoxyphenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OXAJYAJKPJZNSC-UHFFFAOYSA-N 0.000 claims description 2
- FEXWOSUPCZKJSG-UHFFFAOYSA-N 2-methyl-6-[2-(4-methylphenyl)ethenyl]pyridine Chemical compound C1=CC(C)=CC=C1C=CC1=CC=CC(C)=N1 FEXWOSUPCZKJSG-UHFFFAOYSA-N 0.000 claims description 2
- JJTTYIHJDMCSOV-UHFFFAOYSA-N 2-methyl-6-[2-(4-methylphenyl)prop-1-enyl]pyridine Chemical compound C=1C=C(C)C=CC=1C(C)=CC1=CC=CC(C)=N1 JJTTYIHJDMCSOV-UHFFFAOYSA-N 0.000 claims description 2
- JIWAIATXURZOOX-UHFFFAOYSA-N 2-methyl-6-[2-(4-nitrophenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C=CC(=CC=2)[N+]([O-])=O)=N1 JIWAIATXURZOOX-UHFFFAOYSA-N 0.000 claims description 2
- QOIJGDDJQSIKFH-UHFFFAOYSA-N 2-methyl-6-[2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethynyl]pyridine Chemical compound CC1=CC=CC(C#CC=2C=C3CCCCC3=CC=2)=N1 QOIJGDDJQSIKFH-UHFFFAOYSA-N 0.000 claims description 2
- COZLMXHBIKRMKP-UHFFFAOYSA-N 2-methyl-6-[2-(5-methylthiophen-2-yl)ethynyl]pyridine Chemical compound S1C(C)=CC=C1C#CC1=CC=CC(C)=N1 COZLMXHBIKRMKP-UHFFFAOYSA-N 0.000 claims description 2
- CQUZMYAHIQTRKE-UHFFFAOYSA-N 2-methyl-6-[2-[3-(2h-tetrazol-5-yl)phenyl]ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C=C(C=CC=2)C2=NNN=N2)=N1 CQUZMYAHIQTRKE-UHFFFAOYSA-N 0.000 claims description 2
- SDGJZGZHYYNZQF-UHFFFAOYSA-N 2-methyl-6-[2-[3-(trifluoromethyl)phenyl]ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C=C(C=CC=2)C(F)(F)F)=N1 SDGJZGZHYYNZQF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- HTGUJQDUODSGHP-UHFFFAOYSA-N 3-(2-pyridin-2-ylethenyl)benzonitrile Chemical compound N#CC1=CC=CC(C=CC=2N=CC=CC=2)=C1 HTGUJQDUODSGHP-UHFFFAOYSA-N 0.000 claims description 2
- CONGMKDBLUGMLN-UHFFFAOYSA-N 3-[2-(6-methylpyridin-2-yl)ethenyl]aniline Chemical compound CC1=CC=CC(C=CC=2C=C(N)C=CC=2)=N1 CONGMKDBLUGMLN-UHFFFAOYSA-N 0.000 claims description 2
- JQHUJAOOMKXXQD-UHFFFAOYSA-N 3-[2-(6-methylpyridin-2-yl)ethenyl]benzoic acid Chemical compound CC1=CC=CC(C=CC=2C=C(C=CC=2)C(O)=O)=N1 JQHUJAOOMKXXQD-UHFFFAOYSA-N 0.000 claims description 2
- ZPGNLPVAULHGNX-UHFFFAOYSA-N 3-[2-(6-methylpyridin-2-yl)ethynyl]phenol Chemical compound CC1=CC=CC(C#CC=2C=C(O)C=CC=2)=N1 ZPGNLPVAULHGNX-UHFFFAOYSA-N 0.000 claims description 2
- GINVUTIGCMRSDL-VOTSOKGWSA-N 3-[2-[(e)-2-(3,5-dichlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1\C=C\C1=CC(Cl)=CC(Cl)=C1 GINVUTIGCMRSDL-VOTSOKGWSA-N 0.000 claims description 2
- QGHDGXBGUUKSRX-UHFFFAOYSA-N 3-[2-[2-(3,5-dimethylphenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C=CC1=CC(C)=CC(C)=C1 QGHDGXBGUUKSRX-UHFFFAOYSA-N 0.000 claims description 2
- OYRRBOXETMQDRU-UHFFFAOYSA-N 3-[2-[2-(3-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C=CC1=CC=CC(Cl)=C1 OYRRBOXETMQDRU-UHFFFAOYSA-N 0.000 claims description 2
- UOOHIXHSKSSXQU-UHFFFAOYSA-N 3-[2-[2-(3-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxypropan-1-amine Chemical compound CC1=CC=C(OCCCN)C(C=CC=2C=C(Cl)C=CC=2)=N1 UOOHIXHSKSSXQU-UHFFFAOYSA-N 0.000 claims description 2
- QDSQLTMQDHIQRP-UHFFFAOYSA-N 3-[2-[2-(3-chlorophenyl)ethynyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C#CC1=CC=CC(Cl)=C1 QDSQLTMQDHIQRP-UHFFFAOYSA-N 0.000 claims description 2
- JBLWEOAONAYYMW-UHFFFAOYSA-N 3-[2-[2-(3-chlorophenyl)ethynyl]-6-methylpyridin-3-yl]oxypropan-1-amine Chemical compound CC1=CC=C(OCCCN)C(C#CC=2C=C(Cl)C=CC=2)=N1 JBLWEOAONAYYMW-UHFFFAOYSA-N 0.000 claims description 2
- UORLYHVPJNPHCM-UHFFFAOYSA-N 3-[2-[2-(3-fluorophenyl)ethenyl]-6-methylpyridin-3-yl]oxypropan-1-ol Chemical compound CC1=CC=C(OCCCO)C(C=CC=2C=C(F)C=CC=2)=N1 UORLYHVPJNPHCM-UHFFFAOYSA-N 0.000 claims description 2
- IIMCMCSGCOZIQJ-UHFFFAOYSA-N 3-[2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridin-3-yl]oxypropan-1-ol Chemical compound CC1=CC=C(OCCCO)C(C#CC=2C=C(F)C=CC=2)=N1 IIMCMCSGCOZIQJ-UHFFFAOYSA-N 0.000 claims description 2
- JCGSMJRDIWHETC-UHFFFAOYSA-N 3-[2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridin-3-yl]oxypropyl 2,2-dimethylpropanoate Chemical compound CC1=CC=C(OCCCOC(=O)C(C)(C)C)C(C#CC=2C=C(F)C=CC=2)=N1 JCGSMJRDIWHETC-UHFFFAOYSA-N 0.000 claims description 2
- JDQVXDBGMVAHGX-UHFFFAOYSA-N 3-[2-[3-[3-(dimethylamino)propoxy]-6-methylpyridin-2-yl]ethynyl]benzonitrile Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C#CC1=CC=CC(C#N)=C1 JDQVXDBGMVAHGX-UHFFFAOYSA-N 0.000 claims description 2
- GBPXHEGUPJRJDJ-UHFFFAOYSA-N 3-[4-bromo-2-methoxy-6-[2-(6-methylpyridin-2-yl)ethenyl]phenoxy]-n,n-dimethylpropan-1-amine Chemical compound COC1=CC(Br)=CC(C=CC=2N=C(C)C=CC=2)=C1OCCCN(C)C GBPXHEGUPJRJDJ-UHFFFAOYSA-N 0.000 claims description 2
- CGGKQIWDEMMCHS-UHFFFAOYSA-N 3-ethoxy-4-[2-(6-methylpyridin-2-yl)ethenyl]-2-nitrophenol Chemical compound C1=CC(O)=C([N+]([O-])=O)C(OCC)=C1C=CC1=CC=CC(C)=N1 CGGKQIWDEMMCHS-UHFFFAOYSA-N 0.000 claims description 2
- KYCYRJCRRPYQPC-UHFFFAOYSA-N 3-methoxy-6-methyl-2-[2-(6-methylpyridin-3-yl)ethynyl]pyridine;hydrochloride Chemical compound Cl.COC1=CC=C(C)N=C1C#CC1=CC=C(C)N=C1 KYCYRJCRRPYQPC-UHFFFAOYSA-N 0.000 claims description 2
- CLDQCVLTEUDPTO-UHFFFAOYSA-N 3-methyl-6-[2-(6-methylpyridin-2-yl)ethynyl]-1,3-benzoxazol-2-one Chemical compound CC1=CC=CC(C#CC=2C=C3OC(=O)N(C)C3=CC=2)=N1 CLDQCVLTEUDPTO-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- QFASETXYYVWSDW-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)ethenyl]-2-nitrophenol Chemical compound CC1=CC=CC(C=CC=2C=C(C(O)=CC=2)[N+]([O-])=O)=N1 QFASETXYYVWSDW-UHFFFAOYSA-N 0.000 claims description 2
- WJTPIAMXQCPRJH-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)ethenyl]-n-(thiophen-2-ylmethyl)aniline Chemical compound CC1=CC=CC(C=CC=2C=CC(NCC=3SC=CC=3)=CC=2)=N1 WJTPIAMXQCPRJH-UHFFFAOYSA-N 0.000 claims description 2
- ZMQDDGROUNRFMA-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)ethenyl]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CC1=CC=CC(C=CC=2C=CC(=CC=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=N1 ZMQDDGROUNRFMA-UHFFFAOYSA-N 0.000 claims description 2
- DOEXXXTWTOXMCS-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)ethenyl]aniline Chemical compound CC1=CC=CC(C=CC=2C=CC(N)=CC=2)=N1 DOEXXXTWTOXMCS-UHFFFAOYSA-N 0.000 claims description 2
- RUGZZQFOFUHVOY-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)ethynyl]-2-nitrophenol Chemical compound CC1=CC=CC(C#CC=2C=C(C(O)=CC=2)[N+]([O-])=O)=N1 RUGZZQFOFUHVOY-UHFFFAOYSA-N 0.000 claims description 2
- LNEWTAKYXVJZGA-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)ethynyl]benzene-1,2-dicarbonitrile Chemical compound CC1=CC=CC(C#CC=2C=C(C(C#N)=CC=2)C#N)=N1 LNEWTAKYXVJZGA-UHFFFAOYSA-N 0.000 claims description 2
- JXGHUOCAHDFHQI-UHFFFAOYSA-N 4-azido-2-hydroxy-5-iodo-n-[3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]benzamide Chemical compound CC1=CC=CC(C#CC=2C=C(NC(=O)C=3C(=CC(=C(I)C=3)N=[N+]=[N-])O)C=CC=2)=N1 JXGHUOCAHDFHQI-UHFFFAOYSA-N 0.000 claims description 2
- XGASITKVVDDLED-UHFFFAOYSA-N 4-azido-2-hydroxy-N-[3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]benzamide Chemical compound Cc1cccc(n1)C#Cc1cccc(NC(=O)c2ccc(cc2O)N=[N+]=[N-])c1 XGASITKVVDDLED-UHFFFAOYSA-N 0.000 claims description 2
- LNLNOZFSVVKCNI-UHFFFAOYSA-N 4-azido-n-[3-[2-[2-(3-chlorophenyl)ethynyl]-6-methylpyridin-3-yl]oxypropyl]-2-hydroxy-5-iodobenzamide Chemical compound C=1C=CC(Cl)=CC=1C#CC1=NC(C)=CC=C1OCCCNC(=O)C1=CC(I)=C(N=[N+]=[N-])C=C1O LNLNOZFSVVKCNI-UHFFFAOYSA-N 0.000 claims description 2
- LRTQMYLFLXLSFW-UHFFFAOYSA-N 4-azido-n-[3-[2-[2-(3-chlorophenyl)ethynyl]-6-methylpyridin-3-yl]oxypropyl]-2-hydroxybenzamide Chemical compound C=1C=CC(Cl)=CC=1C#CC1=NC(C)=CC=C1OCCCNC(=O)C1=CC=C(N=[N+]=[N-])C=C1O LRTQMYLFLXLSFW-UHFFFAOYSA-N 0.000 claims description 2
- NSGHJJQWYQTMSB-UHFFFAOYSA-N 4-bromo-2-[2-(6-methylpyridin-2-yl)ethenyl]phenol Chemical compound CC1=CC=CC(C=CC=2C(=CC=C(Br)C=2)O)=N1 NSGHJJQWYQTMSB-UHFFFAOYSA-N 0.000 claims description 2
- DFDQFAVSDCDWDO-UHFFFAOYSA-N 4-bromo-2-methoxy-6-[2-(6-methylpyridin-2-yl)ethenyl]phenol Chemical compound COc1cc(Br)cc(C=Cc2cccc(C)n2)c1O DFDQFAVSDCDWDO-UHFFFAOYSA-N 0.000 claims description 2
- BNWAIGHAJOTJSN-UHFFFAOYSA-N 4-chloro-2-[2-(6-methylpyridin-2-yl)ethenyl]phenol Chemical compound CC1=CC=CC(C=CC=2C(=CC=C(Cl)C=2)O)=N1 BNWAIGHAJOTJSN-UHFFFAOYSA-N 0.000 claims description 2
- WKDVOZQBUXLNRI-FNORWQNLSA-N 5-[(e)-2-(6-methylpyridin-2-yl)ethenyl]-2-nitrophenol Chemical compound CC1=CC=CC(\C=C\C=2C=C(O)C(=CC=2)[N+]([O-])=O)=N1 WKDVOZQBUXLNRI-FNORWQNLSA-N 0.000 claims description 2
- WKDVOZQBUXLNRI-ALCCZGGFSA-N 5-[(z)-2-(6-methylpyridin-2-yl)ethenyl]-2-nitrophenol Chemical compound CC1=CC=CC(\C=C/C=2C=C(O)C(=CC=2)[N+]([O-])=O)=N1 WKDVOZQBUXLNRI-ALCCZGGFSA-N 0.000 claims description 2
- FBQZZVVBGFFALD-UHFFFAOYSA-N 5-[2-(6-methylpyridin-2-yl)ethynyl]-2,3-dihydroinden-1-one Chemical compound CC1=CC=CC(C#CC=2C=C3CCC(=O)C3=CC=2)=N1 FBQZZVVBGFFALD-UHFFFAOYSA-N 0.000 claims description 2
- MFCIUCRAEPOBPG-UHFFFAOYSA-N 5-[2-(6-methylpyridin-2-yl)ethynyl]pyrimidine Chemical compound CC1=CC=CC(C#CC=2C=NC=NC=2)=N1 MFCIUCRAEPOBPG-UHFFFAOYSA-N 0.000 claims description 2
- VQTSRZHAPBISEI-UHFFFAOYSA-N 5-[2-bromo-2-(6-methylpyridin-2-yl)ethenyl]-2-nitrophenol Chemical compound CC1=CC=CC(C(Br)=CC=2C=C(O)C(=CC=2)[N+]([O-])=O)=N1 VQTSRZHAPBISEI-UHFFFAOYSA-N 0.000 claims description 2
- IUUAFXGBWAUNKK-UHFFFAOYSA-N 5-azido-2-[2-(6-methylpyridin-2-yl)ethenyl]phenol Chemical compound CC1=CC=CC(C=CC=2C(=CC(=CC=2)N=[N+]=[N-])O)=N1 IUUAFXGBWAUNKK-UHFFFAOYSA-N 0.000 claims description 2
- BVFAOFCJLNOGRD-UHFFFAOYSA-N 5-azido-4-iodo-2-[2-(6-methylpyridin-2-yl)ethenyl]phenol Chemical compound CC1=CC=CC(C=CC=2C(=CC(=C(I)C=2)N=[N+]=[N-])O)=N1 BVFAOFCJLNOGRD-UHFFFAOYSA-N 0.000 claims description 2
- LCMAQJOCQCMORU-UHFFFAOYSA-N 6-(2-phenylethenyl)-n-[3-(trifluoromethyl)phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2N=C(C=CC=3C=CC=CC=3)C=CC=2)=C1 LCMAQJOCQCMORU-UHFFFAOYSA-N 0.000 claims description 2
- MFSODSPULJWESH-UHFFFAOYSA-N 6-(2-phenylethenyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C=CC=2C=CC=CC=2)=N1 MFSODSPULJWESH-UHFFFAOYSA-N 0.000 claims description 2
- IXAWTXIZYPWDQK-UHFFFAOYSA-N 6-[2-(2-chlorophenyl)ethenyl]-2-methylpyridine-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(C)=NC(C=CC=2C(=CC=CC=2)Cl)=C1 IXAWTXIZYPWDQK-UHFFFAOYSA-N 0.000 claims description 2
- ZCAHQNDVWALNIV-UHFFFAOYSA-N 6-[2-(2-chlorophenyl)ethenyl]pyridin-3-ol Chemical compound N1=CC(O)=CC=C1C=CC1=CC=CC=C1Cl ZCAHQNDVWALNIV-UHFFFAOYSA-N 0.000 claims description 2
- WMRWYPHTUIELPI-UHFFFAOYSA-N 6-[2-(3,5-dichlorophenyl)ethenyl]-2-methylpyridin-3-ol Chemical compound C1=C(O)C(C)=NC(C=CC=2C=C(Cl)C=C(Cl)C=2)=C1 WMRWYPHTUIELPI-UHFFFAOYSA-N 0.000 claims description 2
- NMDWDTGAJGKMGY-UHFFFAOYSA-N 6-[2-(3,5-dichlorophenyl)ethenyl]-3-methoxy-2-methylpyridine Chemical compound N1=C(C)C(OC)=CC=C1C=CC1=CC(Cl)=CC(Cl)=C1 NMDWDTGAJGKMGY-UHFFFAOYSA-N 0.000 claims description 2
- ISTKUMVGSKRGDR-UHFFFAOYSA-N 6-[2-(3-chlorophenyl)ethenyl]-2-methylpyridin-3-ol Chemical compound C1=C(O)C(C)=NC(C=CC=2C=C(Cl)C=CC=2)=C1 ISTKUMVGSKRGDR-UHFFFAOYSA-N 0.000 claims description 2
- CBSCMLSUDSAFEG-UHFFFAOYSA-N 6-[2-(3-fluorophenyl)ethynyl]-n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC(C#CC=2C=C(F)C=CC=2)=N1 CBSCMLSUDSAFEG-UHFFFAOYSA-N 0.000 claims description 2
- FANYTZIQHUOWCQ-UHFFFAOYSA-N 6-[2-(3-fluorophenyl)ethynyl]-n-[(5-methoxy-2,3-dihydro-1h-inden-2-yl)methyl]-2-methylpyridine-3-carboxamide Chemical compound C1C2=CC(OC)=CC=C2CC1CNC(=O)C(C(=N1)C)=CC=C1C#CC1=CC=CC(F)=C1 FANYTZIQHUOWCQ-UHFFFAOYSA-N 0.000 claims description 2
- MHGCZFLREWWYEV-UHFFFAOYSA-N 6-[2-(3-fluorophenyl)ethynyl]pyridine-3-carboxylic acid Chemical compound N1=CC(C(=O)O)=CC=C1C#CC1=CC=CC(F)=C1 MHGCZFLREWWYEV-UHFFFAOYSA-N 0.000 claims description 2
- QZHALUSBXAZGLJ-UHFFFAOYSA-N 6-[2-(6-methylpyridin-2-yl)ethynyl]-2,3-dihydroinden-1-one Chemical compound CC1=CC=CC(C#CC=2C=C3C(=O)CCC3=CC=2)=N1 QZHALUSBXAZGLJ-UHFFFAOYSA-N 0.000 claims description 2
- IIXYGQZNERUFLB-UHFFFAOYSA-N 6-[2-(6-methylpyridin-2-yl)ethynyl]-3,4-dihydro-1h-quinolin-2-one Chemical compound CC1=CC=CC(C#CC=2C=C3CCC(=O)NC3=CC=2)=N1 IIXYGQZNERUFLB-UHFFFAOYSA-N 0.000 claims description 2
- VANDBORJEYJCTH-UHFFFAOYSA-N 6-azido-2,4-diiodo-3-[2-(6-methylpyridin-2-yl)ethynyl]phenol Chemical compound CC1=CC=CC(C#CC=2C(=C(O)C(N=[N+]=[N-])=CC=2I)I)=N1 VANDBORJEYJCTH-UHFFFAOYSA-N 0.000 claims description 2
- VZNUVALUIMQCKX-UHFFFAOYSA-N 6-methyl-2-(2-phenylethenyl)-1h-pyrimidin-4-one Chemical compound CC1=CC(O)=NC(C=CC=2C=CC=CC=2)=N1 VZNUVALUIMQCKX-UHFFFAOYSA-N 0.000 claims description 2
- YDWCMHMLMAYBOQ-VOTSOKGWSA-N 6-methyl-2-[(E)-2-pyridin-2-ylethenyl]pyridin-3-ol Chemical compound CC1=CC=C(O)C(\C=C\C=2N=CC=CC=2)=N1 YDWCMHMLMAYBOQ-VOTSOKGWSA-N 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- DWOCEOJVCFJYHE-UHFFFAOYSA-N [1-[6-[2-(2-chlorophenyl)ethenyl]-2-methylpyridine-3-carbonyl]piperidin-4-yl]-(4-fluorophenyl)methanone Chemical compound C=1C=C(C(=O)N2CCC(CC2)C(=O)C=2C=CC(F)=CC=2)C(C)=NC=1C=CC1=CC=CC=C1Cl DWOCEOJVCFJYHE-UHFFFAOYSA-N 0.000 claims description 2
- PDXBNAZLCRYRHS-UHFFFAOYSA-N [2,6-ditert-butyl-4-[2-(6-methylpyridin-2-yl)ethenyl]phenyl] acetate Chemical compound C1=C(C(C)(C)C)C(OC(=O)C)=C(C(C)(C)C)C=C1C=CC1=CC=CC(C)=N1 PDXBNAZLCRYRHS-UHFFFAOYSA-N 0.000 claims description 2
- TZSIHFULLZNEEW-UHFFFAOYSA-N [2-[2-(2-chlorophenyl)ethenyl]-6-methylpyridin-3-yl] acetate Chemical compound CC(=O)OC1=CC=C(C)N=C1C=CC1=CC=CC=C1Cl TZSIHFULLZNEEW-UHFFFAOYSA-N 0.000 claims description 2
- FRWGAHLSIKYRAD-UHFFFAOYSA-N [2-[2-(2-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]-morpholin-4-ylmethanone Chemical compound C=1C=CC=C(Cl)C=1C=CC1=NC(C)=CC=C1C(=O)N1CCOCC1 FRWGAHLSIKYRAD-UHFFFAOYSA-N 0.000 claims description 2
- AERXNWTWYLJXHX-UHFFFAOYSA-N [2-[2-(2-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]methanol Chemical compound CC1=CC=C(CO)C(C=CC=2C(=CC=CC=2)Cl)=N1 AERXNWTWYLJXHX-UHFFFAOYSA-N 0.000 claims description 2
- KFTYRMUMHLZCDI-UHFFFAOYSA-N [2-[2-(2-chlorophenyl)ethenyl]pyridin-3-yl] acetate Chemical compound CC(=O)OC1=CC=CN=C1C=CC1=CC=CC=C1Cl KFTYRMUMHLZCDI-UHFFFAOYSA-N 0.000 claims description 2
- PWBZOHVAHQVFJA-UHFFFAOYSA-N [2-[2-(3,5-dichlorophenyl)ethenyl]-6-methylpyridin-3-yl] acetate Chemical compound CC(=O)OC1=CC=C(C)N=C1C=CC1=CC(Cl)=CC(Cl)=C1 PWBZOHVAHQVFJA-UHFFFAOYSA-N 0.000 claims description 2
- SOQUKJVMBVJAIA-UHFFFAOYSA-N [2-[2-(3,5-dichlorophenyl)ethenyl]pyridin-3-yl] acetate Chemical compound CC(=O)OC1=CC=CN=C1C=CC1=CC(Cl)=CC(Cl)=C1 SOQUKJVMBVJAIA-UHFFFAOYSA-N 0.000 claims description 2
- FVZOKTDMDOBXJN-UHFFFAOYSA-N [2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridin-4-yl]-morpholin-4-ylmethanone Chemical compound N=1C(C)=CC(C(=O)N2CCOCC2)=CC=1C#CC1=CC=CC(F)=C1 FVZOKTDMDOBXJN-UHFFFAOYSA-N 0.000 claims description 2
- PBTPZSVLSMOVPW-UHFFFAOYSA-N [2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridin-4-yl]methanol Chemical compound CC1=CC(CO)=CC(C#CC=2C=C(F)C=CC=2)=N1 PBTPZSVLSMOVPW-UHFFFAOYSA-N 0.000 claims description 2
- BMKZYFHZCMHZSN-UHFFFAOYSA-N [2-[2-(6-methylpyridin-2-yl)ethenyl]-4-nitrophenyl] acetate Chemical compound CC(=O)OC1=CC=C([N+]([O-])=O)C=C1C=CC1=CC=CC(C)=N1 BMKZYFHZCMHZSN-UHFFFAOYSA-N 0.000 claims description 2
- HCWMEUHLVVQXDX-UHFFFAOYSA-N [2-[2-(6-methylpyridin-2-yl)ethenyl]-6-nitrophenyl] acetate Chemical compound C1=CC=C([N+]([O-])=O)C(OC(=O)C)=C1C=CC1=CC=CC(C)=N1 HCWMEUHLVVQXDX-UHFFFAOYSA-N 0.000 claims description 2
- IWPRFNPCOWLGEX-UHFFFAOYSA-N [2-methyl-6-(2-phenylethenyl)pyridin-3-yl] acetate Chemical compound N1=C(C)C(OC(=O)C)=CC=C1C=CC1=CC=CC=C1 IWPRFNPCOWLGEX-UHFFFAOYSA-N 0.000 claims description 2
- SPYRWZPHRPACGG-UHFFFAOYSA-N [3-(hydroxymethyl)-5-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methanol Chemical compound CC1=CC=CC(C#CC=2C=C(CO)C=C(CO)C=2)=N1 SPYRWZPHRPACGG-UHFFFAOYSA-N 0.000 claims description 2
- SUNUSYRFQWHYNM-UHFFFAOYSA-N [3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]methanol Chemical compound CC1=CC=CC(C=CC=2C=C(CO)C=CC=2)=N1 SUNUSYRFQWHYNM-UHFFFAOYSA-N 0.000 claims description 2
- KGIWHDRBIZOVHB-UHFFFAOYSA-N [3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]-phenylmethanone Chemical compound CC1=CC=CC(C#CC=2C=C(C=CC=2)C(=O)C=2C=CC=CC=2)=N1 KGIWHDRBIZOVHB-UHFFFAOYSA-N 0.000 claims description 2
- JXFCEBHIXVYVFX-UHFFFAOYSA-N [3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methanol Chemical compound CC1=CC=CC(C#CC=2C=C(CO)C=CC=2)=N1 JXFCEBHIXVYVFX-UHFFFAOYSA-N 0.000 claims description 2
- JSAMCRQFIQJQKS-UHFFFAOYSA-N [4-(4-azido-2-hydroxybenzoyl)piperazin-1-yl]-[6-[2-(3-fluorophenyl)ethynyl]-2-methylpyridin-3-yl]methanone Chemical compound CC1=NC(C#CC=2C=C(F)C=CC=2)=CC=C1C(=O)N(CC1)CCN1C(=O)C1=CC=C(N=[N+]=[N-])C=C1O JSAMCRQFIQJQKS-UHFFFAOYSA-N 0.000 claims description 2
- PMKZENGLSIRFGW-UHFFFAOYSA-N [4-[2-(6-methylpyridin-2-yl)ethenyl]-2-nitrophenyl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1C=CC1=CC=CC(C)=N1 PMKZENGLSIRFGW-UHFFFAOYSA-N 0.000 claims description 2
- YVOUIVJKJWXMAF-MDZDMXLPSA-N [6-[(e)-2-phenylethenyl]pyridin-2-yl]methanol Chemical compound OCC1=CC=CC(\C=C\C=2C=CC=CC=2)=N1 YVOUIVJKJWXMAF-MDZDMXLPSA-N 0.000 claims description 2
- YVOUIVJKJWXMAF-KTKRTIGZSA-N [6-[(z)-2-phenylethenyl]pyridin-2-yl]methanol Chemical compound OCC1=CC=CC(\C=C/C=2C=CC=CC=2)=N1 YVOUIVJKJWXMAF-KTKRTIGZSA-N 0.000 claims description 2
- OJIRIZYKNSRGPQ-UHFFFAOYSA-N [6-[2-(2-chlorophenyl)ethenyl]-2-methylpyridin-3-yl]methanol Chemical compound C1=C(CO)C(C)=NC(C=CC=2C(=CC=CC=2)Cl)=C1 OJIRIZYKNSRGPQ-UHFFFAOYSA-N 0.000 claims description 2
- STFZGNLNGPXOIK-UHFFFAOYSA-N [6-[2-(2-chlorophenyl)ethenyl]pyridin-3-yl] acetate Chemical compound N1=CC(OC(=O)C)=CC=C1C=CC1=CC=CC=C1Cl STFZGNLNGPXOIK-UHFFFAOYSA-N 0.000 claims description 2
- UVCJZTPPXCCHJK-UHFFFAOYSA-N [6-[2-(3,5-dichlorophenyl)ethenyl]-2-methylpyridin-3-yl] acetate Chemical compound N1=C(C)C(OC(=O)C)=CC=C1C=CC1=CC(Cl)=CC(Cl)=C1 UVCJZTPPXCCHJK-UHFFFAOYSA-N 0.000 claims description 2
- MNPPHPDOMPGBRH-UHFFFAOYSA-N [6-[2-(3-fluorophenyl)ethynyl]-2-methylpyridin-3-yl]-piperazin-1-ylmethanone Chemical compound CC1=NC(C#CC=2C=C(F)C=CC=2)=CC=C1C(=O)N1CCNCC1 MNPPHPDOMPGBRH-UHFFFAOYSA-N 0.000 claims description 2
- ZIGDJMBAJHDWJD-UHFFFAOYSA-N [6-[2-(3-fluorophenyl)ethynyl]-2-methylpyridin-3-yl]methanol Chemical compound C1=C(CO)C(C)=NC(C#CC=2C=C(F)C=CC=2)=C1 ZIGDJMBAJHDWJD-UHFFFAOYSA-N 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- HPISARXJLHVEOF-UHFFFAOYSA-N ethyl 2-[2-[2-(2-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxyacetate Chemical compound CCOC(=O)COC1=CC=C(C)N=C1C=CC1=CC=CC=C1Cl HPISARXJLHVEOF-UHFFFAOYSA-N 0.000 claims description 2
- AGMKUVHHWFZYHZ-UHFFFAOYSA-N ethyl 2-[benzyl-[2-[2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridin-3-yl]oxyacetyl]amino]acetate Chemical compound C=1C=C(C)N=C(C#CC=2C=C(F)C=CC=2)C=1OCC(=O)N(CC(=O)OCC)CC1=CC=CC=C1 AGMKUVHHWFZYHZ-UHFFFAOYSA-N 0.000 claims description 2
- GEJUPRQRBSBVHM-UHFFFAOYSA-N ethyl 3-[2-(6-methylpyridin-2-yl)ethynyl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C#CC=2N=C(C)C=CC=2)=C1 GEJUPRQRBSBVHM-UHFFFAOYSA-N 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- HUNGDNCRSLZMEL-UHFFFAOYSA-N n,n-diethyl-3-[2-(6-methylpyridin-2-yl)ethenyl]aniline Chemical compound CCN(CC)C1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1 HUNGDNCRSLZMEL-UHFFFAOYSA-N 0.000 claims description 2
- YCBIRDRVGOAPBB-UHFFFAOYSA-N n,n-dimethyl-1-[3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N(C)C)N=CN1C1=CC=CC(C#CC=2N=C(C)C=CC=2)=C1 YCBIRDRVGOAPBB-UHFFFAOYSA-N 0.000 claims description 2
- WSKORZBASRKRSM-UHFFFAOYSA-N n-(1-dimethoxyphosphorylethyl)-4-[2-(6-methylpyridin-2-yl)ethenyl]aniline Chemical compound C1=CC(NC(C)P(=O)(OC)OC)=CC=C1C=CC1=CC=CC(C)=N1 WSKORZBASRKRSM-UHFFFAOYSA-N 0.000 claims description 2
- QJGFCRZMHYNMFD-UHFFFAOYSA-N n-(cyclohexylmethyl)-3-[2-(6-methylpyridin-2-yl)ethenyl]aniline;hydrochloride Chemical compound Cl.CC1=CC=CC(C=CC=2C=C(NCC3CCCCC3)C=CC=2)=N1 QJGFCRZMHYNMFD-UHFFFAOYSA-N 0.000 claims description 2
- XWKZBXLTMIWSAR-UHFFFAOYSA-N n-(cyclohexylmethyl)-4-[2-(6-methylpyridin-2-yl)ethenyl]aniline Chemical compound CC1=CC=CC(C=CC=2C=CC(NCC3CCCCC3)=CC=2)=N1 XWKZBXLTMIWSAR-UHFFFAOYSA-N 0.000 claims description 2
- GHVQXMCTVXAEDJ-UHFFFAOYSA-N n-[(2,3-dimethoxy-7-nitroquinoxalin-5-yl)methyl]-3-[2-(6-methylpyridin-2-yl)ethenyl]aniline Chemical compound C=12N=C(OC)C(OC)=NC2=CC([N+]([O-])=O)=CC=1CNC(C=1)=CC=CC=1C=CC1=CC=CC(C)=N1 GHVQXMCTVXAEDJ-UHFFFAOYSA-N 0.000 claims description 2
- WHXLCBNQSRMONO-UHFFFAOYSA-N n-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]-2-phenylacetamide Chemical compound CC1=CC=CC(C=CC=2C=C(NC(=O)CC=3C=CC=CC=3)C=CC=2)=N1 WHXLCBNQSRMONO-UHFFFAOYSA-N 0.000 claims description 2
- VXKZNJMKHUNXLI-UHFFFAOYSA-N n-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]cyclohexanecarboxamide Chemical compound CC1=CC=CC(C=CC=2C=C(NC(=O)C3CCCCC3)C=CC=2)=N1 VXKZNJMKHUNXLI-UHFFFAOYSA-N 0.000 claims description 2
- LWAHKNCLKDKOGE-UHFFFAOYSA-N n-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]thiophene-2-carboxamide Chemical compound CC1=CC=CC(C=CC=2C=C(NC(=O)C=3SC=CC=3)C=CC=2)=N1 LWAHKNCLKDKOGE-UHFFFAOYSA-N 0.000 claims description 2
- IJSGAPFXQYGNNY-UHFFFAOYSA-N n-methyl-n-[3-[4-[2-(6-methylpyridin-2-yl)ethenyl]phenoxy]propyl]acetamide Chemical compound C1=CC(OCCCN(C)C(C)=O)=CC=C1C=CC1=CC=CC(C)=N1 IJSGAPFXQYGNNY-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000018198 spasticity Diseases 0.000 claims description 2
- IULOCEKPADTWDT-UHFFFAOYSA-N tert-butyl 2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridine-4-carboxylate Chemical compound CC1=CC(C(=O)OC(C)(C)C)=CC(C#CC=2C=C(F)C=CC=2)=N1 IULOCEKPADTWDT-UHFFFAOYSA-N 0.000 claims description 2
- FAJFHFNHZWPFBE-UHFFFAOYSA-N tert-butyl 6-[2-(3-fluorophenyl)ethynyl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC(C)(C)C)=CC=C1C#CC1=CC=CC(F)=C1 FAJFHFNHZWPFBE-UHFFFAOYSA-N 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- WZHDDGLXLMYETM-UHFFFAOYSA-N trimethyl-[2-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]ethynyl]silane Chemical compound CC1=CC=CC(C=CC=2C=C(C=CC=2)C#C[Si](C)(C)C)=N1 WZHDDGLXLMYETM-UHFFFAOYSA-N 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- MAQAGRJURDEYDQ-UHFFFAOYSA-N 6-methylpyridine Chemical compound CC1=C=CC=C[N]1 MAQAGRJURDEYDQ-UHFFFAOYSA-N 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- HRMPKWFLBWVYIS-UHFFFAOYSA-N 1-[3-[6-methyl-2-(2-phenylethynyl)pyridin-3-yl]oxypropyl]piperidin-3-ol Chemical compound C=1C=CC=CC=1C#CC1=NC(C)=CC=C1OCCCN1CCCC(O)C1 HRMPKWFLBWVYIS-UHFFFAOYSA-N 0.000 claims 1
- UCLXPXNCJNTRJI-UHFFFAOYSA-N 1-[3-[6-methyl-2-(2-phenylethynyl)pyridin-3-yl]oxypropyl]piperidin-4-ol Chemical compound C=1C=CC=CC=1C#CC1=NC(C)=CC=C1OCCCN1CCC(O)CC1 UCLXPXNCJNTRJI-UHFFFAOYSA-N 0.000 claims 1
- KCSONDPEIWSCSO-UHFFFAOYSA-N 2-[2-(2,5-difluorophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C(=CC=C(F)C=2)F)=N1 KCSONDPEIWSCSO-UHFFFAOYSA-N 0.000 claims 1
- FHUVBJVWOYKTSG-UHFFFAOYSA-N 2-[2-(2-ethoxy-3,6-difluorophenyl)ethynyl]-6-methylpyridine Chemical compound CCOC1=C(F)C=CC(F)=C1C#CC1=CC=CC(C)=N1 FHUVBJVWOYKTSG-UHFFFAOYSA-N 0.000 claims 1
- XSMWNEXQCVDBEY-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(Cl)C(Cl)=CC=2)=N1 XSMWNEXQCVDBEY-UHFFFAOYSA-N 0.000 claims 1
- XSKBFZGPCXVAQD-UHFFFAOYSA-N 2-[2-(3,4-difluorophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(F)C(F)=CC=2)=N1 XSKBFZGPCXVAQD-UHFFFAOYSA-N 0.000 claims 1
- UNMWLAOYWMMNSA-UHFFFAOYSA-N 2-[2-(3,5-dibromophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(Br)C=C(Br)C=2)=N1 UNMWLAOYWMMNSA-UHFFFAOYSA-N 0.000 claims 1
- ZNVBPIQDLXSOAX-UHFFFAOYSA-N 2-[2-(3,5-dichlorophenyl)ethenyl]-3-methoxypyridine Chemical compound COC1=CC=CN=C1C=CC1=CC(Cl)=CC(Cl)=C1 ZNVBPIQDLXSOAX-UHFFFAOYSA-N 0.000 claims 1
- NZLCXPSFFADWRF-UHFFFAOYSA-N 2-[2-(3,5-dichlorophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(Cl)C=C(Cl)C=2)=N1 NZLCXPSFFADWRF-UHFFFAOYSA-N 0.000 claims 1
- IDFBRTPULOIPPY-UHFFFAOYSA-N 2-[2-(3,5-difluorophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(F)C=C(F)C=2)=N1 IDFBRTPULOIPPY-UHFFFAOYSA-N 0.000 claims 1
- IRDDRVRZFAUJGG-UHFFFAOYSA-N 2-[2-(3,5-dimethylphenyl)ethynyl]-3-methoxy-6-methylpyridine Chemical compound COC1=CC=C(C)N=C1C#CC1=CC(C)=CC(C)=C1 IRDDRVRZFAUJGG-UHFFFAOYSA-N 0.000 claims 1
- VKAUPFRKTVQUJC-UHFFFAOYSA-N 2-[2-(3,5-dimethylphenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC(C)=CC(C#CC=2N=C(C)C=CC=2)=C1 VKAUPFRKTVQUJC-UHFFFAOYSA-N 0.000 claims 1
- SFHKKZDMFOEMLO-UHFFFAOYSA-N 2-[2-(3-ethynylphenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(C=CC=2)C#C)=N1 SFHKKZDMFOEMLO-UHFFFAOYSA-N 0.000 claims 1
- LFVASYNASMGQTB-UHFFFAOYSA-N 2-[2-[3,6-difluoro-2-[(2-methylpropan-2-yl)oxy]phenyl]ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C(=C(F)C=CC=2F)OC(C)(C)C)=N1 LFVASYNASMGQTB-UHFFFAOYSA-N 0.000 claims 1
- DQKKIGZVAILNBS-UHFFFAOYSA-N 2-[2-[4-methoxy-3-(trifluoromethyl)phenyl]ethynyl]-6-methylpyridine Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C#CC1=CC=CC(C)=N1 DQKKIGZVAILNBS-UHFFFAOYSA-N 0.000 claims 1
- IWXWBSZRWUDHDW-UHFFFAOYSA-N 2-methyl-6-(2-naphthalen-1-ylethenyl)pyridine Chemical compound CC1=CC=CC(C=CC=2C3=CC=CC=C3C=CC=2)=N1 IWXWBSZRWUDHDW-UHFFFAOYSA-N 0.000 claims 1
- KLKCXIQOBMQOPL-UHFFFAOYSA-N 2-methyl-6-[2-(2,3,4-trifluorophenyl)ethynyl]pyridine Chemical compound CC1=CC=CC(C#CC=2C(=C(F)C(F)=CC=2)F)=N1 KLKCXIQOBMQOPL-UHFFFAOYSA-N 0.000 claims 1
- OONJJBQNBKMFFT-UHFFFAOYSA-N 2-methyl-6-[2-(2,3,5-trichlorophenyl)ethynyl]pyridine Chemical compound CC1=CC=CC(C#CC=2C(=C(Cl)C=C(Cl)C=2)Cl)=N1 OONJJBQNBKMFFT-UHFFFAOYSA-N 0.000 claims 1
- FTGVBHXWNKCCMS-UHFFFAOYSA-N 2-methyl-6-[2-(2,3,5-trimethylphenyl)ethynyl]pyridine Chemical compound CC1=CC(C)=C(C)C(C#CC=2N=C(C)C=CC=2)=C1 FTGVBHXWNKCCMS-UHFFFAOYSA-N 0.000 claims 1
- BTASHIOTGXPUOS-UHFFFAOYSA-N 2-methyl-6-[2-(2-methylphenyl)ethynyl]pyridine Chemical compound CC1=CC=CC(C#CC=2C(=CC=CC=2)C)=N1 BTASHIOTGXPUOS-UHFFFAOYSA-N 0.000 claims 1
- ABCCXFNEJPKVCV-UHFFFAOYSA-N 2-methyl-6-[2-(3-methylsulfonylphenyl)ethynyl]pyridine Chemical compound CC1=CC=CC(C#CC=2C=C(C=CC=2)S(C)(=O)=O)=N1 ABCCXFNEJPKVCV-UHFFFAOYSA-N 0.000 claims 1
- PGFOPILFCBXMFO-UHFFFAOYSA-N 2-methyl-6-[2-(3-nitrophenyl)ethynyl]pyridine Chemical compound CC1=CC=CC(C#CC=2C=C(C=CC=2)[N+]([O-])=O)=N1 PGFOPILFCBXMFO-UHFFFAOYSA-N 0.000 claims 1
- CFIIVZHKCDMONP-UHFFFAOYSA-N 2-methyl-6-[2-[3-(1,2,4-triazol-1-yl)phenyl]ethynyl]pyridine Chemical compound CC1=CC=CC(C#CC=2C=C(C=CC=2)N2N=CN=C2)=N1 CFIIVZHKCDMONP-UHFFFAOYSA-N 0.000 claims 1
- SJBWUBBLOZYBMP-UHFFFAOYSA-N 2-methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine Chemical compound CC1=CC=CC(C#CC=2C=C(C=CC=2)C(F)(F)F)=N1 SJBWUBBLOZYBMP-UHFFFAOYSA-N 0.000 claims 1
- NMLKDPNBPGIFRD-UHFFFAOYSA-N 3-[2-(6-methylpyridin-2-yl)ethenyl]-n-(thiophen-2-ylmethyl)aniline;hydrochloride Chemical compound Cl.CC1=CC=CC(C=CC=2C=C(NCC=3SC=CC=3)C=CC=2)=N1 NMLKDPNBPGIFRD-UHFFFAOYSA-N 0.000 claims 1
- GLKZBNXOLYXUOU-UHFFFAOYSA-N 3-[2-[2-(2,3-dichlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C=CC1=CC=CC(Cl)=C1Cl GLKZBNXOLYXUOU-UHFFFAOYSA-N 0.000 claims 1
- SEYNCGWEMGPMKP-UHFFFAOYSA-N 3-[2-[2-(2,4-dichlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C=CC1=CC=C(Cl)C=C1Cl SEYNCGWEMGPMKP-UHFFFAOYSA-N 0.000 claims 1
- HIHBUXNNAGQXOI-UHFFFAOYSA-N 3-[2-[2-(2,6-dichlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C=CC1=C(Cl)C=CC=C1Cl HIHBUXNNAGQXOI-UHFFFAOYSA-N 0.000 claims 1
- GYMLBEQJLVRUQG-UHFFFAOYSA-N 3-[2-[2-(3,4-dichlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C=CC1=CC=C(Cl)C(Cl)=C1 GYMLBEQJLVRUQG-UHFFFAOYSA-N 0.000 claims 1
- GINVUTIGCMRSDL-UHFFFAOYSA-N 3-[2-[2-(3,5-dichlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C=CC1=CC(Cl)=CC(Cl)=C1 GINVUTIGCMRSDL-UHFFFAOYSA-N 0.000 claims 1
- AGGWOQSRHJDNLY-UHFFFAOYSA-N 3-[2-[2-(3,5-dichlorophenyl)ethenyl]pyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=CN=C1C=CC1=CC(Cl)=CC(Cl)=C1 AGGWOQSRHJDNLY-UHFFFAOYSA-N 0.000 claims 1
- KKILLVLMMSPSOJ-UHFFFAOYSA-N 3-[2-[2-(3,5-dichlorophenyl)ethynyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C#CC1=CC(Cl)=CC(Cl)=C1 KKILLVLMMSPSOJ-UHFFFAOYSA-N 0.000 claims 1
- ICEPCYJIPUZSGU-UHFFFAOYSA-N 3-[2-[2-(3,5-dichlorophenyl)ethynyl]-6-methylpyridin-3-yl]oxypropan-1-amine Chemical compound CC1=CC=C(OCCCN)C(C#CC=2C=C(Cl)C=C(Cl)C=2)=N1 ICEPCYJIPUZSGU-UHFFFAOYSA-N 0.000 claims 1
- YIABWJNVAAOBMN-UHFFFAOYSA-N 3-[2-[2-(3,5-dichlorophenyl)prop-1-enyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C=C(C)C1=CC(Cl)=CC(Cl)=C1 YIABWJNVAAOBMN-UHFFFAOYSA-N 0.000 claims 1
- NBTKHKQJFAHUOA-UHFFFAOYSA-N 3-[2-[2-(4-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C=CC1=CC=C(Cl)C=C1 NBTKHKQJFAHUOA-UHFFFAOYSA-N 0.000 claims 1
- NLCWQOQGIMHJHX-UHFFFAOYSA-N 3-methoxy-6-methyl-2-[2-(3-methylphenyl)ethynyl]pyridine Chemical compound COC1=CC=C(C)N=C1C#CC1=CC=CC(C)=C1 NLCWQOQGIMHJHX-UHFFFAOYSA-N 0.000 claims 1
- VWPKTTBIPBQNCZ-UHFFFAOYSA-N 4-[4-[2-(6-methylpyridin-2-yl)ethenyl]anilino]-4-oxobutanoic acid Chemical compound CC1=CC=CC(C=CC=2C=CC(NC(=O)CCC(O)=O)=CC=2)=N1 VWPKTTBIPBQNCZ-UHFFFAOYSA-N 0.000 claims 1
- AAXIMSDMNMYWJG-UHFFFAOYSA-N 4-[6-[2-(3-fluorophenyl)ethynyl]-2-methylpyridine-3-carbonyl]piperazine-1-carboxylic acid Chemical compound CC1=NC(C#CC=2C=C(F)C=CC=2)=CC=C1C(=O)N1CCN(C(O)=O)CC1 AAXIMSDMNMYWJG-UHFFFAOYSA-N 0.000 claims 1
- ODQPZHOXLYATLC-UHFFFAOYSA-N 5-chloro-1,3-benzodioxole Chemical compound ClC1=CC=C2OCOC2=C1 ODQPZHOXLYATLC-UHFFFAOYSA-N 0.000 claims 1
- SQJUMSDXIABPHQ-UHFFFAOYSA-N 6-[2-(3,5-dichlorophenyl)ethynyl]-5-[3-(dimethylamino)propoxy]pyridine-2-carboxylic acid Chemical compound CN(C)CCCOC1=CC=C(C(O)=O)N=C1C#CC1=CC(Cl)=CC(Cl)=C1 SQJUMSDXIABPHQ-UHFFFAOYSA-N 0.000 claims 1
- JEAVIRYCMBDJIU-UHFFFAOYSA-N 6-methyl-1h-pyridin-2-one Chemical compound CC1=CC=CC(O)=N1 JEAVIRYCMBDJIU-UHFFFAOYSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- FJJBLWKZWFUGJT-UHFFFAOYSA-N [2-(2-phenylethynyl)pyridin-3-yl] acetate Chemical compound CC(=O)OC1=CC=CN=C1C#CC1=CC=CC=C1 FJJBLWKZWFUGJT-UHFFFAOYSA-N 0.000 claims 1
- XJQKBQJCAXEZOQ-UHFFFAOYSA-N [6-methyl-2-[2-(3-methylphenyl)ethynyl]pyridin-3-yl] acetate Chemical compound CC(=O)OC1=CC=C(C)N=C1C#CC1=CC=CC(C)=C1 XJQKBQJCAXEZOQ-UHFFFAOYSA-N 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- NSUBJIPSPLEECA-UHFFFAOYSA-N ethyl 1-[3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]-1,2,4-triazole-3-carboxylate Chemical compound N1=C(C(=O)OCC)N=CN1C1=CC=CC(C#CC=2N=C(C)C=CC=2)=C1 NSUBJIPSPLEECA-UHFFFAOYSA-N 0.000 claims 1
- PLDDNCXQANUBIU-UHFFFAOYSA-N ethyl 2-[2-(3-fluorophenyl)ethenyl]-6-methylpyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC(C)=NC(C=CC=2C=C(F)C=CC=2)=C1 PLDDNCXQANUBIU-UHFFFAOYSA-N 0.000 claims 1
- HPTTXTLOGBLNEB-UHFFFAOYSA-N ethyl 2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(C)N=C1C#CC1=CC=CC(F)=C1 HPTTXTLOGBLNEB-UHFFFAOYSA-N 0.000 claims 1
- RYHSPMUANLCILF-UHFFFAOYSA-N ethyl 2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC(C)=NC(C#CC=2C=C(F)C=CC=2)=C1 RYHSPMUANLCILF-UHFFFAOYSA-N 0.000 claims 1
- ZLNKSVOHLASHPS-UHFFFAOYSA-N ethyl 5-[3-(dimethylamino)propoxy]-6-(2-phenylethynyl)pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(OCCCN(C)C)C(C#CC=2C=CC=CC=2)=N1 ZLNKSVOHLASHPS-UHFFFAOYSA-N 0.000 claims 1
- XSTIEUSZKJILGU-UHFFFAOYSA-N ethyl 6-[2-(2-chlorophenyl)ethenyl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC=C1C=CC1=CC=CC=C1Cl XSTIEUSZKJILGU-UHFFFAOYSA-N 0.000 claims 1
- HKFPYLGHMOOBIW-UHFFFAOYSA-N ethyl 6-[2-(3-fluorophenyl)ethynyl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC=C1C#CC1=CC=CC(F)=C1 HKFPYLGHMOOBIW-UHFFFAOYSA-N 0.000 claims 1
- VAUZRJZXZWKUCY-UHFFFAOYSA-N methyl 2-[[6-[2-(3-fluorophenyl)ethynyl]-2-methylpyridine-3-carbonyl]amino]-2-phenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)OC)NC(=O)C(C(=N1)C)=CC=C1C#CC1=CC=CC(F)=C1 VAUZRJZXZWKUCY-UHFFFAOYSA-N 0.000 claims 1
- SXBVBAYXIIZCIJ-UHFFFAOYSA-N n,n-diethyl-3-[2-(6-methylpyridin-2-yl)ethenyl]benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1 SXBVBAYXIIZCIJ-UHFFFAOYSA-N 0.000 claims 1
- XHOXTLYTYPNJEF-UHFFFAOYSA-N n,n-diethyl-4-[2-(6-methylpyridin-2-yl)ethenyl]benzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1C=CC1=CC=CC(C)=N1 XHOXTLYTYPNJEF-UHFFFAOYSA-N 0.000 claims 1
- QTZJFIZALKGUDW-UHFFFAOYSA-N n,n-dimethyl-3-[2-(2-phenylethynyl)pyridin-3-yl]oxypropan-1-amine Chemical compound CN(C)CCCOC1=CC=CN=C1C#CC1=CC=CC=C1 QTZJFIZALKGUDW-UHFFFAOYSA-N 0.000 claims 1
- OMGWGTOCYAKDKO-UHFFFAOYSA-N n,n-dimethyl-3-[6-methyl-2-(2-phenylethynyl)pyridin-3-yl]oxypropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1C#CC1=CC=CC=C1 OMGWGTOCYAKDKO-UHFFFAOYSA-N 0.000 claims 1
- LFWVZVCRTMFSFL-UHFFFAOYSA-N n-hexyl-6-(2-phenylethenyl)pyridine-2-carboxamide Chemical compound CCCCCCNC(=O)C1=CC=CC(C=CC=2C=CC=CC=2)=N1 LFWVZVCRTMFSFL-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 229960000581 salicylamide Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- CSJWNHJJHIAAIG-SVOQZPEWSA-N ster Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](OC(C)=O)[C@@]3(OC(=O)CCCCCCCCC)C(C)(C)[C@H]3[C@@H]21 CSJWNHJJHIAAIG-SVOQZPEWSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 description 44
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 17
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 15
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 150000003254 radicals Chemical class 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 7
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 7
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 4
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000008054 signal transmission Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- SISOFUCTXZKSOQ-UHFFFAOYSA-N 2-methyl-6-(2-phenylethenyl)pyridine Chemical compound CC1=CC=CC(C=CC=2C=CC=CC=2)=N1 SISOFUCTXZKSOQ-UHFFFAOYSA-N 0.000 description 2
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- TZRFKCVOZCOVCD-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]urea Chemical compound CC1=CC=CC(C=CC=2C=C(NC(=O)NC=3C=CC(Br)=CC=3)C=CC=2)=N1 TZRFKCVOZCOVCD-UHFFFAOYSA-N 0.000 description 1
- RLUADOYXXCEGQK-UHFFFAOYSA-N 1-[2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridin-4-yl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(C)=NC(C#CC=2C=C(F)C=CC=2)=C1 RLUADOYXXCEGQK-UHFFFAOYSA-N 0.000 description 1
- CKSMGUWEKGMBCV-UHFFFAOYSA-N 1-[4-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C=CC1=CC=CC(C)=N1 CKSMGUWEKGMBCV-UHFFFAOYSA-N 0.000 description 1
- HLPYKDBFDQXXAM-UHFFFAOYSA-N 1-oxido-2-(2-phenylethenyl)pyridin-1-ium Chemical compound [O-][N+]1=CC=CC=C1C=CC1=CC=CC=C1 HLPYKDBFDQXXAM-UHFFFAOYSA-N 0.000 description 1
- RNWPNCVXHKPRMO-UHFFFAOYSA-N 1-tert-butyl-3-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]urea Chemical compound CC1=CC=CC(C=CC=2C=C(NC(=O)NC(C)(C)C)C=CC=2)=N1 RNWPNCVXHKPRMO-UHFFFAOYSA-N 0.000 description 1
- GDXZVOURRVVXTG-UHFFFAOYSA-N 2,2-dimethyl-n-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]propanamide Chemical compound CC1=CC=CC(C=CC=2C=C(NC(=O)C(C)(C)C)C=CC=2)=N1 GDXZVOURRVVXTG-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- YEZHQUGOABFELJ-HJWRWDBZSA-N 2-[(z)-2-(2-chlorophenyl)ethenyl]pyridine Chemical compound ClC1=CC=CC=C1\C=C/C1=CC=CC=N1 YEZHQUGOABFELJ-HJWRWDBZSA-N 0.000 description 1
- XHPPWPVROZXXSG-UHFFFAOYSA-N 2-[1,2-dibromo-2-(3-bromophenyl)ethyl]-6-methylpyridine Chemical compound CC1=CC=CC(C(Br)C(Br)C=2C=C(Br)C=CC=2)=N1 XHPPWPVROZXXSG-UHFFFAOYSA-N 0.000 description 1
- KAYVIBYPAMXKCR-UHFFFAOYSA-N 2-[2-(2,3-difluorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C(=C(F)C=CC=2)F)=N1 KAYVIBYPAMXKCR-UHFFFAOYSA-N 0.000 description 1
- RKKIYCHXZGVTJT-UHFFFAOYSA-N 2-[2-(2,6-dichlorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C(=CC=CC=2Cl)Cl)=N1 RKKIYCHXZGVTJT-UHFFFAOYSA-N 0.000 description 1
- MFNCFACUOPIETK-UHFFFAOYSA-N 2-[2-(2-chlorophenyl)ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C(=CC=CC=2)Cl)=N1 MFNCFACUOPIETK-UHFFFAOYSA-N 0.000 description 1
- SARWEEZYKGDDHZ-UHFFFAOYSA-N 2-[2-(2-fluorophenyl)ethenyl]pyridine Chemical compound FC1=CC=CC=C1C=CC1=CC=CC=N1 SARWEEZYKGDDHZ-UHFFFAOYSA-N 0.000 description 1
- RLUQDYFMFROVLZ-UHFFFAOYSA-N 2-[2-(2-methoxyphenyl)ethenyl]-6-methylpyridine Chemical compound COC1=CC=CC=C1C=CC1=CC=CC(C)=N1 RLUQDYFMFROVLZ-UHFFFAOYSA-N 0.000 description 1
- YADNATDOWRSAOC-UHFFFAOYSA-N 2-[2-(2-nitrophenyl)ethenyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CC=C1C=CC1=CC=CC=N1 YADNATDOWRSAOC-UHFFFAOYSA-N 0.000 description 1
- GRQGGEJBKKMGIU-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)prop-1-enyl]-6-methylpyridine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)=CC1=CC=CC(C)=N1 GRQGGEJBKKMGIU-UHFFFAOYSA-N 0.000 description 1
- VQDUMOJSZUJFIA-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethenyl]-6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C(C=CC=2C=C(Cl)C=CC=2)=N1 VQDUMOJSZUJFIA-UHFFFAOYSA-N 0.000 description 1
- YYZHKOPANDKPAX-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethenyl]pyridine Chemical compound ClC1=CC=CC(C=CC=2N=CC=CC=2)=C1 YYZHKOPANDKPAX-UHFFFAOYSA-N 0.000 description 1
- DRHQSVSFHJACPT-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-5-methylpyridine Chemical compound N1=CC(C)=CC=C1C#CC1=CC=CC(F)=C1 DRHQSVSFHJACPT-UHFFFAOYSA-N 0.000 description 1
- IJBYZPOKBGCMAW-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)ethenyl]-6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C(C=CC=2C=CC(Cl)=CC=2)=N1 IJBYZPOKBGCMAW-UHFFFAOYSA-N 0.000 description 1
- VXHPPMLEUUDNCS-UHFFFAOYSA-N 2-[2-(6-chloro-1,3-benzodioxol-5-yl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C(=CC=3OCOC=3C=2)Cl)=N1 VXHPPMLEUUDNCS-UHFFFAOYSA-N 0.000 description 1
- ASSOCFMCHWDVRV-UHFFFAOYSA-N 2-[2-(6-methylpyridin-2-yl)ethynyl]pyrazine Chemical compound CC1=CC=CC(C#CC=2N=CC=NC=2)=N1 ASSOCFMCHWDVRV-UHFFFAOYSA-N 0.000 description 1
- NYSFCQFARZRPQA-UHFFFAOYSA-N 2-[2-[2-(3-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylethanamine Chemical compound CN(C)CCOC1=CC=C(C)N=C1C=CC1=CC=CC(Cl)=C1 NYSFCQFARZRPQA-UHFFFAOYSA-N 0.000 description 1
- OTGICZNBEXIBID-UHFFFAOYSA-N 2-[2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=N1 OTGICZNBEXIBID-UHFFFAOYSA-N 0.000 description 1
- XSAIACHKNRQMNB-UHFFFAOYSA-N 2-[2-[4-fluoro-3-(trifluoromethyl)phenyl]ethenyl]-6-methylpyridine Chemical compound CC1=CC=CC(C=CC=2C=C(C(F)=CC=2)C(F)(F)F)=N1 XSAIACHKNRQMNB-UHFFFAOYSA-N 0.000 description 1
- KCHFKVZCVZMFRA-UHFFFAOYSA-N 2-amino-n-[4-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]acetamide Chemical compound CC1=CC=CC(C=CC=2C=CC(NC(=O)CN)=CC=2)=N1 KCHFKVZCVZMFRA-UHFFFAOYSA-N 0.000 description 1
- QWJKVBBPHGDIRV-UHFFFAOYSA-N 2-azido-4-[2-(6-methylpyridin-2-yl)ethenyl]phenol Chemical compound CC1=CC=CC(C=CC=2C=C(C(O)=CC=2)N=[N+]=[N-])=N1 QWJKVBBPHGDIRV-UHFFFAOYSA-N 0.000 description 1
- OJBDHNZBCYRUCW-UHFFFAOYSA-N 2-azido-5-[2-(6-methylpyridin-2-yl)ethynyl]phenol Chemical compound CC1=CC=CC(C#CC=2C=C(O)C(N=[N+]=[N-])=CC=2)=N1 OJBDHNZBCYRUCW-UHFFFAOYSA-N 0.000 description 1
- RUFOVPQUNXLVFW-UHFFFAOYSA-N 2-ethynyl-6-methylpyridine Chemical compound CC1=CC=CC(C#C)=N1 RUFOVPQUNXLVFW-UHFFFAOYSA-N 0.000 description 1
- QVTPWONEVZJCCS-UHFFFAOYSA-N 2-formylbenzonitrile Chemical compound O=CC1=CC=CC=C1C#N QVTPWONEVZJCCS-UHFFFAOYSA-N 0.000 description 1
- CRRZGYORJCEIRS-UHFFFAOYSA-N 2-methoxy-6-[2-(6-methylpyridin-2-yl)ethenyl]phenol Chemical compound COC1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1O CRRZGYORJCEIRS-UHFFFAOYSA-N 0.000 description 1
- VTTRSNANMDUZEJ-UHFFFAOYSA-N 2-methyl-1-oxido-6-(2-phenylethenyl)pyridin-1-ium Chemical compound CC1=CC=CC(C=CC=2C=CC=CC=2)=[N+]1[O-] VTTRSNANMDUZEJ-UHFFFAOYSA-N 0.000 description 1
- YODWZULXARKXFO-CMDGGOBGSA-N 2-methyl-6-[(e)-2-pyridin-2-ylethenyl]pyridine Chemical compound CC1=CC=CC(\C=C\C=2N=CC=CC=2)=N1 YODWZULXARKXFO-CMDGGOBGSA-N 0.000 description 1
- WQUGXOLLBBZDOR-UHFFFAOYSA-N 2-methyl-6-[2-(2,3,6-trifluorophenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C(=C(F)C=CC=2F)F)=N1 WQUGXOLLBBZDOR-UHFFFAOYSA-N 0.000 description 1
- OIQQCJBMDXAFLF-UHFFFAOYSA-N 2-methyl-6-[2-(2-nitrophenyl)ethenyl]pyridin-3-ol Chemical compound C1=C(O)C(C)=NC(C=CC=2C(=CC=CC=2)[N+]([O-])=O)=C1 OIQQCJBMDXAFLF-UHFFFAOYSA-N 0.000 description 1
- QTQSVEDYUWUCNH-UHFFFAOYSA-N 2-methyl-6-[2-(3-methylphenyl)ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1 QTQSVEDYUWUCNH-UHFFFAOYSA-N 0.000 description 1
- HKCQLDAWLZMZHC-UHFFFAOYSA-N 2-methyl-6-[2-[3-[3-(trifluoromethyl)phenoxy]phenyl]ethenyl]pyridine Chemical compound CC1=CC=CC(C=CC=2C=C(OC=3C=C(C=CC=3)C(F)(F)F)C=CC=2)=N1 HKCQLDAWLZMZHC-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- FGJHYEVFDNXSSV-UHFFFAOYSA-N 3-[2-(6-methylpyridin-2-yl)ethynyl]aniline Chemical compound CC1=CC=CC(C#CC=2C=C(N)C=CC=2)=N1 FGJHYEVFDNXSSV-UHFFFAOYSA-N 0.000 description 1
- IPVONRLBOYCOLA-UHFFFAOYSA-N 3-[2-(6-methylpyridin-2-yl)ethynyl]benzamide Chemical compound CC1=CC=CC(C#CC=2C=C(C=CC=2)C(N)=O)=N1 IPVONRLBOYCOLA-UHFFFAOYSA-N 0.000 description 1
- WAFTWLGFYWKAFQ-UHFFFAOYSA-N 3-[6-[2-(3-chlorophenyl)ethenyl]-2-methylpyridin-3-yl]oxy-N,N-dimethylpropan-1-amine Chemical compound ClC=1C=C(C=CC1)C=CC1=CC=C(C(=N1)C)OCCCN(C)C WAFTWLGFYWKAFQ-UHFFFAOYSA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- HGZJJKZPPMFIBU-UHFFFAOYSA-N 3-formylbenzonitrile Chemical compound O=CC1=CC=CC(C#N)=C1 HGZJJKZPPMFIBU-UHFFFAOYSA-N 0.000 description 1
- KTKZCNMXOHSFRC-UHFFFAOYSA-N 3-methoxy-6-methyl-2-(2-phenylethenyl)pyridine Chemical compound COC1=CC=C(C)N=C1C=CC1=CC=CC=C1 KTKZCNMXOHSFRC-UHFFFAOYSA-N 0.000 description 1
- JRWZIBFSQJJDSM-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)ethenyl]benzoic acid Chemical compound CC1=CC=CC(C=CC=2C=CC(=CC=2)C(O)=O)=N1 JRWZIBFSQJJDSM-UHFFFAOYSA-N 0.000 description 1
- YEXYCIAPVPNBTC-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)ethenyl]benzonitrile Chemical compound CC1=CC=CC(C=CC=2C=CC(=CC=2)C#N)=N1 YEXYCIAPVPNBTC-UHFFFAOYSA-N 0.000 description 1
- DZIHAKBBLXIDHF-UHFFFAOYSA-N 4-azido-n-[3-[2-[2-(3-chlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxypropyl]-2-hydroxybenzamide Chemical compound C=1C=CC(Cl)=CC=1C=CC1=NC(C)=CC=C1OCCCNC(=O)C1=CC=C(N=[N+]=[N-])C=C1O DZIHAKBBLXIDHF-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- HGMUCGLQSRCODE-UHFFFAOYSA-N 5-[2-(6-methylpyridin-2-yl)ethynyl]-2-nitrophenol Chemical compound CC1=CC=CC(C#CC=2C=C(O)C(=CC=2)[N+]([O-])=O)=N1 HGMUCGLQSRCODE-UHFFFAOYSA-N 0.000 description 1
- MXYRHLHQIBBEKY-UHFFFAOYSA-N 6-(2-phenylethenyl)pyridine-2-carbonitrile Chemical compound N#CC1=CC=CC(C=CC=2C=CC=CC=2)=N1 MXYRHLHQIBBEKY-UHFFFAOYSA-N 0.000 description 1
- OTOJGZLCTLHBOE-UHFFFAOYSA-N 6-(2-phenylethenyl)pyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC(C=CC=2C=CC=CC=2)=N1 OTOJGZLCTLHBOE-UHFFFAOYSA-N 0.000 description 1
- CTWJPGPUZLFOFG-UHFFFAOYSA-N 6-[2-(4-chlorophenyl)ethenyl]-2-methylpyridin-3-ol Chemical compound C1=C(O)C(C)=NC(C=CC=2C=CC(Cl)=CC=2)=C1 CTWJPGPUZLFOFG-UHFFFAOYSA-N 0.000 description 1
- XYKGZOGRIPBICU-UHFFFAOYSA-N 6-methyl-2-(2-phenylethenyl)pyridin-3-ol Chemical compound CC1=CC=C(O)C(C=CC=2C=CC=CC=2)=N1 XYKGZOGRIPBICU-UHFFFAOYSA-N 0.000 description 1
- YDWCMHMLMAYBOQ-SREVYHEPSA-N 6-methyl-2-[(Z)-2-pyridin-2-ylethenyl]pyridin-3-ol Chemical compound CC1=CC=C(O)C(\C=C/C=2N=CC=CC=2)=N1 YDWCMHMLMAYBOQ-SREVYHEPSA-N 0.000 description 1
- XYKGZOGRIPBICU-HJWRWDBZSA-N 6-methyl-2-[(z)-2-phenylethenyl]pyridin-3-ol Chemical compound CC1=CC=C(O)C(\C=C/C=2C=CC=CC=2)=N1 XYKGZOGRIPBICU-HJWRWDBZSA-N 0.000 description 1
- KZCKHZWLIXJSAD-UHFFFAOYSA-N 6-methyl-2-[2-(2-nitrophenyl)ethenyl]pyridin-3-ol Chemical compound CC1=CC=C(O)C(C=CC=2C(=CC=CC=2)[N+]([O-])=O)=N1 KZCKHZWLIXJSAD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- QANQCDWRNLSBBE-UHFFFAOYSA-N Cl.C(C)N(C(C1=CC(=CC=C1)C=CC1=NC(=CC=C1)C)=O)CC Chemical compound Cl.C(C)N(C(C1=CC(=CC=C1)C=CC1=NC(=CC=C1)C)=O)CC QANQCDWRNLSBBE-UHFFFAOYSA-N 0.000 description 1
- JEXGFQKESLEVJJ-UHFFFAOYSA-N Cl.C(C)N(C(C1=CC=C(C=C1)C=CC1=NC(=CC=C1)C)=O)CC Chemical compound Cl.C(C)N(C(C1=CC=C(C=C1)C=CC1=NC(=CC=C1)C)=O)CC JEXGFQKESLEVJJ-UHFFFAOYSA-N 0.000 description 1
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- RBAGSTGJZNXVHJ-UHFFFAOYSA-N [2-[2-(3-chlorophenyl)ethenyl]-6-methylpyridin-3-yl] acetate Chemical compound CC(=O)OC1=CC=C(C)N=C1C=CC1=CC=CC(Cl)=C1 RBAGSTGJZNXVHJ-UHFFFAOYSA-N 0.000 description 1
- VSYYJLIZYKQLDK-UHFFFAOYSA-N [2-[2-(4-chlorophenyl)ethenyl]-6-methylpyridin-3-yl] acetate Chemical compound CC(=O)OC1=CC=C(C)N=C1C=CC1=CC=C(Cl)C=C1 VSYYJLIZYKQLDK-UHFFFAOYSA-N 0.000 description 1
- BPXMVNOHUGSKGX-UHFFFAOYSA-N [2-[2-(6-methylpyridin-2-yl)ethenyl]phenyl] acetate Chemical compound CC(=O)OC1=CC=CC=C1C=CC1=CC=CC(C)=N1 BPXMVNOHUGSKGX-UHFFFAOYSA-N 0.000 description 1
- DZWHDUUGYIPFPU-UHFFFAOYSA-N [2-methoxy-4-[2-(6-methylpyridin-2-yl)ethenyl]phenyl] acetate Chemical compound C1=C(OC(C)=O)C(OC)=CC(C=CC=2N=C(C)C=CC=2)=C1 DZWHDUUGYIPFPU-UHFFFAOYSA-N 0.000 description 1
- NEPZYBMWHMKPLG-UHFFFAOYSA-N [2-methoxy-6-[2-(6-methylpyridin-2-yl)ethenyl]phenyl] acetate Chemical compound COC1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1OC(C)=O NEPZYBMWHMKPLG-UHFFFAOYSA-N 0.000 description 1
- AULNBWIEFDVHTR-UHFFFAOYSA-N [2-methyl-6-[2-(2-nitrophenyl)ethenyl]pyridin-3-yl] acetate Chemical compound N1=C(C)C(OC(=O)C)=CC=C1C=CC1=CC=CC=C1[N+]([O-])=O AULNBWIEFDVHTR-UHFFFAOYSA-N 0.000 description 1
- HSFOKZXGHSSBKS-UHFFFAOYSA-N [3-(acetyloxymethyl)-5-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methyl acetate Chemical compound CC(=O)OCC1=CC(COC(C)=O)=CC(C#CC=2N=C(C)C=CC=2)=C1 HSFOKZXGHSSBKS-UHFFFAOYSA-N 0.000 description 1
- JSMRAWHXGKKYNA-UHFFFAOYSA-N [3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl] acetate Chemical compound CC(=O)OC1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1 JSMRAWHXGKKYNA-UHFFFAOYSA-N 0.000 description 1
- LTSVTRGCOYCEMP-UHFFFAOYSA-N [3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methyl acetate Chemical compound CC(=O)OCC1=CC=CC(C#CC=2N=C(C)C=CC=2)=C1 LTSVTRGCOYCEMP-UHFFFAOYSA-N 0.000 description 1
- FUQURELQGNKXBN-UHFFFAOYSA-N [4-(4-azido-2-hydroxy-5-iodobenzoyl)piperazin-1-yl]-[6-[2-(3-fluorophenyl)ethynyl]-2-methylpyridin-3-yl]methanone Chemical compound CC1=NC(C#CC=2C=C(F)C=CC=2)=CC=C1C(=O)N(CC1)CCN1C(=O)C1=CC(I)=C(N=[N+]=[N-])C=C1O FUQURELQGNKXBN-UHFFFAOYSA-N 0.000 description 1
- QXMPBMORWQTXIB-UHFFFAOYSA-N [4-bromo-2-[2-(6-methylpyridin-2-yl)ethenyl]phenyl] acetate Chemical compound CC(=O)OC1=CC=C(Br)C=C1C=CC1=CC=CC(C)=N1 QXMPBMORWQTXIB-UHFFFAOYSA-N 0.000 description 1
- VSHWRGWKZYMNTP-UHFFFAOYSA-N [4-bromo-2-methoxy-6-[2-(6-methylpyridin-2-yl)ethenyl]phenyl] acetate Chemical compound COC1=CC(Br)=CC(C=CC=2N=C(C)C=CC=2)=C1OC(C)=O VSHWRGWKZYMNTP-UHFFFAOYSA-N 0.000 description 1
- QDVJNGWZMOZGIK-UHFFFAOYSA-N [4-chloro-2-[2-(6-methylpyridin-2-yl)ethenyl]phenyl] acetate Chemical compound CC(=O)OC1=CC=C(Cl)C=C1C=CC1=CC=CC(C)=N1 QDVJNGWZMOZGIK-UHFFFAOYSA-N 0.000 description 1
- NTJILDWJIQVMOZ-UHFFFAOYSA-N [6-[2-(3-chlorophenyl)ethenyl]-2-methylpyridin-3-yl] acetate Chemical compound N1=C(C)C(OC(=O)C)=CC=C1C=CC1=CC=CC(Cl)=C1 NTJILDWJIQVMOZ-UHFFFAOYSA-N 0.000 description 1
- DMFQRLLXAWOANH-UHFFFAOYSA-N [6-[2-(4-chlorophenyl)ethenyl]-2-methylpyridin-3-yl] acetate Chemical compound N1=C(C)C(OC(=O)C)=CC=C1C=CC1=CC=C(Cl)C=C1 DMFQRLLXAWOANH-UHFFFAOYSA-N 0.000 description 1
- KUOHABYLMPSYPT-UHFFFAOYSA-N [6-methyl-2-[2-(2-nitrophenyl)ethenyl]pyridin-3-yl] acetate Chemical compound CC(=O)OC1=CC=C(C)N=C1C=CC1=CC=CC=C1[N+]([O-])=O KUOHABYLMPSYPT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- VUPMMXDGVJUHBM-DHZHZOJOSA-N ethyl 4-[(e)-2-pyridin-2-ylethenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1\C=C\C1=CC=CC=N1 VUPMMXDGVJUHBM-DHZHZOJOSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009206 glutamatergic signaling Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AGKCNDHYPPNDIG-UHFFFAOYSA-N methyl 3-[2-(6-methylpyridin-2-yl)ethenyl]benzoate Chemical compound COC(=O)C1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1 AGKCNDHYPPNDIG-UHFFFAOYSA-N 0.000 description 1
- VAQRTIKBWDNDIC-UHFFFAOYSA-N methyl 4-[2-(6-methylpyridin-2-yl)ethenyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C=CC1=CC=CC(C)=N1 VAQRTIKBWDNDIC-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- KJEPFINGCPLCRN-UHFFFAOYSA-N n,n-dimethyl-3-[4-[2-(6-methylpyridin-2-yl)ethenyl]phenoxy]propan-1-amine Chemical compound C1=CC(OCCCN(C)C)=CC=C1C=CC1=CC=CC(C)=N1 KJEPFINGCPLCRN-UHFFFAOYSA-N 0.000 description 1
- PGBDZAYDMVIRRU-UHFFFAOYSA-N n-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=CC=2N=C(C)C=CC=2)=C1 PGBDZAYDMVIRRU-UHFFFAOYSA-N 0.000 description 1
- WALNXPQCZZFFLU-UHFFFAOYSA-N n-[3-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]oxolane-2-carboxamide Chemical compound CC1=CC=CC(C=CC=2C=C(NC(=O)C3OCCC3)C=CC=2)=N1 WALNXPQCZZFFLU-UHFFFAOYSA-N 0.000 description 1
- FSFBWPSVWXMWKM-UHFFFAOYSA-N n-[3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]-2-phenylacetamide Chemical compound CC1=CC=CC(C#CC=2C=C(NC(=O)CC=3C=CC=CC=3)C=CC=2)=N1 FSFBWPSVWXMWKM-UHFFFAOYSA-N 0.000 description 1
- CRYBQCTZQHNFKT-UHFFFAOYSA-N n-[3-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]thiophene-2-carboxamide Chemical compound CC1=CC=CC(C#CC=2C=C(NC(=O)C=3SC=CC=3)C=CC=2)=N1 CRYBQCTZQHNFKT-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- YQWXDBJCHHLIPH-UHFFFAOYSA-N n-[4-[2-(6-methylpyridin-2-yl)ethenyl]phenyl]-2-phenylacetamide Chemical compound CC1=CC=CC(C=CC=2C=CC(NC(=O)CC=3C=CC=CC=3)=CC=2)=N1 YQWXDBJCHHLIPH-UHFFFAOYSA-N 0.000 description 1
- QZKHLLJITABEHV-UHFFFAOYSA-N n-tert-butyl-6-(2-phenylethenyl)pyridine-2-carboxamide Chemical compound CC(C)(C)NC(=O)C1=CC=CC(C=CC=2C=CC=CC=2)=N1 QZKHLLJITABEHV-UHFFFAOYSA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003572 second messenger assay Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- FJRRKHJUPGGVLO-UHFFFAOYSA-N tert-butyl 4-[6-[2-(3-fluorophenyl)ethynyl]-2-methylpyridine-3-carbonyl]piperazine-1-carboxylate Chemical compound CC1=NC(C#CC=2C=C(F)C=CC=2)=CC=C1C(=O)N1CCN(C(=O)OC(C)(C)C)CC1 FJRRKHJUPGGVLO-UHFFFAOYSA-N 0.000 description 1
- AUKNAUAVKQLRGA-UHFFFAOYSA-N tert-butyl n-[1-[3-[2-(6-methylpyridin-2-yl)ethenyl]anilino]-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound CC1=CC=CC(C=CC=2C=C(NC(=O)C(CC=3C=CC=CC=3)NC(=O)OC(C)(C)C)C=CC=2)=N1 AUKNAUAVKQLRGA-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/52—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
- Die Erfindung bezieht sich auf die Verwendung von 2-Arylalkenyl-, 2-Heteroarylalkenyl-, 2-Arylalkinyl-, 2-Heteroarylalkinyl-, 2-Arylazo- und 2-Heteroarylazopyridinen für eine Modulation der Aktivität von mGluRs und für eine Behandlung von durch mGluR5 mediierten Krankheiten, auf pharmazeutische Zusammensetzungen zur Verwendung bei einer solchen Therapie, und auch auf neue 2-Arylalkenyl-, 2-Heteroarylalkenyl-, 2-Arylalkinyl-, 2-Heteroarylalkinyl-, 2-Arylazo- and 2-Heteroarylazopyridine.
- Es hat sich nun gezeigt, dass 2-Arylalkenyl-, 2-Heteroarylalkenyl-, 2-Arylalkinyl-, 2-Heteroarylalkinyl-, 2-Arylazo- and 2-Heteroarylazopyridine unter Einschluss der pharmazeutisch akzeptablen Salze hiervon (im Folgenden als erfindungsgemäße Mittel bezeichnet) brauchbar sind als Modulatoren von mGluRs. Eine Modulation von mGluRs kann nach einer Reihe an Wegen demonstriert werden, unter anderem durch Bindungsassays und funktionale Assays, wie zweiten Messenger Assays oder durch Messung von Veränderungen in den intrazellularen Calciumkonzentrationen. So hat beispielsweise eine Messung des Inositolphosphatumsatzes in rekombinanten Zelllinien, die hmGluR5a exprimieren, von selektiven erfindungsgemäßen Mitteln IC50 Werte von etwa 1 nM bis etwa 50 μM gezeigt.
- Besonders haben die erfindungsgemäßen Mittel wertvolle pharmakologische Eigenschaften. Sie verfügen beispielsweise über eine ausgeprägte und selektive Modulation, besonders eine antagonistische Wirkung bei humanen metabotrophen Glutamatrezeptoren (mGluRs). Dies kann in vitro beispielsweise gemessen werden an rekombinanten humanen metabotrophen Glutamatrezeptoren, besonders an PLC gekuppelten Subtypen hiervon, wie mGluR5, unter Verwendung unterschiedlicher Verfahren, wie beispielsweise einer Messung der Inhibition der durch einen Agonisten induzierten Erhöhung der Konzentration an intrazellularem Ca2+, nach dem Verfahren von L. P. Daggett et al., Neuropharm. Band 34, Seiten 871 bis 886 (1995), oder von P. J. Flor et al., J. Neurochem. Band 67, Seiten 58 bis 63 (1996), oder durch Bestimmung des Ausmaßes, in welchem eine durch einen Agonisten induzierte Erhöhung des Inositolphosphatumsatzes gehemmt wird, wie dies beschrieben wird von T. Knoepfel et al., Euro. J. Pharmacol. Band 268, Seiten 389 bis 392 (1994) oder von L. P. Daggett et al., Neuropharm. Band 67, Seiten 58 bis 63 (1996), und den darin zitierten Veröffentlichungen. Eine Isolation und Expression von humanen Subtypen von mGluR wird in
US 5 521 297 A beschrieben. Dabei zeigen ausgewählte erfindungsgemäße Mittel IC50 Werte für die Inhibition des durch Quisqualat induzierten Umsatzes an Inositolphosphat, der in rekombinanten Zellen gemessen wird, die hmGluR5a von etwa 1 nM bis etwa 50 μM exprimieren. - Demnach bezieht sich die Erfindung auf erfindungsgemäße Mittel zur Verwendung für die Behandlung von Störungen, die assoziiert sind mit Irregularitäten der glutamatergen Signalübertragung, und von Störungen des Nervensystems, die vollständig oder zum Teil durch mGluR5 mediiert werden.
- Störungen, die mit Irregularitäten der glutamatergischen Signaltransmission assoziiert sind, sind beispielsweise Epilepsie, cerebrale Ischämien, besonders akute Ischämien, ischämische Krankheiten des Auges, Muskelspasmen, wie lokale oder generale Spastizität, und, besonders, Konvulsionen oder Schmerz.
- Störungen des Nervensystems, die insgesamt oder teilweise durch mGluR5 mediiert werden, sind beispielsweise akute, traumatische und chronische degenerative Prozesse des Nervensystems, wie Parkinson-Krankheit, senile Demenz, Alzheimer-Krankheit, Huntington-Chores, amyotrophe laterale Skle rose und multiple Sklerose, psychiatrische Krankheiten, wie Schizophrenie und Angst, Depression und Schmerz.
- Die Erfindung bezieht sich nun auf die Verwendung erfindungsgemäßer Mittel für die Behandlung von Störungen, die mit Irregularitäten der glutamatergischen Signaltransmission assoziiert sind, und auf Störungen des Nervensystems, die vollständig oder zum Teil durch mGluRs der Gruppe I mediiert werden.
- Weiter betrifft die Erfindung die Verwendung erfindungsgemäßer Mittel zur Herstellung einer pharmazeutischen Zusammensetzung, die zur Behandlung von Störungen abgestellt sind, welche mit Irregularitäten der glutamatergischen Signaltransmission assoziiert sind, und auf Störungen des Nervensystems, die vollständig oder zum Teil durch mGluRs der Gruppe I mediiert werden.
- Ein weiterer Aspekt der Erfindung betrifft ein Verfahren zur Behandlung von Störungen, die vollständig oder zum Teil durch mGluRs der Gruppe I, präferentiell durch mGluR5, mediiert werden, wobei dieses Verfahren umfasst eine Verabreichung einer therapeutisch wirksamen Menge eines erfindungsgemäßen Mittels an einen warmblütigen Organismus, der einer solchen Behandlung bedarf.
- Ein wiederum weiterer Aspekt der Erfindung bezieht sich auf neue 2-Arylalkenyl-, 2-Heteroarylalkenyl-, 2-Arylalkinyl-, 2-Heteroarylalkinyl-, 2-Arylazo- und 2-Heteroarylazopyridine und deren Salze und ein Verfahren zu deren Herstellung.
- Darüber hinaus bezieht sich die Erfindung auf eine pharmazeutische Zusammensetzung, die als Wirkstoff zusammen mit herkömmlichen pharmazeutischen Exzipientien ein neues 2-Arylalkenyl-, 2-Heteroarylalkenyl-, 2-Arylalkinyl-, 2-Heteroarylalkinyl-, 2-Arylazo- und 2-Heteroarylazopyridin oder ein pharmazeutisch akzeptables Salz hiervon umfasst.
- Die erfindungsgemäßen Mittel sind beispielsweise Verbindungen der folgenden Formel I worin
X für eine optional durch Halogen substituierte (C2-C4)-Alkylen- oder (C2-C4)-Alkinylengruppe steht, die über vicinale ungesättigte Kohlenstoffatome gebunden ist,
R1 für Wasserstoff, (C1-C4)-Alkyl, (C1-C4)-Alkoxy, Hydroxy-(C1-C4)-alkyl, Cyano, Ethinyl, Carboxy, (C1-C4)-Alkoxycarbonyl, Di-(C1-C4)-alkylamino, (C1-C6)-Alkylaminocarbonyl oder Trifluormethylphenylaminocarbonyl steht,
R2 für Wasserstoff, Hydroxy, (C1-C4)-Alkyl, Hydroxy-(C1-C4)-alkyl, (C1-C4)-Alkoxy, Carboxy, (C2-C5)-Alkanoyloxy, (C1-C4)-Alkoxycarbonyl, Di-(C1-C4)-alkylamino-(C1-C4)-alkanoyl, Di-(C1-C4)-alkylaminomethyl, 4-(4-Fluorbenzoyl)-piperidin-1-ylcarboxy, 4-t.-Butyloxycarbonylpiperazin-1-ylcarboxy, 4-(4-Azido-2-hydroxybenzoyl)-piperazin-1-ylcarboxy oder 4-(4-Azido-2-hydroxy-3-iodbenzoyl)-piperazin-1-ylcarboxy steht,
R3 für Wasserstoff, (C1-C4)-Alkyl, Carboxy, (C1-C4)-Alkoxycarbonyl, (C1-C4)-Alkylcarbamoyl, Hydroxy-(C1-C4)-alkyl, Di-(C1-C4)-alkylaminomethyl, Morpholinocarbonyl oder 4-(4-Fluorbenzoyl)-piperidin-1-ylcarboxy steht,
R4 für Wasserstoff, Hydroxy, (C1-C4)-Alkoxy, Carboxy, (C2-C5)-Alkanoyloxy, (C1-C4)-Alkoxycarbonyl, Amino-(C1-C4)-alkoxy, Di-(C1-C4)-alkylamino-(C1-C4)-alkoxy, Di-(C1-C4)-alkylamino-(C1-C4)-alkyl, Carboxy-(C1-C4)-alkylcarbonyl, (C1-C4)-Alkoxycarbonyl-(C1-C4)-alkoxy, Hydroxy-(C1-C4)-alkyl, Di-(C1-C4)-alkylamino-(C1-C4)-alkoxy oder m-Hydroxy-p-azidophenylcarbonylamino-(C1-C4)-alkoxy steht, und
R5 eine Gruppe der folgenden Formeln ist worin
Ra und Rb unabhängig stehen für Wasserstoff, Hydroxy, Halogen, Nitro, Cyano, Carboxy, (C1-C4)-Alkyl, (C1-C4)-Alkoxy, Hydroxy-(C1-C4)-alkyl, (C1-C4)-Alkoxycarbonyl, (C2-C7)-Alkanoyl, (C2-C5)-Alkanoyloxy, (C2-C5)-Alkanoyloxy-(C1-C4)-alkyl, Trifluormethyl, Trifluormethoxy, Trimethylsilylethinyl, (C2-C5)-Alkinyl, Amino, Azido, Amino-(C1-C4)-alkoxy, (C2-C5)-Alkanoylamino-(C1-C4)-alkoxy, (C1-C4)-Alkylamino-(C1-C4)-alkoxy, Di-(C1-C4)-Alkylamino-(C1-C4)-alkoxy, (C1-C4)-Alkylamino, Di-(C1-C4)-alkylamino, Monohalogenbenzylamino, Thienylmethylamino, Thienylcarbonylamino, Trifluormethylphenylaminocarbonyl, Tetrazolyl, (C2-C5)-Alkanoylamino, Benzylcarbonylamino, (C1-C4)-Alkylaminocarbonylamino, (C1-C4)-Alkoxycarbonylaminocarbonylamino oder (C1-C4)-Alkylsulfonyl,
Rc für Wasserstoff, Fluor, Chlor, Brom, Hydroxy, (C1-C4)-Alkyl, (C2-C5)-Alkanoyloxy, (C1-C4)-Alkoxy oder Cyano steht, und
R4 für Wasserstoff, Halogen oder (C1-C4)-Alkyl steht. - Die Verbindungen der Formel I, die basische Gruppen enthalten, die Säureadditionssalze bilden können, und die Verbindungen der Formel I, die saure Gruppen enthalten, können mit Basen Salze bilden. Die Verbindungen der Formel I, die basische Gruppen haben, und die zusätzlich wenigstens eine saure Gruppe aufweisen, können auch innere Salze bilden.
- Ebenfalls eingeschlossen sind sowohl gesamte als auch partiale Salze, und somit Salze mit 1, 2, 3, vorzugsweise 2 Äquivalenten einer Base pro Molekül einer Säure der Formel I, oder Salze mit 1, 2 oder 3 AÄquivalenten, vorzugsweise 1 Äquivalent, einer Säure pro Mol einer Base der Formel I.
- Für die Zwecke einer Isolation und Reinigung ist auch die Verwendung pharmazeutisch nicht akzeptabler Salze möglich. Nur die pharmazeutisch akzeptablen nichttoxischen Salze werden aber in der Therapie verwendet, so dass sie bevorzugt sind.
- Unter Halogen werden in der vorliegenden Beschreibung Fluor, Chlor, Brom oder Iod verstanden.
- Wenn X für eine Alkenylengruppe steht, dann ist die trans-Konfiguration bevorzugt.
- Bevorzugter sind die Verbindungen der Formel I, worin X wie oben definiert ist und
R1 für Wasserstoff, (C1-C4)-Alkyl, (C1-C4)-Alkoxy, Cyano, Ethinyl oder Di-(C1-C4)-alkylamino steht,
R2 für Wasserstoff, Hydroxy, Carboxy, (C1-C4)-Alkoxycarbonyl, Di-(C1-C4)-alkylaminomethyl, 4-(4-Fluorbenzoyl)-piperidin-1-ylcarboxy, 4-t.-Butyloxycarbonylpiperazin-1-ylcarboxy, 4-(4-Azido-2-hydroxybenzoyl)-piperazin-1-ylcarboxy oder 4-(4-Azido-2-hydroxy-3-iodbenzoyl)-piperazin-1-ylcarboxy steht,
R3 wie oben definiert ist,
R4 für Wasserstoff, Hydroxy, Carboxy, (C2-C5)-Alkanoyloxy, (C1-C4)-Alkoxycarbonyl, Amino-(C1-C4)-alkoxy, Di-(C1-C4)-alkylamino-(C1-C4)-akoxy, Di-(C1-C4)-alkylamino-(C1-C4)-alkyl oder Hydroxy-(C1-C4)-alkyl steht, und
R5 eine Gruppe der folgenden Formeln ist worin
Ra und Rb unabhängig für Wasserstoff, Halogen, Nitro, Cyano, (C1-C4)-Alkyl, (C1-C4)-Alkoxy, Trifluormethyl, Trifluormethoxy oder (C2-C5)-Alkinyl stehen, und
Rc und Rd wie oben definiert sind. - Zu den erfindungsgemäßen Mitteln gehören beispielsweise die Verbindungen, wie sie in den späteren Beispielen beschrieben sind.
- Die Brauchbarkeit der erfindungsgemäßen Mittel für die Behandlung der oben erwähnten Zustände ist in einer Reihe an Standardtests unter Einschluss der später angegebenen Tests bestätigt worden.
- Bei Dosen von etwa 10 bis 100 mg/kg i. p. oder p. o. mit Vorbehandlungszeiten von 5 min bis 8 h zeigen die erfindungsgemäßen Mittel eine antikonvulsive Aktivität im Elektroschock, der durch ein Konvulsionsmodell induziert wird, wozu beispielsweise hingewiesen wird auf E. A. Swinyard, J. Pharm. Assoc. Scient., Ausg. 38, 201 (1949) und J. Pharmacol. Exptl. Therap. 106, Seite 319 (1952).
- Bei Dosen von etwa 4 bis etwa 40 mg/kg p. o. zeigen die erfindungsgemäßen Mittel eine Umkehr von komplettem Adjuvant von Freund (FCA), die durch eine Hyperalgesie induziert wird, wozu beispielsweise hingewiesen wird auf J. Donnerer et al., Neuroscience 49, Seiten 693 bis 698 (1992) und C. J. Woolf, Neuroscience 62, Seiten 327 bis 331 (1994).
- Für alle oben erwähnten Indikationen schwankt die geeignete Wirkstoffdosis natürlich in Abhängigkeit von beispielsweise der verwendeten Verbindung, dem Wirt, der Art der Verabreichung und der Natur und Schwere des zu behandelnden Zustands. Im Allgemeinen sind aber zufrieden stellende Resultate bei Tieren angezeigt, die eine Tagesdosis von etwa 0,5 bis etwa 100 mg/kg Körpergewicht des Tiers erhalten. Bei größeren Säugern, beispielsweise beim Menschen, liegt eine indizierte Tagesdosis im Bereich von etwa 5 bis 1500 mg, vorzugsweise etwa 10 bis etwa 1000 mg, der Verbindung, die zweckmäßig in unterteilten Dosen von bis zu 4-mal täglich oder in einer verzögert freisetzenden Form verabreicht wird, was auch als Sustained Release Form bezeichnet wird.
- Zu bevorzugten Verbindungen für die oben erwähnten Indikationen gehören (3-{2-[2-Trans-(3,5-dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin (A), 2-Methyl-6-styrylpyridin (B), 2-(3-Fluorphenylethinyl)-6-methylpyridin (C) und 2-(4-Ethoxy-3-trifluormethylphenylethinyl)-6-methylpyridin (D). Es ist beispielsweise bestimmt worden, dass beim oben erwähnten und durch einen Elektroschock induzierten Konvulsionsmodell die Verbindungen A und B eine antikonvulsive Aktivität mit ED50 Werten von 30 bzw. 35 mg/kg i. p. zeigen, und zwar bei Vorbehandlungszeiten von 4 h bzw. 15 min, und dass beim oben erwähnten und durch FCA induzierten Hyperalgesiemodell die Verbindungen C und D eine Umkehr der Hyperalgesie mit ED50 Werten von 4,2 bzw. 19 mg/kg p. o. bei einer Nachbehandlungszeit von 3 h zeigen.
- Wie oben angegeben, gehören zu den erfindungsgemäßen Mitteln neue 2-Arylalkenyl-, 2-Heteroarylalkenyl-, 2-Arylalkinyl-, 2-Heteroarylalkinyl-, 2-Arylazo- und 2-Heteroarylazopyridine und ihre Salze, welche im Folgenden als erfindungsgemäße Verbindungen bezeichnet werden.
- Zu erfindungsgemäßen Verbindungen gehören Verbindungen der Formel I gemäß obiger Definition und deren Salze, worin X und R1 bis R5 wie oben definiert sind, mit der Maßgabe, dass, falls R3 für Wasserstoff steht,
- a) in Verbindungen der Formel I, worin R1, R2 und R4 für Wasserstoff stehen, R5 dann unterschiedlich ist von Phenyl, Monohalogenphenyl, 2,4- und 3,4-Dichlorphenyl, 3- und 4-Trifluormethylphenyl, Methylphenyl, 3,4- und 2,5-Dimethylphenyl, 4-Isopropylphenyl, 3,5-Di-tert-butylphenyl, Methoxyphenyl, 3,4-Dimethoxyphenyl, 2,4,5- und 3,4,5-Trimethoxyphenyl, Hydroxyphenyl, 3,5-Dihydroxyphenyl, 4-Hydroxy-3,5-dimethylphenyl, 3-Hydroxy-4-methoxy- und 4-Hydroxy-3-methoxyphenyl, 4-Hydroxy-(3-methyl-5-tert-butyl-, 2- und 4-Acetylaminophenyl, 3,5-Diisopropyl- und 3,5-Di-tert-butyl)-phenyl, 4-Carboxy- und 4-Ethoxycarbonylphenyl, 4-Cyanophenyl, 3-Methoxycarbonylphenyl, 3-Carboxy-5-methoxyphenyl, 2-Pyridinyl, 5-Chlor-2-pyridinyl und 6-Methyl-2-pyridinyl, wenn X für Ethenylen steht, oder worin R5 unterschiedlich ist von Phenyl, 4-Methylphenyl, 4-Methoxyphenyl, 4-Bromphenyl und 2- und 4-Chlorphenyl, wenn X für 1,2-Propylen steht, das an R5 in der Position 2 gebunden ist, oder R5 unterschiedlich von Phenyl, 2- und 4-Chlorphenyl und 3-Methoxyphenyl ist, wenn X für 1,2-Propylen steht, das an R5 in der Position 1 gebunden ist, oder R5 unterschiedlich ist von 4-Methoxyphenyl, wenn X für 2,3-But-2-enylen oder 1,2-But-1-enylen steht, das an R5 in der Position 2 gebunden ist, oder wenn R5 unterschiedlich ist von 4-Methoxyphenyl und 4-Isopropylphenyl, wenn X für 2,3-Pent-2-enylen steht, das an R5 in der Position 3 gebunden ist, oder R5 unterschiedlich ist von Phenyl, 4-Methylphenyl, Methoxyphenyl und 4-Hydroxyphenyl, wenn X für 3,4-Hex-3-enylen steht,
- b) in Verbindungen der Formel I, worin R1 für Methyl steht und R2 und R4 für Wasserstoff stehen, R5 dann unterschiedlich ist von Phenyl, 3-Methylphenyl, 2-Methoxyphenyl, 2-Chlorphenyl, 4-Cyanophenyl, 2-Pyridinyl und 6-Methyl-2-pyridinyl, wenn X für Ethenylen steht,
- c) in Verbindungen der Formel I, worin R1 und R2 für Wasserstoff stehen und R4 für Carboxy steht, R5 dann unterschiedlich ist von Phenyl, 3-Methylphenyl, 4-Methoxyphenyl und 4-Bromphenyl, wenn X für Ethenylen steht,
- d) in Verbindungen der Formel I, worin R1 und R2 für Wasserstoff stehen und R4 für Methyl steht, R5 dann unterschiedlich ist von Phenyl, 3-Methoxy-, 4-Methoxy- und 3,4-Dimethoxyphenyl, 2-Chlor- und 2,4-Dichlorphenyl und 6-Methylpyrid-2-yl, wenn X für Ethenylen steht oder R5 unterschiedlich ist von Phenyl, wenn X für 1,2-Prop-1-enylen steht, das an R5 in der Position 2 gebunden ist,
- e) in Verbindungen der Formel I, worin R1 und R2 für Wasserstoff stehen und R4 für Dimethylaminoethoxycarbonyl oder 3-Dimethylaminopropyloxycarbonyl steht, R5 dann unterschiedlich von 4-Methoxyphenyl ist, wenn X für Ethenylen steht,
- f) in Verbindungen der Formel I, worin R1 und R2 für Wasserstoff stehen und R4 für 2-Dimethoxyethoxy steht, R5 dann unterschiedlich ist von Phenyl, 4-Methylphenyl und 4-Methoxycarbonylphenyl, wenn X für Ethenylen steht,
- g) R5 unterschiedlich ist von Phenyl, wenn R1 und R2 für Wasserstoff stehen und R4 für Hydroxy oder Ethoxycarbonyl steht, oder wenn R1 und R2 für Wasserstoff stehen und R4 für Hydroxy steht, oder wenn R1 für Methyl steht, R2 für Wasserstoff steht und R4 für Methoxy steht, oder R1 für But-1-enyl steht, R2 für Wasserstoff steht und R4 für Wasserstoff steht, oder R1 für Wasserstoff steht oder R4 für 2-Dimethoxyethoxy steht, und X in jedem Fall für Ethenylen steht, und mit der Maßgabe, dass, wenn R3 für Wasserstoff steht und X für Ethinylen steht,
- a') R5 unterschiedlich ist von Phenyl, 2- und 4-Nitrophenyl, 4-Aminophenyl, 4-Chlorphenyl, 4-Methylphenyl, 4-Methoxyphenyl, 4-Ethoxycarbonylphenyl, 5-Formyl-2-methoxyphenyl, 5-Carboxy-2-methoxyphenyl und Pyridyl, wenn R1 und R2 für Wasserstoff stehen,
- b') in Verbindungen der Formel I, worin R2 und R4 für Wasserstoff stehen, R5 unterschiedlich ist von Phenyl, 3-Methylphenyl, 5-Methylpyridin-2-yl und 2-Methoxyphenyl, wenn R1 für Methyl steht, R5 unterschiedlich ist von 6-Brompyridin-2-yl, wenn R1 für Brom steht, und R5 unterschiedlich ist von 6-Hexyloxypyridin-2-yl, wenn R1 für Hexyloxy steht,
- c') in Verbindungen der Formel I, worin R1 und R4 für Wasserstoff stehen, R5 unterschiedlich ist von Phenyl, 4-Aminophenyl und 4-Propylphenyl, wenn R2 für Methyl steht, R5 unterschiedlich ist von Phenyl, 4-Cyanophenyl oder 4-Pentylphenyl, wenn R2 für Ethyl steht, R5 unterschiedlich ist von 3-Cyano-4-ethoxyphenyl und 3-Brom-4-methoxyphenyl, wenn R2 für Butyl steht, R5 unterschiedlich ist von 4-Methoxyphenyl und 4-Butyloxyphenyl, wenn R2 für Pentyl steht, R5 unterschiedlich ist von 4-tert-Butylphenyl, 3-tert-Butyl-4-hydroxyphenyl, 4-tert-Butyl-3-hydroxyphenyl, und 4-Hexyloxyphenyl, wenn R2 für Carboxy steht, R4 unterschiedlich ist von Phenyl, wenn R2 für Methoxycarbonyl oder Methylcarbamoyl steht, R4 unterschiedlich ist von 3-tert-Butylphenyl, 3-tert-Butyl-4-hydroxyphenyl und 4-(4-Methylphenyl)-phenyl, wenn R2 für Ethoxycarbonyl steht, und R5 unterschiedlich ist von 4-Pentyloxyphenyl, wenn R2 für 2-Methylbutyloxycarbonyl steht,
- d') in Verbindungen der Formel I, worin R1 und R2 für Wasserstoff stehen, R5 unterschiedlich ist von Phenyl, wenn R4 für Hydroxy, Methyl, Ethyl, Carboxy, Methoxycarbonyl oder Carbamoyl steht.
- Bevorzugt sind Verbindungen der Erfindung, die wie oben angegeben als erfindungsgemäße Mittel verwendet werden.
- Die erfindungsgemäßen Verbindungen können in Analogie zu den Synthesen für bekannte Verbindungen der Formel I hergestellt werden. Die erfindungsgemäßen Verbindungen, die der Formel I entsprechen, können daher beispielsweise durch ein Verfahren hergestellt werden, das umfasst a) eine Umsetzung der Verbindung II mit einer Verbindung der Formel Y2-R5 (III), worin entweder einer der Reste Y1 und Y2 für Niederalkanoyl steht und der andere dieser Reste für Alkyl oder Triarylphosphoranylidenmethyl steht, oder einer der Reste Y1 und Y2 für eine reaktive veresterte Hydroxygruppe und der andere dieser Reste für eine Gruppe Y3-X- steht, worin Y3 für Wasserstoff oder eine metallische Gruppe steht, und R1, R2, R3, R4 und R5 die oben angegebenen Bedeutungen haben, und funktionale Gruppen R1, R2, R3 und R4 und auch funktionale Substituenten von R5 temporär geschützt sein können, oder b) eine Elimination von H-Y4 von einer Verbindung der Formel IV worin Y4 für eine elektrofugale Gruppe steht, und R1, R2, R3 und R4, X und R5 die oben angegebenen Bedeutungen haben, und funktionale Gruppen R1, R2, R3 und R4 und auch funktionale Substituenten von R5 temporär geschützt sein können, unter Entfernung irgendwelcher temporärer Schutzgruppen, und gewünschtenfalls Umwandlung einer Verbindung der Formel I, die durch die oben definierten Verfahren erhältlich ist, in eine unterschiedliche Verbindung der Formel I, Auftrennung eines Gemisches von Isomeren, das erhalten werden kann, in die einzelnen Isomeren und/oder Umwandlung einer Verbindung der Formel I, die wenigstens eine salzbildende Gruppe aufweist, die durch die oben definierten Verfahren erhältlich ist, in ein Salz, oder Umwandlung eines Salzes, das durch die oben definierten Verfahren erhältlich ist, in die entsprechende freie Verbindung oder in ein anderes Salz.
- Ein niederes Alkanoyl Y2 oder bevorzugter eine Gruppe Y1 ist beispielsweise eine C1-C3-Alkanoylgruppe, wie Formyl, Acetyl oder Propionyl, besonders Formyl. Eine niedere Alkylgruppe Y1 oder bevorzugter eine Gruppe Y2 ist beispielsweise eine C1-C3-Alkylgruppe, wie Methyl, Ethyl oder Propyl, besonders Methyl. Triarylphosphoranylidenmethyl Y2 oder bevorzugter Y1 ist beispielsweise Triphenylphosphoranylidenmethyl.
- Steht einer der Reste Y1 und Y2 für eine reaktive veresterte Hydroxygruppe und steht der andere dieser Reste für eine Gruppe der Formel Y3-X, worin Y3 für Wasserstoff steht, dann wird die Kondensation vorzugsweise nach dem Kupplungsverfahren von Heck durchgeführt, beispielsweise in Gegenwart von Kupfer oder einem Kupferkatalysator oder einem Edelmetall/Phosphinkatalysator, wie Palladium oder einem PdII Salz, in Gegenwart von Triarylphosphin, beispielsweise Palladiumacetat, und Triphenylphosphin, oder in Gegenwart von Bistriphenylphosphinpalladiumdichlorid, vorzugsweise in Anwesenheit eines Triniederalkylam ins, beispielsweise von Trimethylamin, vorzugsweise in Gegenwart von Cu1-I, in einem polaren organischen Lösemittel, wie N,N-Diniederalkylalkansäureamid, beispielsweise Dimethylformamid, einem Diniederalkylsulfoxid, beispielsweise Dimethylsulfoxid, oder Dioxan, bei Temperaturen von zweckmäßig 15°C bis etwa 120°C, vorzugsweise bei Siedetemperatur.
- Steht einer der Reste Y1 und Y2 für eine reaktive veresterte Hydroxygruppe und steht der andere dieser Reste für eine Gruppe der Formel Y3-X, worin Y3 für eine metallische Gruppe steht, wie eine Halogenmagnesiumgruppe, dann wird die Umsetzung vorzugsweise nach einer Grignard-Reaktion durchgeführt, worin das metallische Zwischenprodukt vorzugsweise in situ gebildet wird. Steht einer der Reste Y1 und Y2 für Niederalkanoyl und der andere dieser Reste für Niederalkyl, dann wird die intermolekulare Kondensation von Verbindungen der Formeln II und III vorzugsweise nach dem Verfahren von Shaw oder nach dem Verfahren von Wagstaff oder einer der vielen Modifikationen durchgeführt.
- Steht einer der Reste Y1 und Y2 für Niederalkanoyl und steht der andere dieser Reste für Triarylphosphoranylidenmethyl, dann wird die Kondensation vorzugsweise unter Anwendung des bekannten Olefin-bildenden Verfahrens von Wittig durchgeführt, vorzugsweise durch Bildung der Phosphoranylidinkomponente aus einem entsprechenden Triarylphosphoniumhalogenid in situ, beispielsweise durch Umsetzung des letzteren mit einer Metallbase, wie einem Alkalimetallhydrid, wie Natriumhydrid, oder mit einer metallorganischen Base, wie einer Niederalkylmetallverbindung, wie Butyllithium, oder mit einem Alkalimetallalkanolat, beispielsweise Kalium-tert-butoxid, vorzugsweise in einem inerten organischen Lösemittel, wie einem aromatischen oder arylaliphatischen Kohlenwasserstoff, beispielsweise Benzol oder Toluol, zweckmäßig bei –10°C bis zweckmäßig 39°C, vorzugsweise erst bei 0°C bis 10°C und dann bei Umgebungstemperatur.
- Elektrofugale Gruppen Y4 sind beispielsweise veresterte Hydroxygruppen, wie Hydroxygruppen, die mit einer organischen Säure verestert sind, beispielsweise Niederalkanoyloxygruppen oder Hydroxygruppen, die mit einer anorganischen Säure verestert sind, beispielsweise Halogengruppen, oder tertiäre Aminogruppen, wie Triniederalkylaminogruppen, beispielsweise Trimethylamino-, oder Niederalkylenamino-, Niederazaalkylenamino-, Niederoxyalkylenamino- oder Niederthiaalkylenaminogruppen, wie Pyrrolidino, Piperidino, Morpholino oder Thiomorpholino, oder die entsprechenden quaternären Ammoniumgruppen.
- Der Schutz funktionaler Gruppen durch solche Schutzgruppen, die Schutzgruppen selbst und die Reaktionen zu ihrer Entfernung, werden beispielsweise in Standardwerken beschrieben.
- Die Elimination von H-Y4 aus Verbindungen der Formel IV kann in herkömmlicher Weise durchgeführt werden. So können beispielsweise Wasser oder Niederalkancarbonsäuren durch eine azeotrope Destillation, beispielsweise in Toluol, zweckmäßig unter milden sauren Bedingungen, eliminiert werden. Wasserstoffhalogenide können unter basischen Bedingungen entfernt werden, wie durch eine Umsetzung mit einem Alkalimetallalkanolat, vorzugsweise im entsprechenden Niederalkanol als ein Lösemittel oder ein Colösemittel oder durch Erhitzung in Gegenwart eines tertiären Amins, wie eines Triniederalkylamins.
- Die Ausgangsmaterialien für die oben beschriebenen Reaktionen sind allgemein bekannt. Neue Ausgangsmaterialien lassen sich in Analogie zu den Verfahren zur Herstellung bekannter Ausgangsmaterialien erhalten.
- Verbindungen der Formel I, die mit diesem Verfahren erhältlich sind, können in unterschiedliche Verbindungen der Formel I in herkömmlicher Weise umgewandelt werden, so dass beispielsweise eine freie Carboxygruppe verestert oder amidiert werden kann, eine veresterte oder amidierte Carboxygruppe in eine freie Carboxygruppe umgewandelt werden kann, eine veresterte Carboxygruppe in eine unsubstituierte oder substituierte Carbamoylgruppe umgewandelt werden kann, eine freie Aminogruppe acyliert oder alkyliert werden kann, und eine freie Hydroxygruppe acyliert werden kann.
- Auch können die Verbindungen der Formel I unter Anwendung herkömmlicher Verfahren oxidiert werden, wie durch Umsetzung mit einer organischen Peroxisäure, unter Erhalt der entsprechenden Pyridin-N-oxidderivate.
- Salze von Verbindungen der Formel I können unter Anwendung an sich bekannter Verfahren auch in die freien Verbindungen umgewandelt werden, beispielsweise durch Behandlung mit einer Base oder mit einer Säure.
- Erhaltene Salze können unter Anwendung an sich bekannter Verfahren in andere Salze überführt werden.
- Die Verbindungen der Formel I einschließlich ihrer Salze können in Form von Hydraten erhalten werden oder können das zur Kristallisation verwendete Lösemittel einschließen.
- Als ein Ergebnis der engen Beziehung zwischen den neuen Verbindungen in freier Form und in Form ihrer Salze ist jegliche obige und folgende Bezugnahme auf die freien Verbindungen und ihre Salze so zu verstehen, dass sie die freien Verbindungen und auch die entsprechenden Salze umfasst.
- In einer Verbindung der Formel I kann die Konfiguration an einzelnen Chiralitätszentren selektiv umgekehrt werden. So kann beispielsweise die Konfiguration asymmetrischer Kohlenstoffatome, die nukleophile Substituenten enthalten, wie Amino oder Hydroxy, umgekehrt werden durch eine nukleophile Substitution zweiter Ordnung, optional nach einer Umwandlung des gebundenen nukleophilen Substituenten in eine geeignete nukleofugale Abgangsgruppe und eine Reaktion mit einem den ursprünglichen Substituenten einführenden Reagenz oder die Konfiguration an Kohlenstoffatomen, die Hydroxygruppen aufweisen, kann durch Oxidation und Reduktion in Analogie zu
EP 0 236 734 A umgekehrt werden. - Die Erfindung bezieht sich auch auf pharmazeutische Zusammensetzungen, die Verbindungen der Formel I umfassen.
- Die pharmazeutisch akzeptablen Verbindungen der vorliegenden Erfindung können beispielsweise verwendet werden zur Herstellung pharmazeutischer Zusammensetzungen, die eine wirksame Menge des aktiven Bestandteils zusammen oder im Gemisch mit einer signifikanten Menge eines anorganischen oder organischen, festen oder flüssigen, pharmazeutisch akzeptablen Trägers enthalten.
- Die erfindungsgemäßen pharmazeutischen Zusammensetzungen sind Zusammensetzungen für eine enterale, wie nasale, rektale oder orale oder parenterale, wie intramuskulare oder intravenöse Verabreichung an Warmblüter, nämlich an Menschen und Tiere, die eine wirksame Dosis des pharmakologischen Wirkstoffs allein oder zusammen mit einer signifikanten Menge eines pharmazeutisch akzeptablen Trägers enthalten. Die Wirkstoffdosis ist abhängig von der Art des Warmblüters, dem Körpergewicht, dem Alter und dem individuellen Zustand, individuellen pharmakokinetischen Daten, der zu behandelnden Krankheit und der Art der Verabreichung.
- Die pharmazeutischen Zusammensetzungen umfassen etwa 1% bis etwa 95%, vorzugsweise etwa 20% bis etwa 90%, Wirkstoff. Erfindungsgemäße pharmazeutische Zusammensetzungen können beispielsweise in Einheitsdosierungsformen vorliegen, wie in der Form von Ampullen, Phiolen, Suppositorien, Dragees, Tabletten oder Kapseln.
- Die erfindungsgemäßen pharmazeutischen Zusammensetzungen können in an sich bekannter Weise hergestellt werden, beispielsweise durch herkömmliche Verfahren zur Auflösung, Lyophilisation, Vermischung, Granulation oder Konfektionierung.
- Die an warmblütige Tiere, beispielsweise an Menschen, mit beispielsweise einem Körpergewicht von 70 kg, zu verabreichenden Dosen, besonders die wirksamen Dosen für Störungen, die hervorgerufen werden durch oder assoziiert sind mit Irregularitäten der glutamatergischen Signaltransmission reichen von etwa 3 mg bis etwa 3 g, vorzugsweise von etwa 10 mg bis etwa 1 g, beispielsweise von etwa 20 mg bis 500 mg, pro Person und pro Tag, und zwar vorzugsweise unterteilt in 1 bis 4 Einzeldosen, die beispielsweise die gleiche Größe haben können. Kinder erhalten gewöhnlich etwa die Hälfte der Dosis Erwachsener. Die für jedes Individuum erforderliche Dosis kann beispielsweise durch Messung der Serumkonzentration des Wirkstoffs ermittelt und auf einen optimalen Wert eingestellt werden.
- Die Erfindung wird nun anhand nichtbeschränkender Beispiele weiter illustriert, wobei alle darin angegebenen Temperaturen in Grad Celsius und alle Drücke in mbar zu verstehen sind.
- BEISPIEL 1
- 3-[2-(6-Methylpyridin-2-yl)-vinyl]-benzonitril
- Eine Lösung von 2,6-Dimethylpyridin (4,2 ml, 36,28 mmol), 3-Cyanobenzaldehyd (4,95 g, 37,74 mmol) in Essigsäureanhydrid (6,85 ml) wird 16 h unter Rückfluss erhitzt. Sodann wird das Essigsäureanhydrid unter Vakuum verdampft und der Rückstand durch Säulenchromatographie (Silicagel 400 g) gereinigt. Dabei wird die Säule zuerst mit Toluol (400 ml) und dann mit Toluol/Ethylacetat 95:5 eluiert. Die die gewünschte Verbindung enthaltenden Fraktionen werden vereinigt und unter Vakuum eingedampft. Der feste Rückstand wird aus Methylenchlorid/Hexan umkristallisiert, wobei 3,18 g weiße Kristalle mit einem Schmelzpunkt von 91 bis 92°C isoliert werden.
- BEISPIEL 2
- 2-[2-(6-Methylpyridin-2-yl)-vinyl]-benzonitril
- Eine Lösung von 2,6-Dimethylpyridin (5,8 ml, 50 mmol), 2-Cyanobenzaldehyd (6,81 g, 52 mmol) in Essigsäureanhydrid (9,5 ml) wird 16 h unter Rückfluss erhitzt. Sodann wird das Essigsäureanhydrid unter Vakuum verdampft und der Rückstand durch Säulenchromatographie (Silicagel 400 g) gereinigt. Dabei wird die Säule zuerst mit Toluol (400 ml) und dann mit Toluol/Ethylacetat 95:5 eluiert. Die die gewünschte Verbindung enthaltenden Fraktionen werden vereinigt und unter Vakuum eingedampft. Der feste Rückstand wird aus Methylenchlorid/Diisopropylether umkristallisiert, wodurch weiße Kristalle mit einem Schmelzpunkt von 113 bis 114°C isoliert werden.
- BEISPIEL 3
- 2-Methyl-6-[2-(pyridin-4-yl)-vinyl]-pyridin
- Eine Lösung von 2,6-Dimethylpyridin (5,8 ml, 50 mmol), Pyridin-4-carbaldehyd (4,9 g, 52 mmol) in Essigsäureanhydrid (9,5 ml) wird 16 h unter Rückfluss erhitzt. Sodann wird das Essigsäureanhydrid unter Vakuum verdampft und der Rückstand durch Säulenchromatographie (Silicagel 900 g) gereinigt. Die Säule wird zuerst mit Toluol/Aceton 4:1 (5 l) und dann mit Toluol/Aceton 3:1 (5 l) und schließlich mit Toluol/Aceton 2:1 (15 l) eluiert. Die die gewünschte Verbindung enthaltenden Fraktionen werden vereinigt und unter Vakuum eingedampft. Der feste Rückstand wird aus Methylenchlorid/Diisopropylether umkristallisiert, wodurch 0,956 g weiße Kristalle mit einem Schmelzpunkt von 72 bis 73°C isoliert werden.
- BEISPIEL 4
- 2-Methyl-6-[2-(pyridin-3-yl)-vinyl]-pyridin
- Eine Lösung von 2,6-Dimethylpyridin (5,8 ml, 50 mmol), Pyridin-3-carbaldehyd (4,9 g, 52 mmol) in Essigsäureanhydrid (9,5 ml) wird 10 h unter Rückfluss erhitzt. Sodann wird das Essigsäureanhydrid unter Vakuum verdampft und der Rückstand durch Säulenchromatographie (Silicagel 900 g) gereinigt. Sodann wird die Säule zuerst mit Toluol/Aceton 9:1 (7 l), dann mit Toluol/Aceton 4:1 (5 l) und schließlich mit Toluol/Aceton 2:1 (5 l) eluiert. Die die gewünschte Verbindung enthaltenden Fraktionen werden vereinigt und unter Vakuum eingedampft. Der feste Rückstand wird aus Methylenchlorid/Diisopropylether umkristallisiert, wodurch 4,28 g eines farblosen Öls erhalten werden, das beim Stehen bei 6 bis 8°C fest wird.
- BEISPIEL 5
- 2-[2-(3-Bromphenyl)-ethinyl]-6-methylpyridin
- 1,2 g (2,8 mmol) 2-[1,2-Brom-2-(3-bromphenyl)-ethyl]-6-methylpyridin werden in 10 ml Ethanol gelöst. Anschließend erfolgt ein Zusatz von 0,9 g (16,1 mmol) Kaliumhydroxid (Pulver), worauf die erhaltene Suspension 4 h unter Rückfluss erhitzt wird. Sodann wird die Suspension auf Raumtemperatur abgekühlt, in 100 ml Kochsalzlösung gegossen und dreimal mit jeweils 30 ml t-Butylether/Methylether extrahiert. Die vereinigten organischen Phasen werden mit 30 ml Kochsalzlösung gewaschen, über Natriumsulfat getrocknet, filtriert und unter Vakuum eingedampft, wodurch 0,720 g der Titelverbindung als ein farbloses Öl erhalten werden, das beim Stehenlassen kristallisiert und dann einen Schmelzpunkt von 60 bis 61°C hat.
- Das Ausgangsmaterial kann wie folgt erhalten werden:
- a) 2-[2-(3-Bromphenyl)-vinyl]-6-methylpyridin
- Eine Lösung von 24 ml (200 mmol) 2,6-Dimethylpyridin und 25,6 ml (207 mmol) 3-Brombenzaldehyd in 38 ml Essigsäureanhydrid wird 7,5 h unter Rückfluss erhitzt. Hierauf wird das Essigsäureanhydrid unter Vakuum verdampft, wonach der Rückstand in 500 ml 4 N Chlorwasserstoffsäure gelöst und die Lösung zweimal mit jeweils 200 ml Hexan extrahiert wird. Die Wasserphase wird viermal mit jeweils 300 ml tert-Butylmethylether extrahiert. Die organischen Phasen werden zweimal mit jeweils 300 ml einer gesättigten NaHCO3 Lösung in Wasser gewaschen und dann dreimal mit jeweils 300 ml Kochsalzlösung (300 ml) gewaschen, über Natriumsulfat getrocknet, filtriert und unter Vakuum eingedampft, wodurch 4,2 g der Titelverbindung in Form farbloser Kristalle mit einem Schmelzpunkt von 58 bis 59°C erhalten werden.
- b) 2-[1,2-Dibrom-2-(3-bromphenyl)-ethyl]-6-methylpyridin
- 1 g (3,6 mmol) 2-(3-Bromphenylethinyl)-6-methylpyridin wird in 5 ml Tetrachlorkohlenstoff gelöst, und die Lösung wird auf 55 bis 60°C erhitzt. Sodann erfolgt ein tropfenweiser Zusatz von 0,23 ml (4,4 mmol) Brom Br2 in 1 ml Tetrachlorkohlenstoff. Das Reaktionsgemisch wird 30 min auf 55 bis 60°C gehalten und dann auf Raumtemperatur abgekühlt. Der erhaltene Niederschlag wird durch Filtration gesammelt und unter Vakuum getrocknet, wodurch 1,3 g der Titelverbindung in Form gelber Kristalle mit einem Schmelzpunkt von 164 bis 166°C isoliert werden.
- BEISPIEL 6
- 3-[2-(6-Methylpyridin-2-yl)-ethinyl]-benzonitril
- Ein Gemisch von 1 g (8,54 mmol) 2-Ethinyl-6-methylpyridin (Herstellung in Analogie zu D. E. Ames et al., Synthesis, 1981, Seiten 364 bis 365), 2,3 g (12,8 mmol) 3-Brombenzonitril, 0,47 g (0,7 mmol) Bis(triphenylphosphin)-palladium-il-chlorid, 80 mg (0,41 mmol) Kupfer(II)iodid und 1,53 ml (15 mmol) Triethylamin in 10 ml Dimethylformamid wird 3 h bei 90°C gerührt. Das Gemisch wird auf Umgebungstemperatur abgekühlt, in Wasser gegossen und mit Dichlormethan extrahiert. Die organische Schicht wird über Natriumsulfat getrocknet, filtriert und zur Trockne eingedampft, wobei der Rückstand durch Chromatographie über Silicagel mit Hexan/Ethylacetat (4:1) als Eluiermittel gereinigt wird. Durch Kristallisation des erhaltenen Produkts aus Hexan ergeben sich 0,53 g (28,4%) der Titelverbindung als braune Kristalle mit einem Schmelzpunkt von 120 bis 123°C.
- BEISPIEL 7
- In Analogie zum Beispiel 1 (wenn X für Alkenylen steht) oder zum Beispiel 5 (wenn X für Alkinylen steht), werden die folgenden Verbindungen der Formel I hergestellt:
Verbindung der Formel I Schmelzpunkt (°C) 2-Styrylpyridin-3-ol 249–252 2-Methyl-6-[2-(3-nitrophenyl)-vinyl]-pyridin 100–101 2-[2-(2-Chlorphenyl)-vinyl]-pyridin Farbloses Öl 2-Methyl-6-styrylpyridin 40–42 Essigsäure-6-[2-(2-chlorphenyl)-vinyl]-pyridin-3-ylester 75–77 6-[2-(2-Chlorphenyl)-vinyl]-pyridin-3-ol 168–171 Essigsäure-2-[2-(2-chlorphenyl)-vinyl]-pyridin-3-ylester 99–102 2-[2-(2-Chlorphenyl)-vinyl]-pyridin-3-ol 232–234 6-Methyl-2-styrylpyridin-3-ol 261–Zer. Essigsäure-2-[2-(2-chlorphenyl)-vinyl]-6-methylpyridin-3-ylester 92–94 2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-ol 232–234 (Z)-6-Methyl-2-styrylpyridin-3-ol 145–148 2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin 51–52 2-[2-(2-Fluorphenyl)-vinyl]-pyridin 69–70 2-[2-(2-Nitrophenyl)-vinyl]-pyridin 97–99 Essigsäure-2-[2-(4-chlorphenyl)-vinyl]-6-methylpyridin-3-ylester 102–103 Essigsäure-6-[2-(4-chlorphenyl)-vinyl]-2-methylpyridin-3-ylester 130–131 2-[2-(4-Chlorphenyl)-vinyl]-6-methylpyridin-3-ol 275–278 Zer. 6-[2-(4-Chlorphenyl)-vinyl]-2-methylpyridin-3-ol 265–270 Zer. Essigsäure-6-methyl-2-[2-(2-nitrophenyl)-vinyl]-pyridin-3-ylester 139–140 6-Methyl-2-[2-(2-nitrophenyl)-vinyl]-pyridin-3-ol 190–195 Zer. Essigsäure-2-methyl-6-[2-(2-nitrophenyl)-vinyl]-pyridin-3-ylester 99–100 2-Methyl-6-[2-(2-nitrophenyl)-vinyl]-pyridin-3-ol 230–233 Zer. Essigsäure-2-[2-(3-chlorphenyl)-vinyl]-6-methylpyridin-3-ylester 97–99 Essigsäure-6-[2-(3-chlorphenyl)-vinyl]-2-methylpyridin-3-ylester 112–114 2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin-3-ol 232–235 6-[2-(3-Chlorphenyl)-vinyl]-2-methylpyridin-3-ol 230–232 (Z)-(6-Styrylpyridin-2-yl)-methanol 69–70 (E)-(6-Styrylpyridin-2-yl)-methanol 58–60 2,2'-(1,2-Ethendiyl)bis[6-methyl]-pyridin 108–110 Dimethyl-[3-(6-methyl-2-styrylpyridin-3-yloxy)-propyl]-aminhydrochloridsalz 136–139 (E)-6-[2-(2-Pyridyl)-vinyl]-2-picolin 56–57 2-Methyl-6-styrylpyridin-1-oxid 102–103 2-Styrylpyridin-1-oxid 156–159 (E)-6-Methyl-2-(2-pyridin-2-yl-vinyl)-pyridin-3-ol 240–242 (Z)-6-Methyl-2-(2-pyridin-2-ylvinyl)-pyridin-3-ol; Hydrochlorid 225–228 6-Styrylpyridin-2-carbonitril 92–93 2-[2-(2,6-Dichlorphenyl)-vinyl]-6-methylpyridin Hellgelbes Öl 3-Methoxy-6-methyl-2-styrylpyridin Hellgelbes Öl 6-Styrylpyridin-2-carbonsäureamid 141–142 2-[2-(6-Methylpyridin-2-yl)-vinyl]-benzonitril 113–114 3-[2-(6-Methylpyridin-2-yl)-vinyl]-benzonitril 91–92 4-[2-(6-Methylpyridin-2-yl)-vinyl]-benzonitril 131–132 6-Styrylpyridin-2-carbonsäure; Hydrochlorid 209–212 6-Styrylpyridin-2-carbonsäuremethylester 87–88 Essigsäure-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester Farbloses Öl 2-[2-(6-Methylpyridin-2-yl)-vinyl]-phenol 227–229 Essigsäure-2-methoxy-4-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester 102–103 2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin 59–61 2-[2-(4-Chlorphenyl)-vinyl]-6-methylpyridin 83–85 2-[2-(2-Chlorphenyl)-vinyl]-5-ethylpyridin 34–35 1-(6-Styrylpyridin-2-yl)-ethanon 67–68 6-[2-(2-Chlorphenyl)-vinyl]-2-methylnicotinsäureethylester 80–82 2-[2-(2-Chlorphenyl)-vinyl]-6-methylnicotinsäureethylester 70–72 2-[2-(6-Methylpyridin-2-yl)-vinyl]-benzoesäure; Hydrochlorid 218–219 3-[2-(6-Methylpyridin-2-yl)-vinyl]-benzoesäure 150–151 4-[2-(6-Methylpyridin-2-yl)-vinyl]-benzoesäure 206–207 3-[2-(6-Methylpyridin-2-yl)-vinyl]-benzoesäuremethylester; Hydrochlorid 237–238 4-[2-(6-Methylpyridin-2-yl)-vinyl]-benzoesäuremethylester 112–113 2-Methoxy-4-[2-(6-methylpyridin-2-yl)-vinyl]-phenol 118–119 {3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-methanol; Hydrochlorid 230–231 6-Styrylpyridin-2-carbonsäure-tert-butylamid 87–88 2-(2-Brom-2-phenylvinyl)-6-methylpyridin; Hydrochlorid 150–154 2-Methyl-6-phenylethinylpyridin; Hydrochlorid 146–148 6-Styrylpyridin-2-carbonsäurehexylamid; Hydrochlorid 118–125 6-[2-(2-Chlorphenyl)-vinyl]-2-methylnicotinsäure 219–221 Zer. 2-[2-(2-Chlorphenyl)-vinyl]-6-methylnicotinsäure 168–170 2-[2-(3,5-Dichlorphenyl)-vinyl]-6-methylpyridin 75–77 2-Methyl-6-[2-(3-trifluormethylphenyl)-vinyl]-pyridin 44–45 (E)-6-[2-(4-Pyridyl)-vinyl]-2-picolin 72–73 N,N-Diethyl-3-[2-(6-methylpyridin-2-yl)-vinyl]-benzamidhydrochlorid 227–228 N,N-Diethyl-4-[2-(6-methylpyridin-2-yl)-vinyl]-benzamidhydrochlorid 183–184 (E)-6-[2-(3-Pyridyl)-vinyl]-2-picolin Gelbliches Öl {2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-essigsäureethylester Farbloser Gummi 3-[2-(6-Methylpyridin-2-yl)-vinyl]-N-(3-trifluormethylphenyl)-benzamid; Hydrochlorid 249–251 4-[2-(6-Methylpyridin-2-yl)-vinyl]-N-(3-trifluormethylphenyl)-benzamid 160–161 2-[2-(3-Nitrophenyl)-vinyl]-pyridin 127–128 6-Styrylpyridin-2-carbonsäure-(3-trifluormethylphenyl)-amid 126–129 2-(6-Styrylpyridin-2-yl)-propan-2-ol; Hydrochlorid 171–174 2-Methyl-6-(2-thiophen-2-ylvinyl)-pyridin 208–211 2-[2-(3-Chlorphenyl)-vinyl]-pyridin 51–53 2-[2-(3-Cyanophenyl)-vinyl]-pyridin 85–86 2-[2-(3-Bromphenyl)-vinyl]-6-methylpyridin 58–59 2-[2-(3-Bromphenyl)-2-fluorvinyl]-6-methylpyridin 58–59 2-[2-(3,5-Dimethylphenyl)-2-fluorvinyl]-6-methylpyridin 70–72 2-[2-(2,3-Dimethoxyphenyl)-vinyl]-6-methylpyridin Farbloses Öl 2-[2-(2,3-Dichlorphenyl)-vinyl]-6-methylpyridin 67–68 2-[2-(3-Chlorphenyl)-1-methylvinyl]-pyridin Farbloses Öl {2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-yl}-methanol 87–90 2-Methyl-6-[2-(3-trimethylsilanylethinylphenyl)-vinyl]-pyridin Gelbliches Öl 2-[2-(3,4-Difluorphenyl)-vinyl]-6-methylpyridin 61–62 2-[2-(3-Ethinylphenyl)-vinyl]-6-methylpyridin Gelbliches Öl 2-[2-(3,5-Difluorphenyl)-vinyl]-6-methylpyridin Gelbliches Öl 2-[2-(3-Fluorphenyl)-vinyl]-6-methylpyridin Gelbliches Öl 2-[2-(3-Methoxyphenyl)-vinyl]-6-methylpyridin Gelbliches Öl 2-Methyl-6-[2-(3-phenoxyphenyl)-vinyl]-pyridin Gelbliches Öl 2-[2-(3-Benzyloxyphenyl)-vinyl]-6-methylpyridin 68–69 2-[2-(2,5-Difluorphenyl)-vinyl]-6-methylpyridin 44–45 {2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-essigsäure 230–233 (3-{2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin 203–205 {6-[2-(2-Chlorphenyl)-vinyl]-2-methylpyridin-3-yl}-methanol 131–133 2-(3-Bromphenylethinyl)-6-methylpyridin 61–63 2-Methyl-6-{2-[3-(3-trifluormethylphenoxy)-phenyl]-vinyl}-pyridin Gelbliches Öl 2-[2-(3,5-Dimethoxyphenyl)-vinyl]-6-methylpyridin 43–45 2-[2-(3-Chlorphenyl)-vinyl]-3-methoxy-6-methylpyridin 52–53 Essigsäure-4-brom-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester Gelbliches Öl Essigsäure-3-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester Gelbliches Öl 2-[2-(3,4-Dichlorphenyl)-vinyl]-6-methylpyridin 73–75 4-Brom-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenol 246–248 Essigsäure-2-[2-(3,5-dichlorphenyl)-vinyl]-6-methylpyridin-3-ylester 156–158 Essigsäure-6-[2-(3,5-dichlorphenyl)-vinyl]-2-methylpyridin-3-ylester 159–161 Essigsäure-2-[2-(3,5-dichlorphenyl)-vinyl]-pyridin-3-ylester 154–156 2-Methyl-6-(2-naphthalin-1-ylvinyl)-pyridin Gelbliches Öl 2-[2-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-vinyl]-6-methylpyridin 99–101 2-Methyl-6-(2-naphthalin-2-ylvinyl)-pyridin 97–99 2-Methyl-6-(2-m-tolylvinyl)-pyridin Gelbliches Öl 2-{2-[3-(3,5-Dichlorphenoxy)-phenyl]-vinyl}-6-methyl-pyridin Gelblicher Gummi 2-[2-(3-Chlorphenyl)-propenyl]-6-methylpyridin Gelbliches Öl 2-[2-(2,3-Dihydrobenzofuran-5-yl)-vinyl]-6-methylpyridin 88–90 2-[2-(4-Fluorphenyl)-vinyl]-6-methylpyridin 50–51 2-Methyl-6-(2-o-tolylvinyl)-pyridin Gelbliches Öl 2-Methyl-6-(2-p-tolylvinyl)-pyridin 85–86 2-Methyl-6-(2-p-tolylpropenyl)-pyridin Gelbliches Öl 3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylamin 126–129 (2,3-Dimethoxy-7-nitrochinoxalin-5-ylmethyl)-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amin Fahloranger Schaum N-{3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-acetamid 147 N-{3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-2-phenylacetamid 156 2,2-Dimethyl-N-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-propionamid 166–168 Thiophen-2-carbonsäure-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amid 197 Zer. Cyclohexancarbonsäure-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amid 215 1-(4-Bromphenyl)-3-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-harnstoff 197 Zer. 2-Methyl-6-[2-(4-nitrophenyl)-vinyl]-pyridin 134–135 4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylamin 147–148 2-[2-(3,5-Dichlorphenyl)-vinyl]-6-methylpyridin-3-ol 218–220 6-[2-(3,5-Dichlorphenyl)-vinyl]-2-methylpyridin-3-ol 286 Zer. 2-[2-(3,5-Dichlorphenyl)-vinyl]-pyridin-3-ol 240–242 2-[2-(6-Chlorbenzo[1,3]dioxo-5-yl)-vinyl]-6-methylpyridin 131–132 2-[2-(2,3-Difluorphenyl)-vinyl]-6-methylpyridin 55–56 2-[2-(3,4-Dichlorphenyl)-propenyl]-6-methylpyridin Gelbliches Öl 2-[2-(3,5-Bistrifluormethylphenyl)-vinyl]-6-methylpyridin 85–86 Essigsäure-2-methoxy-6-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester Gelbliches Öl 2-Methoxy-6-[2-(6-methylpyridin-2-yl)-vinyl]-phenol 118–120 2-Methyl-6-[2-(2,3,6-trifluorphenyl)-vinyl]-pyridin 59–62 2-[2-(4-Fluor-3-trifluormethylphenyl)-vinyl]-6-methylpyridin Gelbliches Öl 2-Methyl-6-(2,3,6-trifluorphenylethinyl)-pyridin 93–94 Essigsäure-4-chlor-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester Gelbliches Öl Essigsäure-2,6-di-tert-butyl-4-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester 127–128 3-(6-Methylpyridin-2-ylethinyl)-benzamid 187–189 Essigsäure-4-brom-2-methoxy-6-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester 151–153 2-(6-Chlorbenzo[1,3]dioxol-5-ylethinyl)-6-methylpyridin 105–106 Hellbraune Kristalle 2-[2-(3,5-Dichlorphenyl)-vinyl]-3-methoxy-6-methylpyridin 127–129 2-[2-(3,5-Dichlorphenyl)-vinyl]-3-methoxypyridin 111–113 5-Azido-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenol 143 Zer. 2-[2-(Pyridin-3-yl)-ethinyl]-6-methylpyridin Hellgelbe Kristalle 60–61 N-{3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-bernsteinsäure 212–213 1-tert-Butyl-3-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-harnstoff 191–192 5-({3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylamino]-methyl)-7-nitro-1,4-dihydrochinoxalin-2,3-dion 250 Zer. Tetrahydrofuran-2-carbonsäure-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amid 160–161 (1-{3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylcarbamoyl}-2-phenylethyl)-carbaminsäure-tert-butylester Farbloser Schaum ({3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylcarbamoyl}-methyl)-carbaminsäure-tert-butylester Farbloser Schaum Diethyl-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amin 217 Zer. Ethyl-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amin 225 Zer. Ethyl-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amin 183 Zer. 2-(2-Ethoxy-3,6-difluorphenylethinyl)-6-methylpyridin Gelbliches Öl 2-(3,5-Difluorphenylethinyl)-6-methylpyridin Gelbliches Öl 2-(3-Fluorphenylethinyl)-6-methylpyridin 26–28 2-[2-(3,5-Dimethylphenyl)-vinyl]-6-methylpyridin 56–57 2-[2-(3,4-Dimethoxyphenyl)-vinyl]-6-methylpyridin 55–56 2-(3,4-Dichlorphenylethinyl)-6-methylpyridin 73–74 2-(4-Ethoxy-3-trifluormethylphenylethinyl)-6-methylpyridin 61–62 2-(4-Fluorphenylethinyl)-6-methylpyridin 98–100 2-Methyl-6-o-tolylethinylpyridin Gelbliches Öl 2-(3,4-Difluorphenylethinyl)-6-methylpyridin 65–68 2-Methyl-6-[2-(2,3,5-trichlorphenyl)-vinyl]-pyridin 80–82 1-[3-(6-Methylpyridin-2-ylethinyl)-phenyl]-ethanon 76–78 2-Methyl-6-(3-trifluormethylphenylethinyl)-pyridin 35–37 2-Methyl-6-(3-nitrophenylethinyl)-pyridin 99,5–102,5 6-[2-(3,5-Dichlorphenyl)-vinyl]-3-methoxy-2-methylpyridin 98–100 {2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-yl}-morpholin-4-ylmethanon 123–125 (3-{2-[2-(3,5-Dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylaminhydrochlorid 207–210 N-{4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-bernsteinsäure 201 Zer. N-{4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-2-phenylacetamid 236–237 Zer. ({4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylcarbamoyl}-methyl)-carbaminsäure-tert-butylester 144–145 Zer. 1-(tert-Butyl-3-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-harnstoff 209 Zer. {3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-thiophen-2-ylmethylaminhydrochlorid 161–162 Cyclohexylmethyl-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-aminhydrochlorid 178–179 Zer. {4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-thiophen-2-ylmethylamin 100 Cyclohexylmethyl-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amin 106–107 2-Amino-N-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-3-phenylpropionamid 102 2-Amino-N-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-acetamid 105 2-Amino-N-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-acetamid 217–219 Zer. 1-[1-({2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-acetyl)-piperidin-4-yl]-imidazolidin-2-on Amorpher Schaum (1-{4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylamino}-ethyl)-phosphonsäuredimethylester Oranger amorpher Feststoff 2-[2-(2Methoxyphenyl)-vinyl]-6-methylpyridin 129–130 2-(3-Ethoxy-4-fluorphenylethinyl)-6-methylpyridin 82–83 2-(3-Chlorphenylethinyl)-6-methylpyridin 57–59 1-(3-Pyridin-2-ylethinylphenyl)-ethanon 48–51 4-Chlor-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenol 256–260 4-Brom-2-methoxy-6-[2-(6-methylpyridin-2-yl)-vinyl]-phenol 121–123 2-Methyl-6-m-tolylethinylpyridin 57–58 2-(2,5-Difluorphenylethinyl)-6-methylpyridin 49–50 2-(3,5-Dimethylphenylethinyl)-6-methylpyridin Gelbliches Öl 2-[2-(3,5-Dibromphenyl)-vinyl]-6-methylpyridin 68–70 2-Methyl-6-[2-(pyrimidin-5-yl)-ethinyl]-pyridin 110–112 (2-{2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-ethyl)-dimethylamin 165–167 Essigsäure-1-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-ethylester 3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenol 250–251 3-(6-Methylpyridin-2-ylethinyl)-phenylamin 129–130 N-[3-(6-Methylpyridin-2-ylethinyl)-phenyl]-2-phenylacetamid 133–135 Zer. Thiophen-2-carbonsäure-[3-(6-methylpyridin-2-ylethinyl)-phenyl]-amid 156–157 Zer. 2-Methyl-6-thiophen-2-ylethinylpyridin 34–36 3-(6-Methylpyridin-2-ylethinyl)-benzoesäureethylester 56–58 2-(3,5-Dibromphenylethinyl)-6-methylpyridin 100:101 {2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-ylmethyl}-dimethylamin 227–229 Zer. (3-{6-[2-(3-Chlorphenyl)-vinyl]-2-methylpyridin-3-yloxy}-propyl)-dimethylamin 184–186 5-Azido-4-iod-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenol Rotes Glas 2,6-Di-tert-butyl-4-[2-(6-methylpyridin-2-yl)-vinyl]-phenol 126–127 1-{4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-ethanol 97–99 2-Methyl-6-[2-(pyrimidin-2-yl)-ethinyl]-pyridin 144–145 [3-(6-Methylpyridin-2-ylethinyl)-phenyl]-phenylmethanon 99–100 6-(6-Methylpyridin-2-ylethinyl)-3,4-dihydro-1H-chinolin-2-on 189–191 2-(3-{2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-isoindol-1,3-dion 101–103 3-Methoxy-6-methyl-2-m-tolylethinylpyridin Braunes Öl Essigsäure-2-[2-(6-methylpyridin-2-yl)-vinyl]-4-nitrophenylester 129–131 6-(6-Methylpyridin-2-ylethinyl)-indan-1-on 160–165 2-Methyl-6-[2-(pyrazin-2-yl)-ethinyl]-pyridin 95–96 N-Methyl-N-(3-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenoxy}-propyl)-acetamid 62–70 2-[2-(3,5-Bistrifluormethylphenyl)-1-ethoxyvinyl]-6-methylpyridin Gelbes Öl Essigsäure-2-phenylethinylpyridin-3-ylester Braunes Öl Essigsäure-6-methyl-2-m-tolylethinylpyridin-3-ylester Braunes Öl Essigsäure-4-[2-(6-methylpyridin-2-yl)-vinyl]-2-nitrophenylester 91–93 2-[2-(6-Methylpyridin-2-yl)-vinyl]-4-nitrophenol 275 Zer. Dimethyl-[3-(2-phenylethinylpyridin-3-yloxy)-propyl]-amin Gelbliches Öl Dimethyl-(3-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenoxy}-propyl)-amin 240–243 1-{4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-ethanon 56–58 2-(3-Fluorphenylethinyl)-chinolin 81–83 Essigsäure-2-methyl-6-styrylpyridin-3-ylester 93–96 4-[2-(6-Methylpyridin-2-yl)-vinyl]-2-nitrophenol 141–143 3-Ethoxy-4-[2-(6-methylpyridin-2-yl)-vinyl]-2-nitrophenol 175–178 Zer. 4-(6-Methylpyridin-2-ylethinyl)-2-nitrophenol 184–187 Zer. Essigsäure-2-[2-(6-methylpyridin-2-yl)-vinyl]-6-nitrophenylester 105–110 Zer. Dimethyl-[3-(6-methyl-2-phenylethinylpyridin-3-yloxy)-propyl]-amin Gelber Gummi 2-Azido-4-[2-(6-methylpyridin-2-yl)-vinyl]-phenol 155–157 Zer. Dimethyl-[3-(6-methyl-2-m-tolylethinylpyridin-3-yloxy)-propyl]-amin Gelbliches Öl 2-(3-Methansulfonylphenylethinyl)-6-methylpyridin 108–110 Zer. 3-{2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propylamin 186–189 4-Azido-N-(3-{2-[2-(3-chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-2-hydroxybenzamid 99–102 Zer. 3-[3-(3-Dimethylaminopropoxy)-6-methylpyridin-2-ylethinyl]-benzonitril Gelber Gummi 5-(6-Methylpyridin-2-ylethinyl)-indan-1-on 133–134 2-Methyl-6-(2,3,5-trichlorphenylethinyl)-pyridin 112–114 2-[2-(6-Methylpyridin-3-yl)-ethinyl]-6-methylpyridin 118–119 Dimethyl-(3-[6-methyl-2-(3-trifluormethylphenylethinyl)-pyridin-3-yloxy]-propyl}-amin Gelber Gummi 2-[2-(6-Methylpyridin-3-yl)-ethinyl]-3-methoxy-6-methylpyridinhydrochlorid 198–199 2-Methyl-6-(5,6,7,8-tetrahydronaphthalin-2-ylethinyl)-pyridin 50–51 3-[2-(3-Chlorphenylethinyl)-6-methylpyridin-3-yloxy]-propylamin 151–153 (3-{4-Brom-2-methoxy-6-[2-(6-methylpyridin-2-yl)-vinyl]-phenoxy}-propyl)-dimethylamin 211–215 [6-(3-Fluorphenylethinyl)-pyridin-2-yl]-dimethylamin Braunes Öl 6'-(3-Fluorphenylethinyl)-3,4,5,6-tetrahydro-2H-[1,2']-bipyridinyl Brauner Gummi {3-[2-(3-Chlorphenylethinyl)-6-methylpyridin-3-yloxy]-propyl}-dimethylamin 158–160 4-Azido-N-{3-[2-(3-chlorphenylethinyl)-6-methylpyridin-3-yloxy]-propyl}-2-hydroxybenzamid 161–163 Zer. 1-[3-(6-Methylpyridin-2-ylethinyl)-phenyl]-1H-[1,2,4]triazol-3-carbonsäureethylester 105–110 Zer. 1-[3-(6-Methyl-2-phenylethinylpyridin-3-yloxy)-propyl]-piperidin-3-ol 108–109 2-Ethinyl-6-(3-fluorphenylethinyl)-pyridin 89–90 3-Methyl-6-(6-methylpyridin-2-ylethinyl)-3H-benzoxazol-2-on 172–174 1-[3-(6-Methylpyridin-2-ylethinyl)-phenyl]-1H-[1,2,4]triazol-3-carbonsäure-dimethylamid 154–157 1-[3-(6-Methyl-2-phenylethinylpyridin-3-yloxy)-propyl]-piperidin-4-ol Amorpher weißer Feststoff 5-(6-Methylpyridin-2-ylethinyl)-2-nitrophenol 150–151 Zer. 5-[2-Brom-2-(6-methylpyridin-2-yl)-vinyl]-2-nitrophenol 158–159 5-[2-(6-Methylpyridin-2-yl)-E-vinyl]-2-nitrophenol 171–173 5-[2-(6-Methylpyridin-2-yl)-Z-vinyl]-2-nitrophenol 108–110 4-Azido-2-hydroxy-N-[3-(6-methylpyridin-2-ylethinyl)-phenyl]-benzamid 180–182 Zer. 5-(3-Dimethylaminopropoxy)-6-phenylethinylpyridin-2-carbonsäureethylester 160–162 6-Methyl-2-styrylpyrimidin-4-ol 221–225 2-Ethyl-6-(3-fluorphenylethinyl)-pyridin Braunes Öl 2-(3,5-Dichlorphenylethinyl)-6-methylpyridin 74–76 2-Methyl-6-(3-trifluormethoxyphenylethinyl)-pyridin < 30; Braune Kristalle 2-Methyl-6-(3-[1,2,4]triazol-1-ylphenylethinyl)-pyridin 128–130 4-(6-Methylpyridin-2-ylethinyl)-phthalonitril 138–140 2-Methyl-6-{2-[3-(1H-tetrazol-5-yl)-phenyl]-vinyl}-pyridin, Verbindung mit Ameisensäure 234–240 3-[2-(3,5-Dichlorphenylethinyl)-6-methylpyridin-3-yloxy]-propylamin 97–100 {3-[2-(3,5-Dichlorphenylethinyl)-6-methylpyridin-3-yloxy]-propyl}-dimethylamin 171–173 2-(3,5-Dimethylphenylethinyl)-3-methoxy-6-methylpyridin Gelbliches Öl 2-[2-(3-Fluorphenyl)-vinyl]-6-methylpyridin-3-ol 251–253 Zer. 6-(3-Fluorphenylethinyl)-2-methylnicotinsäureethylester 84–86 2-Azido-5-(6-methylpyridin-2-ylethinyl)-phenol 153–155 Zer. 6-(3,4-Dimethoxyphenylethinyl)-5-(3-dimethylaminopropoxy)-pyridin-2-carbonsäureethylester 149–152 2-(4-Methoxy-3-trifluormethylphenylethinyl)-6-methylpyridin 86–87 2-(3-Fluorphenylethinyl)-6-methoxypyridin Braunes Öl 2-(3-Fluorphenylethinyl)-5-methylpyridin 74–76 6-(3,5-Dichlorphenylethinyl)-5-(3-dimethylaminopropoxy)-pyridin-2-carbonsäureethylester 195–198 5-(3-Dimethylaminopropoxy)-6-(3,5-dimethylphenylethinyl)-pyridin-2-carbonsäureethylester 187–190 6-(3-Fluorphenylethinyl)-2-methylnicotinsäure 173–175 [6-(3-Fluorphenylethinyl)-2-methylpyridin-3-yl]-methanol 116–118 [4-(4-Fluorbenzoyl)-piperidin-1-yl]-[6-(3-fluorphenylethinyl)-2-methylpyridin-3-yl]-methanon 138–140 2-(3-Fluorphenylethinyl)-6-methylnicotinsäureethylester Braunes Öl 2-(3-Fluorphenylethinyl)-4,6-dimethylpyridin Braunes Öl 6-(3-Fluorphenylethinyl)-N-(5-methoxyindan-2-ylmethyl)-2-methylnicotinamid 157–159 {[6-(3-Fluorphenylethinyl)-2-methylpyridin-3-carbonyl]-amino}-phenylessigsäuremethylester 133–135 2-Methyl-6-(5-methylthiophen-2-ylethinyl)-pyridin 58–59 2-Methyl-6-(2,3,5-trimethylphenylethinyl)-pyridin Braunes Öl 3-{2-[2-(3-Fluorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propan-1-ol 86–88 [6-(3-Fluorphenylethinyl)-2-methylpyridin-3-ylmethyl]-dimethylamin 220–222 2,2-Dimethylpropionsäure-3-[2-(3-fluorphenylethinyl)-6-methylpyridin-3-yloxy]-propylester Gelbliches Öl 2-Azido-4-iod-5-(6-methylpyridin-2-ylethinyl)-phenol 140 Zer. 6-Azido-2,4-diiod-3-(6-methylpyridin-2-ylethinyl)-phenol 162 Zer. 4-Azido-2-hydroxy-5-iod-N-[3-(6-methylpyridin-2-ylethinyl)-phenyl]-benzamid 185 Zer. Essigsäure-3-acetoxymethyl-5-(6-methylpyridin-2-ylethinyl)-benzylester Braunes Öl (Benzyl-{[2-(3-fluorphenylethinyl)-6-methylpyridin-3-yloxy]-acetyl}-amino)-essigsäureethylester Braunes Öl 2-[2-(3-Fluorphenyl)-vinyl]-6-methylisonicotinsäureethylester 76–77 3-[2-(3-Fluorphenylethinyl)-6-methylpyridin-3-yloxy]-propan-1-ol 72–74 [3-Hydroxymethyl-5-(6-methylpyridin-2-ylethinyl)-phenyl]-methanol 115–117 (3-{2-[2-(3,5-Dimethylphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin Gelblicher Gummi [4-(4-Fluorbenzoyl)-piperidin-1-yl]-{6-[2-(3-fluorphenyl)-vinyl]-2-methylpyridin-3-yl}-methanon 156–158 2-[2-(3-Fluorphenyl)-vinyl]-6-methylisonicotinsäure 245–248 {6-[2-(2-Chlorphenyl)-vinyl]-2-methylpyridin-3-yl}-[4-(4-fluorbenzoyl)-piperidin-1-yl]-methanon 109–112 2-(3-Ethinylphenylethinyl)-6-methylpyridin 48–49 (3-{2-[2-(2,6-Dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylaminhydrochlorid 207–210 (3-{2-[2-(2,3-Dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylaminhydrochlorid 161–169 4-[6-(3-Fluorphenylethinyl)-2-methylpyridin-3-carbonyl]-piperazin-1-carbonsäure-tert-butylester 97–99 [6-(3-Fluorphenylethinyl)-2-methylpyridin-3-yl]-piperazin-1-ylmethanon 250–252 Zer. [4-(4-Azido-2-hydroxybenzoyl)-piperazin-1-yl]-[6-(3-fluorphenylethinyl)-2-methylpyridin-3-yl]-methanon 186–188 Zer. (3-{2-[2-(2,4-Dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylaminhydrochlorid 170–176 2-(3-Fluorphenylethinyl)-6-methylisonicotinsäureethylester 89–91 2-(3-Fluorphenylethinyl)-6-methylisonicotinsäure-tert-butylester 94–96 2-(3-Fluorphenylethinyl)-6-methylisonicotinsäure 231 Zer. [2-(3-Fluorphenylethinyl)-6-methylpyridin-4-yl]-methanol 143–146 [4-(4-Fluorbenzoyl)-piperidin-1-yl]-[2-(3-fluorphenylethinyl)-6-methylpyridin-4-yl]-methanon 156–158 3-Allyloxy-2-[2-(3,5-dichlorphenyl)-vinyl]-6-methylpyridin 105–106 [2-(3-Fluorphenylethinyl)-6-methylpyridin-4-yl]-morpholin-4-ylmethanon 114–116 Essigsäure-3-(6-methylpyridin-2-ylethinyl)-benzylester Braunes Öl [2-(3-Fluorphenylethinyl)-6-methylpyridin-4-ylmethyl]-dimethylamin 209–212 (3-{2-[2-(3,5-Dichlorphenyl)-propenyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylaminhydrochlorid 182–184 2-(3-Fluorphenylethinyl)-3-methoxy-6-methylpyridin Gelbliches Öl (3-{2-[2-(3,5-Dichlorphenyl)-vinyl]-pyridin-3-yloxy}-propyl)-dimethylaminhydrochiorid 171–174 (4-Azido-2-hydroxy-5-iodphenyl)-{4-[6-(3-fluorphenylethinyl)-2-methylpyridin-3-carbonyl]-piperazin-1-yl}-methanon 195–200 Zer. 4-Azido-N-{3-[2-(3-chlorphenylethinyl)-6-methylpyridin-3-yloxy]-propyl}-2-hydroxy-5-iodbenzamid 142–150 Zer. 4-(2-Pyridin-2-ylvinyl)-benzoesäureethylester 100–102 (3-{2-[2-(4-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylaminhydrochlorid 159–171 [3-(6-Methylpyridin-2-ylethinyl)-phenyl]-methanol 43–45 6-(3-Fluorphenylethinyl)-nicotinsäure-tert-butylester 96–98 (3-{2-[2-(3,4-Dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylaminhydrochlorid 174–177 2-(1-Brom-2-phenylvinyl)-4-methylpyrimidin Gelbes Öl 6-(3-Fluorphenylethinyl)-nicotinsäure 223 Zer. [4-(4-Fluorbenzoyl)-piperidin-1-yl]-[6-(3-fluorphenylethinyl)-pyridin-3-yl]-methanon 136,0–139,0 2-(2-tert-Butoxy-3,6-difluorphenylethinyl)-6-methylpyridin 72,0–74,0 2-Methyl-6-[2-(2,4,5-trifluorphenyl)-vinyl]-pyridin 74–76 2-Methyl-6-[2-(2,3,4-trifluorphenyl)-vinyl]-pyridin 79–82 3-(6-Methylpyridin-2-ylethinyl)-phenol 142–144 2-Methyl-6-[2-(3,4,5-trifluorphenyl)-vinyl]-pyridin 74–76 2-(3-Methoxyphenylethinyl)-6-methylpyridin 55–57 2-Methyl-6-(2,3,4-trifluorphenylethinyl)-pyridin 104–106 - (Zer. = Zersetzung)
Claims (8)
- Verwendung einer Verbindung der Formel I worin X für eine optional durch Halogen substituierte (C2-C4)-Alkylen- oder (C2-C4)-Alkinylengruppe steht, die über vicinale ungesättigte Kohlenstoffatome gebunden sind, R1 für Wasserstoff, (C1-C4)-Alkyl, (C1-C4)-Alkoxy, Hydroxy-(C1-C4)-alkyl, Cyano, Ethinyl, Carboxy, (C1-C4)-Alkoxycarbonyl, Di-(C1-C4)-alkylamino, (C1-C5)-Alkylaminocarbonyl oder Trifluormethylphenylaminocarbonyl steht, R2 für Wasserstoff, Hydroxy, (C1-C4)-Alkyl, Hydroxy-(C1-C4)-alkyl, (C1-C4)-Alkoxy, Carboxy, (C2-C5)-Alkanoyloxy, (C1-C4)-Alkoxycarbonyl, Di-(C1-C4)-alkylamino-(C1-C4)-alkanoyl, Di-(C1-C4)-alkylaminomethyl, 4-(4-Fluorbenzoyl)-piperidin-1-ylcarboxy, 4-t.-Butyloxycarbonylpiperazin-1-ylcarboxy, 4-(4-Azido-2-hydroxybenzoyl)-piperazin-1-ylcarboxy oder 4-(4-Azido-2-hydroxy-3-iodbenzoyl)-piperazin-1-ylcarboxy steht, R3 für Wasserstoff, (C1-C4)-Alkyl, Carboxy, (C1-C4)-Alkoxycarbonyl, (C1-C4)-Alkylcarbamoyl, Hydroxy-(C1-C4)-alkyl, Di-(C1-C4)-alkylaminomethyl, Morpholinocarbonyl oder 4-(4-Fluorbenzoyl)-piperidin-1-ylcarboxy steht, R4 für Wasserstoff, Hydroxy, (C1-C4)-Alkoxy, Carboxy, (C2-C5)-Alkanoyloxy, (C1-C4)-Alkoxycarbonyl, Amino-(C1-C4)-alkoxy, Di-(C1-C4)-alkylamino-(C1-C4)-alkoxy, Di-(C1-C4)-alkylamino)-(C1-C4)-alkyl, Carboxy-(C1-C4)-alkylcarbonyl, (C1-C4)-Alkoxycarbonyl-(C1-C4)-alkoxy, Hydroxy-(C1-C4)-alkyl, Di-(C1-C4)-alkylamino-(C1-C4)-alkoxy oder m-Hydroxy-p-azidophenylcarbonylamino-(C1-C4)-alkoxy steht, und R5 eine Gruppe der folgenden Formeln ist worin Ra und Rb unabhängig stehen für Wasserstoff, Hydroxy, Halogen, Nitro, Cyano, Carboxy, (C1-C4)-Alkyl, (C1-C4)-Alkoxy, Hydroxy-(C1-C4)-alkyl, (C1-C4)-Alkoxycarbonyl, (C2-C7)-Alkanoyl, (C2-C5)-Alkanoyloxy, (C2-C5)-Alkanoyloxy-(C1-C4)-alkyl, Trifluormethyl, Trifluormethoxy, Trimethylsilylethinyl, (C2-C5)-Alkinyl, Amino, Azido, Amino-(C1-C4)-alkoxy, (C2-C5)-Alkanoylamino-(C1-C4)-alkoxy, (C1-C4)-Alkylamino-(C1-C4)- alkoxy, Di-(C1-C4)-Alkylamino-(C1-C4)-alkoxy, (C1-C4)-Alkylamino, Di-(C1-C4)-alkylamino, Monohalogenbenzylamino, Thienylmethylamino, Thienylcarbonylamino, Trifluormethylphenylaminocarbonyl, Tetrazolyl, (C2-C5)-Alkanoylamino, Benzylcarbonylamino, (C1-C4)-Alkylaminocarbonylamino, (C1-C4)-Alkoxycarbonylaminocarbonylamino oder (C1-C4)-Alkylsulfonyl, Rc für Wasserstoff, Fluor, Chlor, Brom, Hydroxy, (C1-C4)-Alkyl, (C2-C5)-Alkanoyloxy, (C1-C4)-Alkoxy oder Cyano steht, und R4 für Wasserstoff, Halogen oder (C1-C4)-Alkyl steht, in freier Form oder in Form eines N-Oxids oder eines pharmazeutisch akzeptablen Salzes, zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von Störungen, die mit Irregularitäten der glutamatergen Signaltransmission assoziiert sind, und von Störungen des Nervensystems, die vollständig oder teilweise durch mGluR5 mediiert sind.
- Verwendung nach Anspruch 1, worin R1 für Wasserstoff, (C1-C4)-Alkyl, (C1-C4)-Alkoxy, Cyano, Ethinyl oder Di-(C1-C4)-alkylamino steht, R2 für Wasserstoff, Hydroxy, Carboxy, (C1-C4)-Alkoxycarbonyl, Di-(C1-C4)-alkylaminomethyl, 4-(4-Fluorbenzoyl)-piperidin-1-ylcarboxy, 4-t.-Butyloxycarbonylpiperazin-1-ylcarboxy, 4-(4-Azido-2-hydroxybenzoyl)-piperazin-1-ylcarboxy oder 4-(4-Azido-2-hydroxy-3-iodbenzoyl)-piperazin-1-ylcarboxy steht, R3 wie im Anspruch 1 definiert ist, R4 für Wasserstoff, Hydroxy, Carboxy, (C2-C5)-Alkanoyloxy, (C1-C4)-Alkoxycarbonyl, Amino-(C1-C4)-alkoxy, Di-(C1-C4)-alkylamino-(C1-C4)-alkoxy, Di-(C1-C4)-alkylamino-(C1-C4)-alkyl oder Hydroxy-(C1-C4)-alkyl steht, und R5 eine Gruppe der folgenden Formeln ist worin Ra und Rb unabhängig für Wasserstoff, Halogen, Nitro, Cyano, (C1-C4)-Alkyl, (C1-C4)-Alkoxy, Trifluormethyl, Trifluormethoxy oder (C2-C5)-Alkinyl stehen, und Rc und Rd wie im Anspruch 1 definiert sind.
- Verwendung einer Verbindung nach Anspruch 1 oder 2 zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von Epilepsie, Zerebralischämien, besonders von akuten Ischämien, Ischämiekrankheiten des Auges, Muskelspasmen, wie lokaler oder allgemeiner Spastizität, und besonders von Konvulsionen oder Schmerz.
- Verwendung einer Verbindung nach Anspruch 1 oder 2 zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung akuter, traumatischer und chronischer degenerativer Prozesse des Nervensystems, wie Parkinson-Krankheit, senile Demenz, Alzheimer-Krankheit, Chores Huntington, amyotrophe Lateralsklerose und multiple Sklerose, psychiatrischer Krankheiten, wie Schizophrenie und Angst, Depression und Schmerz.
- Verbindung, die ausgewählt ist aus 3-[2-(6-Methylpyridin-2-yl)-vinyl]-benzonitril, 2-[2-(6-Methylpyridin-2-yl)-vinyl]-benzonitril, 2-Methyl-6-[2-(pyridin-4-yl)-vinyl]-pyridin, 2-Methyl-6-[2-(pyridin-3-yl)-vinyl]-pyridin, 2-[2-(3-Bromphenyl)-ethinyl]-6-methylpyridin, 3-[2-(6-Methylpyridin-2-yl)-ethinyl]-benzonitril, 2-Styrylpyridin-3-ol, 2-Methyl-6-[2-(3-nitrophenyl)-vinyl]-pyridin, Essigsäure-6-[2-(2-chlorphenyl)-vinyl]-pyridin-3-ylester, 6-[2-(2-Chlorphenyl)-vinyl]-pyridin-3-ol, Essigsäure-2-[2-(2-chlorphenyl)-vinyl]-pyridin-3-ylester, 2-[2-(2-Chlorphenyl)-vinyl]-pyridin-3-ol, 6-Methyl-2-styrylpyridin-3-ol, Essigsäure-2-[2-(2-chlorphenyl)-vinyl]-6-methylpyridin-3-ylester, 2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-ol, (Z)-6-Methyl-2-styrylpyridin-3-ol, 2-[2-(2-Nitrophenyl)-vinyl]-pyridin, Essigsäure-2-[2-(4-chlorphenyl)-vinyl]-6-methylpyridin-3-ylester, Essigsäure-6-[2-(4-chlorephenyl)-vinyl]-2-methylpyridin-3-ylester, 2-[2-(4-Chlorphenyl)-vinyl]-6-methylpyridin-3-ol, 6-[2-(4-Chlorphenyl)-vinyl]-2-methylpyridin-3-ol, Essigsäure-6-methyl-2-[2-(2-nitrophenyl)-vinyl]-pyridin-3-ylester, 6-Methyl-2-[2-(2-nitrophenyl)-vinyl]-pyridin-3-ol, Essigsäure-2-methyl-6-[2-(2-nitrophenyl)-vinyl]-pyridin-3-ylester, 2-Methyl-6-[2-(2-nitrophenyl)-vinyl]-pyridin-3-ol, Essigsäure-2-[2-(3-chlorphenyl)-vinyl]-6-methylpyridin-3-ylester, Essigsäure-6-[2-(3-chlorphenyl)-vinyl]-2-methylpyridin-3-ylester, 2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin-3-ol, 6-[2-(3-Chlorphenyl)-vinyl]-2-methylpyridin-3-ol, (Z)-(6-Styrylpyridin-2-yl)-methanol, (E)-(6-Styrylpyridin-2-yl)-methanol, Dimethyl-[3-(6-methyl-2-styrylpyridin-3-yloxy)-propyl]-amin 2-Methyl-6-styrylpyridin-1-oxid, 2-Styrylpyridin-1-oxid, (E)-6-Methyl-2-(2-pyridin-2-ylvinyl)-pyridin-3-ol, (Z)-6-Methyl-2-(2-pyridin-2-ylvinyl)-pyridin-3-ol, 6-Styrylpyridin-2-carbonitril, 2-[2-(2,6-Dichlorphenyl)-vinyl]-6-methylpyridin, 3-Methoxy-6-methyl-2-styrylpyridin, 6-Styrylpyridin-2-carbonsäureamid, 2-[2-(6-Methylpyridin-2-yl)-vinyl]-benzonitril, 6-Styrylpyridin-2-carbonsäure, 6-Styrylpyridin-2-carbonsäuremethylester, Essigsäure-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester, 2-[2-(6-Methylpyridin-2-yl)-vinyl]-phenol, Essigsäure-2-methoxy-4-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester, 2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin, 2-[2-(4-Chlorphenyl)-vinyl]-6-methylpyridin, 2-[2-(2-Chlorphenyl)-vinyl]-5-ethylpyridin, 1-(6-Styrylpyridin-2-yl)-ethanon, 6-[2-(2-Chlorphenyl)-vinyl]-2-methylnicotinsäureethylester, 2-[2-(2-Chlorphenyl)-vinyl]-6-methylnicotinsäureethylester, 2-[2-(6-Methylpyridin-2-yl)-vinyl]-benzoesäure, 3-[2-(6-Methylpyridin-2-yl)-vinyl]-benzoesäure, 4-[2-(6-Methylpyridin-2-yl)-vinyl]-benzoesäure, 3-[2-(6-Methylpyridin-2-yl)-vinyl]-benzoesäuremethylester, 4-[2-(6-Methylpyridin-2-yl)-vinyl]-benzoesäuremethylester, 2-Methoxy-4-[2-(6-methylpyridin-2-yl)-vinyl]-phenol, {3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-methanol, 6-Styrylpyridin-2-carbonsäure-tert.-butylamid, 2-(2-Brom-2-phenylvinyl)-6-methylpyridin, 6-Styrylpyridin-2-carbonsäurehexylamid, 6-[2-(2-Chlorphenyl)-vinyl]-2-methylnicotinsäure, 2-[2-(2-Chlorphenyl)-vinyl]-6-methylnicotinsäure, 2-[2-(3,5-Dichlorphenyl)-vinyl]-6-methylpyridin, 2-Methyl-6-[2-(3-trifluormethylphenyl)-vinyl]-pyridin, (E)-6-[2-(4-Pyridyl)-vinyl]-2-picolin, N,N-Diethyl-3-[2-(6-methylpyridin-2-yl)-vinyl]-benzamid, N,N-Diethyl-4-[2-(6-methylpyridin-2-yl)-vinyl]-benzamid, (E)-6-[2-(3-Pyridyl)-vinyl]-2-picolin, {2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-essigsäureethylester, 3-[2-(6-Methylpyridin-2-yl)-vinyl]-N-(3-trifluormethylphenyl)-benzamid, 4-[2-(6-Methylpyridin-2-yl)-vinyl]-N-(3-trifluormethylphenyl)-benzamid, 2-[2-(3-Nitrophenyl)-vinyl]-pyridin, 6-Styrylpyridin-2-carbonsäure-(3-trifluormethylphenyl)-amid, 2-(6-Styrylpyridin-2-yl)-propan-2-ol, 2-Methyl-6-(2-thiophen-2-ylvinyl)-pyridin, 2-[2-(3-Cyanophenyl)-vinyl]-pyridin, 2-[2-(3-Bromphenyl)-vinyl]-6-methylpyridin, 2-[2-(3-Bromphenyl)-2-fluorvinyl]-6-methylpyridin, 2-[2-(3,5-Dimethylphenyl)-2-fluorvinyl]-6-methylpyridin, 2-[2-(2,3-Dimethoxyphenyl)-vinyl]-6-methylpyridin, 2-[2-(2,3-Dichlorphenyl)-vinyl]-6-methylpyridin, 2-[2-(3-Chlorphenyl)-1-methylvinyl]-pyridin, {2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-yl}-methanol, 2-Methyl-6-[2-(3-trimethylsilanylethinylphenyl)-vinyl]-pyridin, 2-[2-(3,4-Difluorphenyl)-vinyl]-6-methylpyridin, 2-[2-(3-Ethinylphenyl)-vinyl]-6-methylpyridin, 2-[2-(3,5-Difluorphenyl)-vinyl]-6-methylpyridin, 2-[2-(3-Fluorphenyl)-vinyl]-6-methylpyridin, 2-[2-(3-Methoxyphenyl)-vinyl]-6-methylpyridin, 2-Methyl-6-[2-(3-phenoxyphenyl)-vinyl]-pyridin, 2-[2-(3-Benzyloxyphenyl)-vinyl]-6-methylpyridin, 2-[2-(2,5-Difluorphenyl)-vinyl]-6-methylpyridin, {2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-essigsäure, (3-{2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin, {6-[2-(2-Chlorphenyl)-vinyl]-2-methylpyridin-3-yl}-methanol, 2-(3-Bromphenylethinyl)-6-methylpyridin, 2-Methyl-6-{2-[3-(3-trifluormethylphenoxy)-phenyl]-vinyl}-pyridin, 2-[2-(3,5-Dimethoxyphenyl)-vinyl]-6-methylpyridin, 2-[2-(3-Chlorphenyl)-vinyl]-3-methoxy-6-methylpyridin, Essigsäure-4-brom-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester, Essigsäure-3-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester, 2-[2-(3,4-Dichlorphenyl)-vinyl]-6-methylpyridin, 4-Brom-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenol, Essigsäure-2-[2-(3,5-dichlorphenyl)-vinyl]-6-methylpyridin-3-ylester, Essigsäure-6-[2-(3,5-dichlorphenyl)-vinyl]-2-methylpyridin-3-ylester, Essigsäure-2-[2-(3,5-dichlorphenyl)-vinyl]-pyridin-3-ylester, 2-Methyl-6-(2-naphthalin-1-ylvinyl)-pyridin, 2-[2-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-vinyl]-6-methylpyridin, 2-Methyl-6-(2-naphthalin-2-ylvinyl)-pyridin, 2-{2-[3-(3,5-Dichlorphenoxy)-phenyl]-vinyl}-6-methyl-pyridin, 2-[2-(3-Chlorphenyl)-propenyl]-6-methylpyridin, 2-[2-(2,3-Dihydrobenzofuran-5-yl)-vinyl]-6-methylpyridin, 2-[2-(4-Fluorphenyl)-vinyl]-6-methylpyridin, 2-Methyl-6-(2-o-tolylvinyl)-pyridin, 2-Methyl-6-(2-p-tolylvinyl)-pyridin, 2-Methyl-6-(2-p-tolylpropenyl)-pyridin, 3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylamin, (2,3-Dimethoxy-7-nitrochinoxalin-5-ylmethyl)-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amin, N-{3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-acetamid, N-{3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-2-phenylacetamid, 2,2-Dimethyl-N-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-propionamid, Thiophen-2-carbonsäure-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amid, Cyclohexancarbonsäure-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amid, 1-(4-Bromphenyl)-3-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-harnstoff, 2-Methyl-6-[2-(4-nitrophenyl)-vinyl]-pyridin, 4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylamin, 2-[2-(3,5-Dichlorphenyl)-vinyl]-6-methylpyridin-3-ol, 6-[2-(3,5-Dichlorphenyl)-vinyl]-2-methylpyridin-3-ol, 2-[2-(3,5-Dichlorphenyl)-vinyl]-pyridin-3-ol, 2-[2-(6-Chlorbenzo[1,3]dioxo-5-yl)-vinyl]-6-methylpyridin, 2-[2-(2,3-Difluorphenyl)-vinyl]-6-methylpyridin, 2-[2-(3,4-Dichlorphenyl)-propenyl]-6-methylpyridin, 2-[2-(3,5-Bistrifluormethylphenyl)-vinyl]-6-methylpyridin, Essigsäure-2-methoxy-6-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester, 2-Methoxy-6-[2-(6-methylpyridin-2-yl)-vinyl]-phenol, 2-Methyl-6-[2-(2,3,6-trifluorphenyl)-vinyl]-pyridin, 2-[2-(4-Fluor-3-trifluormethylphenyl)-vinyl]-6-methylpyridin, 2-Methyl-6-(2,3,6-trifluorphenylethinyl)-pyridin, Essigsäure-4-chlor-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester, Essigsäure-2,6-di-tert.-butyl-4-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester, 3-(6-Methylpyridin-2-ylethinyl)-benzamid, Essigsäure-4-brom-2-methoxy-6-[2-(6-methylpyridin-2-yl)-vinyl]-phenylester, 2-(6-Chlorbenzo[1,3]dioxol-5-ylethinyl)-6-methylpyridin, 2-[2-(3,5-Dichlorphenyl)-vinyl]-3-methoxy-6-methylpyridin, 2-[2-(3,5-Dichlorphenyl)-vinyl]-3-methoxypyridin, 5-Azido-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenol, 2-[2-(Pyridin-3-yl)-ethinyl]-6-methylpyridin, N-{3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-succinsäure, 1-tert.-Butyl-3-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-harnstoff, 5-({3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylamino]-methyl)-7-nitro-1,4-dihydrochinoxalin-2,3-dion, Tetrahydrofuran-2-carbonsäure-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amid, (1-{3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylcarbamoyl}-2-phenylethyl)-carbaminsäure-tert.-butylester, ({3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylcarbamoyl}-methyl)-carbaminsäure-tert.-butylester, Diethyl-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amin, Ethyl-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amin, Ethyl-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amin, 2-(2-Ethoxy-3,6-difluorphenylethinyl)-6-methylpyridin, 2-(3,5-Difluorphenylethinyl)-6-methylpyridin, 2-(3-Fluorphenylethinyl)-6-methylpyridin, 2-[2-(3,5-Dimethylphenyl)-vinyl]-6-methylpyridin, 2-[2-(3,4-Dimethoxyphenyl)-vinyl]-6-methylpyridin, 2-(3,4-Dichlorphenylethinyl)-6-methylpyridin, 2-(4-Ethoxy-3-trifluormethylphenylethinyl)-6-methylpyridin, 2-(4-Fluorphenylethinyl)-6-methylpyridin, 2-Methyl-6-o-tolylethinylpyridin, 2-(3,4-Difluorphenylethinyl)-6-methylpyridin, 2-Methyl-6-[2-(2,3,5-trichlorphenyl)-vinyl]-pyridin, 1-[3-(6-Methylpyridin-2-ylethinyl)-phenyl]-ethanon, 2-Methyl-6-(3-trifluormethylphenylethinyl)-pyridin, 2-Methyl-6-(3-nitrophenylethinyl)-pyridin, 6-[2-(3,5-Dichlorphenyl)-vinyl]-3-methoxy-2-methylpyridin, {2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-yl}-morpholin-4-ylmethanon, (3-{2-[2-(3,5-Dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin, N-{4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-succinaminsäure, N-{4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-2-phenylacetamid, ({4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylcarbamoyl}-methyl)-carbaminsäure-tert.-butylester, 1-(tert.-Butyl-3-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-harnstoff, {3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-thiophen-2-ylmethylaminhydrochloridsalz, Cyclohexylmethyl-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-aminhydrochloridsalz, {4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-thiophen-2-ylmethylamin, Cyclohexylmethyl-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-amin, 2-Amino-N-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-3-phenylpropionamid, 2-Amino-N-{3-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-acetamid, 2-Amino-N-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-acetamid, 1-[1-({2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-acetyl)-piperidin-4-yl]-imidazolidin-2-on, (1-{4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenylamino}-ethyl)-phosphonsäuredimethylester, 2-(3-Ethoxy-4-fluorphenylethinyl)-6-methylpyridin, 2-(3-Chlorphenylethinyl)-6-methylpyridin, 1-(3-Pyridin-2-ylethinylphenyl)-ethanon, 4-Chlor-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenol, 4-Brom-2-methoxy-6-[2-(6-methylpyridin-2-yl)-vinyl]-phenol, 2-(2,5-Difluorphenylethinyl)-6-methylpyridin, 2-(3,5-Dimethylphenylethinyl)-6-methylpyridin, 2-[2-(3,5-Dibromphenyl)-vinyl]-6-methylpyridin, 3-(6-Methylpyridin-2-ylethinyl)-benzonitril, 2-Methyl-6-[2-(pyrimidin-5-yl)-ethinyl]-pyridin, (2-{2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-ethyl)-dimethylamin, Essigsäure-1-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenyl}-ethylester, 3-[2-(6-Methylpyridin-2-yl)-vinyl]-phenol, 3-(6-Methylpyridin-2-ylethinyl)-phenylamin, N-[3-(6-Methylpyridin-2-ylethinyl)-phenyl]-2-phenylacetamid, Thiophen-2-carbonsäure-[3-(6-methylpyridin-2-ylethinyl)-phenyl]-amid, 2-Methyl-6-thiophen-2-ylethinylpyridin, 3-(6-Methylpyridin-2-ylethinyl)-benzoesäureethylester, 2-(3,5-Dibromphenylethinyl)-6-methylpyridin, {2-[2-(2-Chlorphenyl)-vinyl]-6-methylpyridin-3-ylmethyl}-dimethylamin, (3-{6-[2-(3-Chlorphenyl)-vinyl]-2-methylpyridin-3-yloxy}-propyl)-dimethyl, 5-Azido-4-iod-2-[2-(6-methylpyridin-2-yl)-vinyl]-phenol, 2,6-Di-tert.-butyl-4-[2-(6-methylpyridin-2-yl)-vinyl]-phenol, 1-{4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-ethanol, 2-Methyl-6-[2-(pyrimidin-2-yl)-ethinyl]-pyridin, [3-(6-Methylpyridin-2-ylethinyl)-phenyl]-phenylmethanon, 6-(6-Methylpyridin-2-ylethinyl)-3,4-dihydro-1H-chinolin-2-on, 2-(3-{2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-isoindol-1,3-dion, 3-Methoxy-6-methyl-2-m-tolylethinylpyridin, Essigsäure-2-[2-(6-methylpyridin-2-yl)-vinyl]-4-nitrophenylester, 6-(6-Methylpyridin-2-ylethinyl)-indan-1-on, 2-Methyl-6-[2-(pyrazin-2-yl)-ethinyl]-pyridin, N-Methyl-N-(3-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenoxy}-propyl)-acetamid, 2-[2-(3,5-Bistrifluormethylphenyl)-1-ethoxyvinyl]-6-methylpyridin Essigsäure-2-phenylethinylpyridin-3-ylester, Essigsäure-6-methyl-2-m-tolylethinylpyridin-3-ylester, Essigsäure-4-[2-(6-methylpyridin-2-yl)-vinyl]-2-nitrophenylester, 2-[2-(6-Methylpyridin-2-yl)-vinyl]-4-nitrophenol, Dimethyl-[3-(2-phenylethinylpyridin-3-yloxy)-propyl]-amin, Dimethyl-(3-{4-[2-(6-methylpyridin-2-yl)-vinyl]-phenoxy}-propyl)-amin, 1-{4-[2-(6-Methylpyridin-2-yl)-vinyl]-phenyl}-ethanon, 2-(3-Fluorphenylethinyl)-chinolin, Essigsäure-2-methyl-6-styrylpyridin-3-ylester, 4-[2-(6-Methylpyridin-2-yl)-vinyl]-2-nitrophenol, 3-Ethoxy-4-[2-(6-methylpyridin-2-yl)-vinyl]-2-nitrophenol, 4-(6-Methylpyridin-2-ylethinyl)-2-nitrophenol, Essigsäure-2-[2-(6-methylpyridin-2-yl)-vinyl]-6-nitrophenylester, Dimethyl-[3-(6-methyl-2-phenylethinylpyridin-3-yloxy)-propyl]-amin, 2-Azido-4-[2-(6-methylpyridin-2-yl)-vinyl]-phenol, Dimethyl-[3-(6-methyl-2-m-tolylethinylpyridin-3-yloxy)-propyl]-amin, 2-(3-Methansulfonylphenylethinyl)-6-methylpyridin, 3-{2-[2-(3-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propylamin, 4-Azido-N-(3-{2-[2-(3-chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-2-hydroxybenzamid, 3-[3-(3-Dimethylaminopropoxy)-6-methylpyridin-2-ylethinyl]-benzonitril, 5-(6-Methylpyridin-2-ylethinyl)-indan-1-on, 2-Methyl-6-(2,3,5-trichlorphenylethinyl)-pyridin, 2-[2-(6-Methylpyridin-3-yl)-ethinyl]-6-methylpyridin, Dimethyl-(3-[6-methyl-2-(3-trifluormethylphenylethinyl)-pyridin-3-yloxy]-propyl}-amin, 2-[2-(6-Methylpyridin-3-yl)-ethinyl]-3-methoxy-6-methylpyridinhydrochloridsalz, 2-Methyl-6-(5,6,7,8-tetrahydronaphthalin-2-ylethinyl)-pyridin, 3-[2-(3-Chlorphenylethinyl)-6-methylpyridin-3-yloxy]-propylamin, (3-{4-Brom-2-methoxy-6-[2-(6-methylpyridin-2-yl)-vinyl]-phenoxy}-propyl)-dimethylamin, [6-(3-Fluorphenylethinyl)-pyridin-2-yl]-dimethylamin, 6'-(3-Fluorphenylethinyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl, {3-[2-(3-Chlorphenylethinyl)-6-methylpyridin-3-yloxy]-propyl}-dimethylamin, 4-Azido-N-{3-[2-(3-chlorphenylethinyl)-6-methylpyridin-3-yloxy]-propyl}-2-hydroxybenzamid, 1-[3-(6-Methylpyridin-2-ylethinyl)-phenyl]-1H-[1,2,4]triazol-3-carbonsäureethylester, 1-[3-(6-Methyl-2-phenylethinylpyridin-3-yloxy)-propyl]-piperidin-3-ol, 2-Ethinyl-6-(3-fluorphenylethinyl)-pyridin, 3-Methyl-6-(6-methylpyridin-2-ylethinyl)-3H-benzooxazol-2-on, 1-[3-(6-Methylpyridin-2-ylethinyl)-phenyl]-1H-[1,2,4]triazol-3-carbonsäure, 1-[3-(6-Methylpyridin-2-ylethinyl)-phenyl]-1H-[1,2,4]triazol-3-carbonsäuredimethylamid, 1-[3-(6-Methyl-2-phenylethinylpyridin-3-yloxy)-propyl]-piperidin-4-ol, 5-(6-Methylpyridin-2-ylethinyl)-2-nitrophenol, 5-[2-Brom-2-(6-methylpyridin-2-yl)-vinyl]-2-nitrophenol, 5-[2-(6-Methylpyridin-2-yl)-E-vinyl]-2-nitrophenol, 5-[2-(6-Methylpyridin-2-yl)-Z-vinyl]-2-nitrophenol, 4-Azido-2-hydroxy-N-[3-(6-methylpyridin-2-ylethinyl)-phenyl]-benzamid, 5-(3-Dimethylaminopropoxy)-6-phenylethinylpyridin-2-carbonsäureethylester, 6-Methyl-2-styrylpyrimidin-4-ol, 2-Ethyl-6-(3-fluorphenylethinyl)-pyridin, 2-(3,5-Dichlorphenylethinyl)-6-methylpyridin, 2-Methyl-6-(3-trifluormethoxyphenylethinyl)-pyridin, 2-Methyl-6-(3-[1,2,4]triazol-1-ylphenylethinyl)-pyridin, 4-(6-Methylpyridin-2-ylethinyl)-phthalonitril, 2-Methyl-6-{2-[3-(1H-tetrazol-5-yl)-phenyl]-vinyl}-pyridin, Verbindung mit Ameisensäure, 3-[2-(3,5-Dichlorphenylethinyl)-6-methylpyridin-3-yloxy]-propylamin, {3-[2-(3,5-Dichlorphenylethinyl)-6-methylpyridin-3-yloxy]-propyl}-dimethylamin, 2-(3,5-Dimethylphenylethinyl)-3-methoxy-6-methylpyridin, 2-[2-(3-Fluorphenyl)-vinyl]-6-methylpyridin-3-ol, 6-(3-Fluorphenylethinyl)-2-methylnicotinsäureethylester, 2-Azido-5-(6-methylpyridin-2-ylethinyl)-phenol, 6-(3,4-Dimethoxyphenylethinyl)-5-(3-dimethylaminopropoxy)-pyridin-2-carbonsäureethylester, 2-(4-Methoxy-3-trifluormethylphenylethinyl)-6-methylpyridin, 2-(3-Fluorphenylethinyl)-6-methoxypyridin, 2-(3-Fluorphenylethinyl)-5-methylpyridin, 6-(3,5-Dichlorphenylethinyl)-5-(3-dimethylaminopropoxy)-pyridin-2-carbonsäureethylester, 5-(3-Dimethylaminopropoxy)-6-(3,5-dimethylphenylethinyl)-pyridin-2-carbonsäureethylester, 6-(3-Fluorphenylethinyl)-6-methylnicotinsäure, [6-(3-Fluorphenylethinyl)-2-methylpyridin-3-yl]-methanol, [4-(4-Fluorbenzoyl)-piperidin-1-yl]-[6-(3-fluorphenylethinyl)-2-methylpyridin-3-yl]-methanon, 2-(3-Fluorphenylethinyl)-6-methylnicotinsäureethylester, 2-(3-Fluorphenylethinyl)-4,6-dimethylpyridin, 6-(3-Fluorphenylethinyl)-N-(5-methoxyindan-2-ylmethyl)-2-methylnicotinamid, {[6-(3-Fluorphenylethinyl)-2-methylpyridin-3-carbonyl]-amino}-phenylessigsäuremethylester, 2-Methyl-6-(5-methylthiophen-2-ylethinyl)-pyridin, 2-Methyl-6-(2,3,5-trimethylphenylethinyl)-pyridin, 3-{2-[2-(3-Fluorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propan-1-ol, [6-(3-Fluorphenylethinyl)-2-methylpyridin-3-ylmethyl]-dimethylamin, 2,2-Dimethylpropionsäure-3-[2-(3-fluorphenylethinyl)-6-methylpyridin-3-yloxy]-propylester, 2-Azido-4-iod-5-(6-methylpyridin-2-ylethinyl)-phenol, 6-Azido-2,4-diiod-3-(6-methylpyridin-2-ylethinyl)-phenol, 4-Azido-2-hydroxy-5-iod-N-[3-(6-methylpyridin-2-ylethinyl)-phenyl]-benzamid, Essigsäure-3-acetoxymethyl-5-(6-methylpyridin-2-ylethinyl)-benzylester, (Benzyl-{[2-(3-fluorphenylethinyl)-6-methylpyridin-3-yloxy]-acetyl}-amino)-essigsäureethylester, 2-[2-(3-Fluorphenyl)-vinyl]-6-methylisonicotinsäureethylester, 3-[2-(3-Fluorphenylethinyl)-6-methylpyridin-3-yloxy]-propan-1-ol, [3-Hydroxymethyl-5-(6-methylpyridin-2-ylethinyl)-phenyl]-methanol, (3-{2-[2-(3,5-Dimethylphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin, [4-(4-Fluorbenzoyl)-piperidin-1-yl]-{6-[2-(3-fluorphenyl)-vinyl]-2-methylpyridin-3-yl}-methanon, 2-[2-(3-Fluorphenyl)-vinyl]-6-methylisonicotinsäure, {6-[2-(2-Chlorphenyl)-vinyl]-2-methylpyridin-3-yl}-[4-(4-fluorbenzoyl)-piperidin-1-yl]-methanon, 2-(3-Ethinylphenylethinyl)-6-methylpyridin, (3-{2-[2-(2,6-Dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin, (3-{2-[2-(2,3-Dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin, 4-[6-(3-Fluorphenylethinyl)-2-methylpyridin-3-carbonyl]-piperazin-1-carbonsäure-tert.-butylester, [6-(3-Fluorphenylethinyl)-2-methylpyridin-3-yl]-piperazin-1-ylmethanon, [4-(4-Azido-2-hydroxybenzoyl)-piperazin-1-yl]-[6-(3-fluorphenylethinyl)-2-methylpyridin-3-yl]-methanon, (3-{2-[2-(2,4-Dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin, 2-(3-Fluorphenylethinyl)-6-methylisonicotinsäureethylester, 2-(3-Fluorphenylethinyl)-6-methylisonicotinsäure-tert.-butylester, 2-(3-Fluorphenylethinyl)-6-methylisonicotinsäure, [2-(3-Fluorphenylethinyl)-6-methylpyridin-4-yl]-methanol, [4-(4-Fluorbenzoyl)-piperidin-1-yl]-[2-(3-fluorphenylethinyl)-6-methylpyridin-4-yl]-methanon, 3-Allyloxy-2-[2-(3,5-dichlorphenyl)-vinyl]-6-methylpyridin, [2-(3-Fluorphenylethinyl)-6-methylpyridin-4-yl]-morpholin-4-ylmethanon, Essigsäure-3-(6-methylpyridin-2-ylethinyl)-benzylester, [2-(3-Fluorphenylethinyl)-6-methylpyridin-4-ylmethyl]-dimethylamin, (3-{2-[2-(3,5-Dichlorphenyl)-propenyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin, 2-(3-Fluorphenylethinyl)-3-methoxy-6-methylpyridin, (3-{2-[2-(3,5-Dichlorphenyl)-vinyl]-pyridin-3-yloxy}-propyl)-dimethylamin, (4-Azido-2-hydroxy-5-iodphenyl)-{4-[6-(3-fluorphenylethinyl)-2-methylpyridin-3-carbonyl]-piperazin-1-yl}-methanon, 4-Azido-N-{3-[2-(3-chlorphenylethinyl)-6-methylpyridin-3-yloxy]-propyl}-2-hydroxy-5-iodbenzamid, 4-(2-Pyridin-2-ylvinyl)-benzoesäureethylester, (3-{2-[2-(4-Chlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin, [3-(6-Methylpyridin-2-ylethinyl)-phenyl]-methanol, 6-(3-Fluorphenylethinyl)-nicotinsäure-tert.-butylester, (3-{2-[2-(3,4-Dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin, 2-(1-Brom-2-phenylvinyl)-4-methylpyrimidin, 6-(3-Fluorphenylethinyl)-nicotinsäure, [4-(4-Fluorbenzoyl)-piperidin-1-yl]-[6-(3-fluorphenylethinyl)-pyridin-3-yl]-methanon, 2-(2-tert.-Butoxy-3,6-difluorphenylethinyl)-6-methylpyridin, 2-Methyl-6-[2-(2,4,5-trifluorphenyl)-vinyl]-pyridin, 2-Methyl-6-[2-(2,3,4-trifluorphenyl)-vinyl]-pyridin, 3-(6-Methylpyridin-2-ylethinyl)-phenol, 2-Methyl-6-[2-(3,4,5-trifluorphenyl)-vinyl]-pyridin, 2-(3-Methoxyphenylethinyl)-6-methylpyridin, 2-Methyl-6-(2,3,4-triffuorphenylethinyl)-pyridin, und pharmazeutisch akzeptable Salze hiervon.
- (3-{2-[2-Trans-(3,5-dichlorphenyl)-vinyl]-6-methylpyridin-3-yloxy}-propyl)-dimethylamin in freier Form oder in Form eines pharmazeutisch akzeptablen Salzes.
- 2-[2-(Pyridin-3-yl)-ethinyl]-6-methylpyridin in freier Form oder in Form eines pharmazeutisch akzeptablen Salzes.
- Pharmazeutische Zusammensetzung, umfassend als einen pharmazeutischen Wirkstoff, zusammen mit üblichen pharmazeutischen Exzipientien, eine Verbindung nach einem der Ansprüche 5 bis 7 in freier Form oder in Form eines pharmazeutisch akzeptablen Salzes.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89169197A | 1997-07-11 | 1997-07-11 | |
US89068997A | 1997-07-11 | 1997-07-11 | |
US890689 | 1997-07-11 | ||
US891691 | 1997-07-11 | ||
PCT/EP1998/004266 WO1999002497A2 (en) | 1997-07-11 | 1998-07-09 | Pyridine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69839398D1 DE69839398D1 (de) | 2008-06-05 |
DE69839398T2 true DE69839398T2 (de) | 2009-05-28 |
Family
ID=27128958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69839398T Expired - Lifetime DE69839398T2 (de) | 1997-07-11 | 1998-07-09 | Pyridinderivate |
Country Status (26)
Country | Link |
---|---|
US (1) | US6656957B1 (de) |
EP (1) | EP0998459B1 (de) |
JP (1) | JP3481208B2 (de) |
KR (1) | KR20010021712A (de) |
CN (1) | CN1203060C (de) |
AR (1) | AR016314A1 (de) |
AT (1) | ATE393145T1 (de) |
AU (1) | AU738973B2 (de) |
BR (1) | BR9811685A (de) |
CA (1) | CA2295678C (de) |
DE (1) | DE69839398T2 (de) |
ES (1) | ES2308811T3 (de) |
HU (1) | HUP0004225A3 (de) |
ID (1) | ID23889A (de) |
IL (1) | IL133904A0 (de) |
MY (1) | MY119800A (de) |
NO (1) | NO20000124L (de) |
NZ (1) | NZ502210A (de) |
PE (1) | PE97799A1 (de) |
PL (1) | PL343865A1 (de) |
PT (1) | PT998459E (de) |
RU (1) | RU2203889C2 (de) |
SK (1) | SK232000A3 (de) |
TR (1) | TR200000059T2 (de) |
TW (1) | TW544448B (de) |
WO (1) | WO1999002497A2 (de) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2232017C2 (ru) * | 1998-10-02 | 2004-07-10 | Новартис Аг | Антагонисты метаботропных глутаматных рецепторов (mglur5) для лечения боли и состояния тревоги |
AU3679800A (en) * | 1999-04-23 | 2000-11-10 | Sumitomo Pharmaceuticals Company, Limited | Apoptosis inhibitors |
FR2793245B1 (fr) * | 1999-05-05 | 2002-10-11 | Adir | Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
JP4815083B2 (ja) * | 1999-08-31 | 2011-11-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環化合物およびそれの使用方法 |
US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
GB0005700D0 (en) * | 2000-03-09 | 2000-05-03 | Glaxo Group Ltd | Therapy |
JP5154728B2 (ja) * | 2000-07-24 | 2013-02-27 | クレニツキー・ファーマシューティカルズ,インコーポレイテッド | 神経栄養活性を有する置換5−アルキニルピリミジン |
BR0115871A (pt) | 2000-12-04 | 2003-10-28 | Hoffmann La Roche | Derivados de feniletenila ou feniletinila como antagonistas de receptores de glutamato |
GB0103045D0 (en) * | 2001-02-07 | 2001-03-21 | Novartis Ag | Organic Compounds |
ATE375340T1 (de) * | 2001-02-21 | 2007-10-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten |
US8124625B2 (en) | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
BR0213233A (pt) * | 2001-10-12 | 2005-01-04 | Warner Lambert Co | Alcinos inibidores de metaloproteinase de matriz |
US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
GB0128996D0 (en) * | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
WO2003093236A1 (en) * | 2002-05-02 | 2003-11-13 | Euro-Celtique, S.A. | 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor |
AU2003253149A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors |
EP1539749A4 (de) * | 2002-09-13 | 2007-06-13 | Merck & Co Inc | Durch kondensierte heterobicyclogruppen substituierte phenylverbindungen als metobotrope glutamat-5-modulatoren |
US20070060618A1 (en) * | 2002-10-24 | 2007-03-15 | Merck & Co., Inc. | Alkyne derivatives as tracers for metabotropic glutamate receptor binding |
DE10250708A1 (de) * | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
ITMI20030151A1 (it) * | 2003-01-30 | 2004-07-31 | Recordati Ind Chimica E Farma Ceutica S P A | Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore. |
UA81464C2 (en) | 2003-03-04 | 2008-01-10 | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS | |
WO2004078715A1 (ja) * | 2003-03-07 | 2004-09-16 | Astellas Pharma Inc. | 2,6-ジ置換スチリルを有する含窒素へテロ環誘導体 |
TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
US7531529B2 (en) | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
CA2527587C (en) * | 2003-06-12 | 2010-09-28 | F. Hoffmann-La Roche Ag | Heteroaryl-substituted imidazole derivatives as glutamate receptor antagonists |
ES2322707T3 (es) * | 2003-07-03 | 2009-06-25 | Euro-Celtique S.A. | Derivados de 2-piridina alquino utiles para tratar el dolor. |
US7091222B2 (en) * | 2003-07-03 | 2006-08-15 | Hoffmann-La Roche Inc. | Imidazole derivatives |
JP4667384B2 (ja) * | 2003-10-07 | 2011-04-13 | レノビス, インコーポレイテッド | イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法 |
JP2007509935A (ja) * | 2003-10-31 | 2007-04-19 | アストラゼネカ アクチボラグ | アルキンズii |
JP2007510645A (ja) * | 2003-10-31 | 2007-04-26 | アストラゼネカ アクチボラグ | アルキン類i |
EP1677788A1 (de) * | 2003-10-31 | 2006-07-12 | AstraZeneca AB | Alkyne iii |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004017930A1 (de) * | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
DE102004017935A1 (de) * | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US20050245529A1 (en) * | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
KR100907108B1 (ko) | 2004-06-01 | 2009-07-09 | 에프. 호프만-라 로슈 아게 | Mglu5 수용체 길항제로서 피리딘-4-일-에틴일-이미다졸및 피라졸 |
ES2332659T3 (es) * | 2004-06-16 | 2010-02-10 | Wyeth | Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa. |
WO2006009655A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase |
GB0413605D0 (en) * | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
JP4966866B2 (ja) | 2005-01-14 | 2012-07-04 | エフ.ホフマン−ラ ロシュ アーゲー | mGluR5アンタゴニストとしてのチアゾール−4−カルボキサミド誘導体 |
EP2264036A1 (de) | 2005-01-14 | 2010-12-22 | Wyeth LLC (Formerly Known As Wyeth) | Amino-Imidazolone als Beta-Sekretase-Hemmer |
MX2007009313A (es) * | 2005-02-01 | 2007-09-12 | Wyeth Corp | Amino-piridinas como inhibidores de ????-secretasa. |
WO2006088711A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | AZOLYLACYLGUANIDINES AS β-SECRETASE INHIBITORS |
US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
BRPI0607583A2 (pt) * | 2005-03-04 | 2009-09-15 | Hoffmann La Roche | derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos |
GB0508319D0 (en) * | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
TW200738683A (en) * | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
WO2007005404A1 (en) * | 2005-06-30 | 2007-01-11 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
FR2889187B1 (fr) * | 2005-07-28 | 2007-09-07 | Servier Lab | Nouveaux composes 1,1-pyridinyloxycyclopropanamines polysusbstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2889188B1 (fr) * | 2005-07-28 | 2007-09-07 | Servier Lab | Nouveaux composes 1,1-pyridinylaminocyclopropanamines polysubstitues, leur procede de preparation et les compositions phamaceutiques qui les contiennent |
TW200730523A (en) * | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
US7531541B2 (en) * | 2005-09-20 | 2009-05-12 | Vanderbilt University | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders |
BRPI0616757A2 (pt) * | 2005-09-26 | 2011-06-28 | Wyeth Corp | composto da fórmula i; processo para o tratamento de uma doença ou de um distúrbio associado com a atividade excessiva de bace; processo para a modulação da atividade de bace; processo para o tratamento da doença de alzheimer; e composição farmacêutica |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
JP2009520027A (ja) * | 2005-12-19 | 2009-05-21 | ワイス | 2−アミノ−5−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用 |
DE102005062985A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln |
WO2007100536A1 (en) * | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
PT1999109E (pt) * | 2006-03-30 | 2012-03-16 | Univ Pennsylvania | Derivados de estirilpiridina e sua utilização para ligação e obtenção de imagens de placas amilóides |
BRPI0710328A2 (pt) * | 2006-05-08 | 2011-08-09 | Ariad Pharma Inc | composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição |
US7700606B2 (en) * | 2006-08-17 | 2010-04-20 | Wyeth Llc | Imidazole amines as inhibitors of β-secretase |
CA2662348A1 (en) * | 2006-09-21 | 2008-03-27 | Wyeth | Indolylalkylpyridin-2-amines for the inhibition of .beta.-secretase |
LT2083811T (lt) | 2006-11-22 | 2017-01-25 | Clinical Research Associates, Llc | Dauno sindromo, trapiosios x chromosomos sindromo ir autizmo gydymo būdai |
CN101568531B (zh) | 2006-12-21 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | Mglur5受体拮抗剂的多晶型物 |
JP2010519267A (ja) * | 2007-02-22 | 2010-06-03 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 新規殺微生物剤 |
WO2008112440A1 (en) * | 2007-03-09 | 2008-09-18 | Astrazeneca Ab | Piperazine and piperidine mglur5 potentiators |
DK2124562T3 (en) | 2007-03-09 | 2016-08-01 | Second Genome Inc | BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof |
CL2008000784A1 (es) * | 2007-03-20 | 2008-05-30 | Wyeth Corp | Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co |
CL2008000791A1 (es) * | 2007-03-23 | 2008-05-30 | Wyeth Corp | Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm |
US8853392B2 (en) * | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
WO2008151184A1 (en) * | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
US8034806B2 (en) * | 2007-11-02 | 2011-10-11 | Vanderbilt University | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same |
CA2748235A1 (en) | 2008-12-24 | 2010-07-01 | Astrazeneca Ab | Ethanamine compounds and their use for treating depression |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
KR101396606B1 (ko) * | 2009-04-20 | 2014-05-16 | 미쓰비시 타나베 파마 코퍼레이션 | 신규 갑상선 호르몬 β 수용체 작동약 |
EP2531510B1 (de) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo-[5,1b-]oxazol-derivate als crf-1-rezeptor-antagonisten |
AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
EP2544688B1 (de) | 2010-03-02 | 2016-09-07 | President and Fellows of Harvard College | Verfahren und zusammensetzungen zur behandlung des angelman-syndroms |
US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
US8772300B2 (en) * | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
EA201491990A1 (ru) | 2012-05-03 | 2015-02-27 | Новартис Аг | L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов |
UA114934C2 (uk) * | 2012-10-18 | 2017-08-28 | Ф. Хоффманн-Ля Рош Аг | Похідне етинілу як модулятор активності метаботропного глутаматного рецептора підтипу 5 |
WO2014060398A1 (en) * | 2012-10-18 | 2014-04-24 | F. Hoffmann-La Roche Ag | Ethynyl derivatives as modulators of mglur5 receptor activity |
UA116023C2 (uk) | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
EP2853565A1 (de) | 2013-09-27 | 2015-04-01 | Consejo Superior De Investigaciones Científicas | Glutamatrezeptor-Photomodulatoren |
CN106146391A (zh) * | 2015-04-15 | 2016-11-23 | 中国科学院上海药物研究所 | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
AU2017214615A1 (en) * | 2016-02-03 | 2018-09-20 | Galderma Research & Development | Novel biaromatic propynyl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof |
US10449186B2 (en) * | 2017-06-21 | 2019-10-22 | University Of Kentucky Research Foundation | Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer |
JP2020529975A (ja) | 2017-07-31 | 2020-10-15 | ノバルティス アーゲー | コカイン使用の低減又はコカイン使用再燃の予防におけるマボグルラントの使用 |
CN107400256B (zh) * | 2017-08-14 | 2019-04-19 | 深圳市精研科洁科技股份有限公司 | 一种抗紫外线塑料添加剂的制备方法 |
WO2023122212A2 (en) | 2021-12-21 | 2023-06-29 | Southern Research Institute | Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of sars virus |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4006240A (en) * | 1975-03-19 | 1977-02-01 | Ho Andrew K S | Alcohol aversion process by enzyme inhibition |
NO174506B (no) * | 1984-10-30 | 1994-02-07 | Usv Pharma Corp | Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser |
DE68907095T2 (de) * | 1988-03-21 | 1994-01-05 | Boehringer Ingelheim Pharma | Verbindungen zur Verhinderung der Biosynthese von der Lipoxygenase abgeleiteten Metaboliten der Arachidonsäure. |
US5013744B1 (en) * | 1989-12-29 | 1994-09-20 | Allegran Inc | Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity |
JPH05500781A (ja) * | 1990-08-08 | 1993-02-18 | ゼネラル・エレクトリック・カンパニイ | 不織フェルトを使った繊維強化熱可塑性合成樹脂の製造方法 |
GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
AU6514296A (en) * | 1995-07-31 | 1997-02-26 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
IT1276153B1 (it) * | 1995-11-17 | 1997-10-27 | Roberto Pellicciari | Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato |
-
1998
- 1998-07-06 TW TW087110887A patent/TW544448B/zh not_active IP Right Cessation
- 1998-07-08 AR ARP980103330A patent/AR016314A1/es unknown
- 1998-07-09 EP EP98941308A patent/EP0998459B1/de not_active Expired - Lifetime
- 1998-07-09 HU HU0004225A patent/HUP0004225A3/hu unknown
- 1998-07-09 RU RU2000102667/04A patent/RU2203889C2/ru not_active IP Right Cessation
- 1998-07-09 DE DE69839398T patent/DE69839398T2/de not_active Expired - Lifetime
- 1998-07-09 NZ NZ502210A patent/NZ502210A/en unknown
- 1998-07-09 PT PT98941308T patent/PT998459E/pt unknown
- 1998-07-09 CN CNB988070502A patent/CN1203060C/zh not_active Expired - Fee Related
- 1998-07-09 ES ES98941308T patent/ES2308811T3/es not_active Expired - Lifetime
- 1998-07-09 JP JP2000502025A patent/JP3481208B2/ja not_active Expired - Fee Related
- 1998-07-09 AU AU89743/98A patent/AU738973B2/en not_active Ceased
- 1998-07-09 CA CA2295678A patent/CA2295678C/en not_active Expired - Fee Related
- 1998-07-09 PE PE1998000606A patent/PE97799A1/es not_active Application Discontinuation
- 1998-07-09 WO PCT/EP1998/004266 patent/WO1999002497A2/en active IP Right Grant
- 1998-07-09 KR KR1020007000271A patent/KR20010021712A/ko not_active Application Discontinuation
- 1998-07-09 PL PL98343865A patent/PL343865A1/xx unknown
- 1998-07-09 TR TR2000/00059T patent/TR200000059T2/xx unknown
- 1998-07-09 SK SK23-2000A patent/SK232000A3/sk unknown
- 1998-07-09 IL IL13390498A patent/IL133904A0/xx unknown
- 1998-07-09 BR BR9811685-1A patent/BR9811685A/pt not_active IP Right Cessation
- 1998-07-09 ID IDW20000009A patent/ID23889A/id unknown
- 1998-07-09 AT AT98941308T patent/ATE393145T1/de not_active IP Right Cessation
- 1998-07-10 MY MYPI98003161A patent/MY119800A/en unknown
-
2000
- 2000-01-10 NO NO20000124A patent/NO20000124L/no not_active Application Discontinuation
- 2000-11-27 US US09/722,803 patent/US6656957B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HUP0004225A3 (en) | 2001-06-28 |
EP0998459A2 (de) | 2000-05-10 |
TW544448B (en) | 2003-08-01 |
HUP0004225A2 (hu) | 2001-05-28 |
AR016314A1 (es) | 2001-07-04 |
CN1262676A (zh) | 2000-08-09 |
TR200000059T2 (tr) | 2000-06-21 |
US6656957B1 (en) | 2003-12-02 |
CA2295678A1 (en) | 1999-01-21 |
CN1203060C (zh) | 2005-05-25 |
AU8974398A (en) | 1999-02-08 |
DE69839398D1 (de) | 2008-06-05 |
KR20010021712A (ko) | 2001-03-15 |
SK232000A3 (en) | 2000-06-12 |
ES2308811T3 (es) | 2008-12-01 |
NO20000124D0 (no) | 2000-01-10 |
ID23889A (id) | 2000-05-25 |
ATE393145T1 (de) | 2008-05-15 |
PE97799A1 (es) | 1999-11-08 |
PT998459E (pt) | 2008-07-31 |
EP0998459B1 (de) | 2008-04-23 |
BR9811685A (pt) | 2000-09-19 |
AU738973B2 (en) | 2001-10-04 |
PL343865A1 (en) | 2001-09-10 |
WO1999002497A3 (en) | 1999-04-01 |
JP3481208B2 (ja) | 2003-12-22 |
NO20000124L (no) | 2000-03-02 |
JP2001509504A (ja) | 2001-07-24 |
IL133904A0 (en) | 2001-04-30 |
NZ502210A (en) | 2002-07-26 |
CA2295678C (en) | 2010-04-13 |
MY119800A (en) | 2005-07-29 |
WO1999002497A2 (en) | 1999-01-21 |
RU2203889C2 (ru) | 2003-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69839398T2 (de) | Pyridinderivate | |
DE69532808T2 (de) | Tri-substituierte phenyl-derivate verwendbar als pde iv hemmer | |
DE69820906T2 (de) | Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren | |
US5422351A (en) | Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compounds, compositions and methods of use | |
DE69534164T2 (de) | Tri-substituierte phenyl-derivate verwendbar als pde iv hemmer | |
US4950674A (en) | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | |
DE60110749T2 (de) | Pyridinderivative als angiogenese- und/oder vegf-rezeptor-tyrosinkinase-inhibitoren | |
JP4758609B2 (ja) | γ−セクレターゼ阻害剤 | |
DE69918687T2 (de) | 4-Phenylpiperidine zur Behandlung von pruritischen Hauterkrankungen | |
US7968724B2 (en) | Ester derivatives as phosphodiesterase inhibitors | |
US5691323A (en) | Muscarine antagonists | |
US5409931A (en) | 1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents | |
JP2002537383A (ja) | Pdeiv阻害化合物、組成物および治療方法 | |
US4978663A (en) | 5-(1-aminocyclohexyl)-2(1H)-pyridinone compounds which have pharmaceutical utility | |
JPH0789939A (ja) | ニューロペプチド−y(npy)拮抗活性を有するグアニジン誘導体医薬製剤組成物 | |
US5514687A (en) | Benzopyrido piperidylidene compounds, compositions, methods of manufacture and method of use | |
DE3522579C2 (de) | Neue 1,4-Dihydropyridin-Derivate und Salze derselben, Verfahren zur Herstellung derselben und pharmazeutische Mittel mit einem Gehalt derselben | |
CZ394991A3 (en) | Pentadienamides and pharmaceutical compositions based thereon | |
US5430032A (en) | Benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use | |
BG61893B2 (bg) | Метаноантрацени като допаминови антагонисти | |
AU2002328576B2 (en) | Cyclic amine compound | |
DE3631334A1 (de) | Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
EP0080154B1 (de) | N-Substituierte 2-Pyridylindole, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen, sowie ihre therapeutische Verwendung | |
US5561117A (en) | Bridged bis-aryl carbinol derivatives, compositions and methods of use | |
DE60012355T2 (de) | Phenyl- und pyridyl-tetrahydro-pyridine mit tnf inhibitorischer wirkung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: MERCK & CO., INC., WHITEHOUSE STATION, N.J., US Owner name: NOVARTIS AG, BASEL, CH |
|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |